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ABSTRACT OF THESIS (Regulation 7.9)
Epidermal growth factor (EGF) receptor expression and modulation of growth rate
by EGF were investigated in the androgen insensitive DU 145 and androgen sensitive
LNCaP prostatic carcinoma cell lines.
Competition and saturation analysis of binding data revealed one high affinity
binding site for both DU 145 (lnmol/1 ±0.6) and LNCaP (2.8nmol/l±2.2), with DU
145 cells expressing high levels of receptor binding sites/cell (2.5xl05±lxl05) and
LNCaP cells expressing 10 fold lower receptor binding sites/cell (2xl04±lxl04).
Addition of exogenous EGF or TGFa to serum free cultures of DU 145 cells only
minimally affected [3H]- Thymidine incorporation and cell proliferation, whereas EGF
was a potent mitogen for LNCaP cells.
Growth of LNCaP cells was also stimulated by the synthetic androgen Mibolerone,
but no additive effect on growth was observed when EGF and Mibolerone were added
together. Moreover, pre-incubation of LNCaP cells with Mibolerone did not affect
either the number or affinity of the EGF receptor.
Further characterization of the EGF receptor demonstrated time and temperature
dependence of EGF binding to its' receptor. The dissociation of EGF from the receptor
was linear over the time period studied and binding sites on both cell lines were down
regulated by pre-treatment with EGF. Specificity studies with ligands other than mEGF
confirmed specificity, with only TGFa and hEGF competing with [^3I]-mEGF for
binding to the receptor. The presence of the EGF receptor was also verified by Western
blotting. Cell lyzates from DU 145 and LNCaP cells were separated by sodium
dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently
analysed for the presence of the EGF receptor using monoclonal antibodies specific for
the native external domain and the internal domain of the EGF receptor. A band of
molecular weight 170 kDa (which is the molecular weight of the EGF receptor) was
visualized with DU 145 cell lyzates, but not from LNCaP cell lyzates. This was
probably due to the low numbers of receptor binding sites expressed by this cell line.
The truncated, v-erb B gene product was not detected from either cell line.
The secretion of growth factors by some transformed cells is thought to enable these
cells to proliferate in low serum concentrations as well as reducing the dependency upon
exogenous growth factors. Since the growth of the DU 145 cell line was only
minimally affected by exogenous EGF, serum free media conditioned by this cell line
was analysed for growth factor production. EGF-like immunological activity as well as
competitive activity in EGF-radio-receptor assays (RRA) was detected in the
conditioned medium (CM) of these cells. Factors in the CM also inhibited and
stimulated DNA synthesis of these cells and this effect was dose-responsive.
Fractionation of the concentrated CM by gel filtration and reverse-phase high
performance liquid chromatography (rHPLC) revealed several peaks of EGF-like
competitive activity. One peak of rTGF-I immunological activity, which was separated
by rHPLC, also demonstrated EGF-RRA competitive activity. None of the peaks
demonstrating EGF-RRA competitive activity were related immunologically to hEGF.
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1.1 THE HUMAN PROSTATE GLAND - LOCATION,
STRUCTURE AND FUNCTION
The human prostate gland is situated at the base of the bladder and surrounds the
top of the urethra. The gland is a composite structure which includes glandular
elements and a stroma of collagenous and muscle tissue. It consists of two sets of
glands, an inner or central periurethral zone (CZ), and an outer peripheral zone (PZ)
(Figure 1).
The normal physiological function of the prostate is unknown. The epithelial cells
secrete a thin, milky alkaline fluid containing citric acid, calcium, acid phosphatase, a
clotting enzyme and a profibrinolysin (Guyton, 1981). The prostate gland is also a
rich source of growth factors, particularly epidermal growth factor (EGF) (Gregory et
al., 1986). During emission, the prostatic capsule contracts simultaneously with the
vas deferens so that the prostatic fluid adds to the bulk of the semen. The acidic
secretions of the vas deferens are subsequently neutralized by the alkaline prostatic
fluid, hence achieving an optimal pH environment for the spermatozoa (pH 6.0-6.5).
The secretions of the prostate may play an important role in male fertility, although this
has not as yet been established.
FIGURE 1: Diagrammatic vertical coronal section through the human prostate. Showing the
central zone (CZ) and peripheral zones (PZ); after Blacklock, (1982).
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1.2 THE HYPERPLASTIC AND MALIGNANT PROSTATE
Disease of the prostate is relatively uncommon in young males but increases in
incidence with age. The two main pathological processes which involve the gland are
benign prostatic hyperplasia (BPH) and carcinoma. BPH, which affects a large
percentage of men over the age of 50, is probably endocrinologically induced,
although the aetiology of the disease is poorly understood. It is thought to begin in the
inner or periurethral region of the prostate gland and is characterized by an increase in
stromal proliferation in the periurethral zone (Franks, 1954).
In contrast to BPH, carcinoma of the prostate is associated with epithelial cells in
the peripheral region of the prostate (McNeal, 1972; Robel, 1980) but like BPH it is
age related. It is relatively uncommon in men before the age of 50, and has the highest
incidence in men between 65 and 75 years of age. Prostate cancer is associated with
an unusually and extremely high prevalence of latent or dormant cancer that is clearly
identified on pathological examination but which in most cases will never grow further
to become clinically manifested (Franks, 1954); for unknown reasons growth is held
in check. About 10% of all men between the ages of 50-59 years and about 50% at
70-79 years have this latent form of prostate cancer. Those latent cancers which are
activated to grow, account for a mortality rate which makes prostate cancer the second
most common cause of male cancer deaths in the United Kingdom (CRC Factsheet
10.1,1988). The aetiology of the disease is unknown, although several hypotheses
including environmental, geographic, racial and dietary factors have been discussed
(Griffiths, 1987). Since the finding in 1986 of the expression of the ras p21 oncogene
in prostatic carcinoma patients (Viola et al., 1986), a genetic factor is indicated,
although as Bouffioux (1984) has commented, prostate cancer like most malignancies,
does not depend upon a single aetiology but on a complex interaction of factors
resulting in oncogenic transformation.
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1.3 FACTORS AFFECTING PROSTATIC GROWTH
It is well accepted that the overall growth, maintenance and functional activity of
the normal prostate is dependent upon androgens and to some extent upon peptide
hormones (Ghanadian, 1982). However, this endocrinological view of the regulatory
mechanisms affecting the growth of the prostate (or any target organ) largely ignores
the interactions between different cell types and the function of growth factors derived
from this "micro-environment" within the target tissue. In recent years attention has
focussed on these intra-glandular growth control mechanisms and the functions of the
diffusible factors derived from this "micro-environment" with a view to obtaining
some insight into normal and malignant prostatic function.
In this section the endocrinology of those factors governing the growth and
regulation of the normal and malignant prostate is discussed. This is followed by a
discussion on the role of paracrine factors, such as polypeptide growth factors, and
how they function within the environment of the prostate.
1.3.1 ANDROGENS
In 1786 John Hunter first established the relationship between testicular secretions
and the growth of the prostate. However, it was the isolation of the active testicular
hormone testosterone (David et al., 1935), that established the basis for the study of
the androgenic steroids in the control of prostatic growth and development. The
pioneering work of Huggins and Hodges (1941) provided supportive evidence that
prostatic cancer is also associated with hormones and, in particular, testicular
androgens. Many attempts have since been made to understand the role of androgens
in the growth and development of the prostate and their role in prostatic cancer
(Griffiths, 1987).
Regulation of androgen secretion
In man the major serum androgen is testosterone, of which 90% is produced by the
testes, with a small contribution from the adrenals. Testosterone release from the
3
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testes is regulated by the hypothalamic-pituitary-gonadal axis. In the hypothalamus,
luteinizing hormone-releasing hormone (LH-RH) is secreted in a pulsatile fashion into
the hypophyseal portal circulation and reaches the anterior pituitary upon stimulus from
the neurotransmitter norepinephrine. The pituitary is stimulated by the actions of LH-
RH to release luteinizing hormone (LH) and follicle stimulating hormone (FSH). The
LH is transported by the blood to the testes, where it binds to specific receptors located
on the membranes of the Leydig cells causing the release of testosterone into the
bloodstream. Plasma levels of testosterone, in turn, regulate the release of both LH-
RH and gonadotrophins by a negative feedback mechanism, thought to operate both at
the hypothalamic and the pituitary level (Gower, 1979). About 2% of the total plasma
testosterone remains in the unbound state whilst the remainder is reversibly bound to
either albumin or steroid hormone binding globulin. It is the free testosterone which is
considered to be biologically active (Vermeulen, 1979). In the prostate testosterone is
converted to the active metabolite, 5a-dihydrotestosterone (DHT), a conversion
catalyzed by the enzyme 5a-reductase, which is thought to be a nuclear membrane
bound protein (Houston et al., 1985a). The conversion of testosterone to DHT is now
believed to be an obligatory step in the mediation of androgen action in the prostate,
with DHT the major androgen regulating the cellular events of growth, differentiation
and function of the prostate (Ghanadian, 1982).
The adrenal cortex, which is also a source of androgen, has been shown to
influence prostatic growth (Huggins, 1945; Sanford et al., 1977). The main androgen
secreted by the adrenals is dehydroepiandrosterone (DHEA) and its sulphate conjugate
(DHEA-SO4), which together account for about 10% of all circulating androgens.
These steroids are released by the adrenal gland in response to adrenocorticotrophic
hormone (ACTH) which in turn is under the influence of the hypothalamic
corticotrophin releasing hormone (CRH). Adrenal androgens undergo metabolic
conversion to testosterone and DHT, either in the plasma or in the prostate itself.






prostate, but the contribution of adrenal androgens to the growth of the prostate, in
particular to prostate cancer, is uncertain (Labrie et al., 1986; Oesterling et al., 1986).
The mechanism of action of androgens
The mechanism of action of androgens is continually being reviewed and adapted.
The 'new' model which is a 'one-step' model for androgen receptor binding is
illustrated in Figure 2. In this model extracellular testosterone diffuses into the cell
through the cytoplasm to the nucleus. On the nuclear membrane testosterone is
reduced to DHT by the enzyme 5a-reductase and DHT then binds, with high affinity,
to a specific receptor site on the nuclear membrane. The resulting complex then
undergoes a conformational change and interacts with specific receptor sites either
located on DNA, chromatin associated proteins, matrix related components or
distributed amongst all three. Binding of DHT to its receptor is then followed by DNA
synthesis, the production of mRNA and ultimately cell division.
Recently the primary structure of the androgen receptor has been described (Chang
et al., 1988; Lubahn et al., 1988). The receptor structure appears to be composed of
several functional domains, which is also true of other steroid hormone receptors.
Included are a ligand binding domain at the C-terminal end, a hinge region, a DNA
binding domain and an N-terminal domain involved in transcriptional response. In
general, steroid binding to the ligand binding domain results in an increased affinity of
the receptor for DNA.
Steroid hormone regulated genes have short cis-acting enhancer sequences termed
hormone-responsive elements, in or near their transcription units (Jantzen et al., 1987;
Strahle et al., 1987). The DNA binding domain of steroid receptors contain highly
conserved cysteine residues which may tetrahedrally coordinate zinc to form a "zinc
FIGURE 2: The mechanism of action of androgens: 'one-step' model where the receptor and the 5a-




finger" (Green et al., 1986b; Weinberger et al., 1986). These zinc fingers are believed
to become unmasked upon hormone binding and to interact with the hormone--
responsive elements ultimately leading to the transcription of the gene.
Malignancy and endocrine status
The growth and function of the normal prostate is primarily dependent upon
androgens (Coffey & Issacs, 1981). The diseased prostate also appears to respond to
endocrine manipulation, as in a large proportion of patients with prostatic cancer the
disease responds well to treatments which lower the plasma levels of testosterone or
which are anti-androgenic (Griffiths et al., 1987). Indeed, as early as 1941 endocrine
therapy was a recognised form of treatment for prostatic carcinoma (Huggins &
Hodges, 1941). Nevertheless, there are few lines of evidence to implicate the
endocrine system in the aetiology of prostatic cancer even though the presence of the
disease in the prepubertaly castrated male has never been reported. Rotkin (1979)
suggested that the conditions which predispose towards the development of prostatic
carcinoma may be imprinted on the gland at puberty. He suggested that early
"oncogene transformation" of the gland may occur as a consequence of the diverse
physiological and secretory patterns involved with the onset of puberty. Rotkin further
suggested that men at risk of developing prostatic cancer would have a "strong
overbalance of androgenic components". McNeal (1975) investigating the
pathogenesis of prostatic cancer described areas of proliferating epithelial tissue within
the prostate gland, which he described as premalignant changes closely associated with
prostatic carcinoma. Perhaps prostatic cancer may develop from these proliferating
epithelial cells induced by high levels of androgens as Rotkin (1979) suggested.
However, there is little evidence to suggest that hormones are concerned in the




It is generally accepted that the more malignant the cancer, the less hormone-
dependent the cells are, and the less the degree of differentiation (Gleason, 1977). In
advanced stages of prostatic cancer, removal of androgens by castration or anti-
androgen treatment results in a marked regression of the cancer, although such
regression is usually only transitory and in the majority of cases there is a recurrence of
cancerous growth; the tumour now no longer responding to endocrine therapy,
possibly as a result of a progression of androgen-independent cells. The processes
concerned in the regulation of the maturation of the prostate gland and its growth must
be complex, requiring a fine balance of growth stimulatory and inhibitory factors.
Minor changes in this balance would allow the activation of cellular oncogenes and
consequently prostatic cancer.
Despite intensive investigations there is at present little evidence to indicate that
initiation of neoplasia, the progress of metastasis, or the aetiology of the disease is
caused by excessive androgen stimulation, although the disease is generally androgen-
dependent.
1.3.2 PROLACTIN, GROWTH HORMONE AND THE PROSTATE
Early experimental studies in animals showed that pituitary hormones influenced
the growth of the prostate gland. Their actions were generally considered permissive
in that they acted with steroids to promote their biological effects (Huggins & Russell,
1946; Lostroh & Li, 1957; Tullner, 1963). Since these early findings evidence has
accumulated to suggest that prolactin has a specific role in the control of prostatic
function. Several studies have indicated that the presence of prolactin increased the
uptake of testosterone into prostatic tissue (Lasnitzki, 1972; Lloyd et al., 1973; Jacobi
etal., 1978; Famsworth 1981). Furthermore, Odoma etal. (1985) demonstrated a
positive correlation between plasma prolactin levels and cytosolic androgen receptor
content in patients with BPH, which complemented the earlier studies of Jacobi et al.
(1978) and Farnsworth (1981). Synergistic effects of prolactin and androgens were
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also observed on the growth of prostatic epithelial cells in culture (Syms et al., 1985),
further indicating a relationship between the roles of these hormones in regulating the
biology of the prostate. The exact mechanism responsible for these modulatory effects
remains far from being understood, but as Odoma et al. (1985) suggested, it is not
inconceivable that prolactin receptors present on human prostate membranes (Leake et
al., 1983) might facilitate the entry of androgens into the prostate cell.
Equally interesting is the role played by growth hormone (GH) in the prostate.
Immunocytochemical procedures have detected endogenous human GH in BPH and
neoplastic lesions (El Etreby & Mahrous, 1979). Furthermore in a study by Sibley et
al. (1984) they found that the gland demonstrated a capacity to bind exogenous levels
of the peptide. The binding of GH was primarily confined to the stroma in both
benign and malignant tissue, although evidence was obtained which suggested binding
within the cytoplasm of epithelial cells. Although receptors for GH have been located
in the prostate, the role of GH in BPH and prostatic cancer remains to be ascertained.
1.3.3 ANDROGENS, POLYPEPTIDE GROWTH FACTORS AND THE
STROMAL, EPITHELIAL RELATIONSHIP OF THE PROSTATE
Since 1941, when Huggins and Hodges first demonstrated the regulatory role of
the testes, and testicular androgens in the progression of prostate cancer, the principle
goal in the treatment of the disease has been to suppress the androgenic stimulation of
prostatic growth and function. However, this approach does not take into account the
intra-glandular growth control mechanisms and the "growth factors" derived from this
"micro-environment" within the prostate.
It has been known for several years that the prostate is composed of both epithelial
and stromal elements. An understanding of the relationship between the two major
prostatic cell types is crucial if we are to understand the biochemical factors involved in
growth of the normal and malignant prostate. For many years the stroma was
considered an inactive matrix and the functional activity attributed to the epithelium.
However, several groups have shown the stroma to be important in the control of
8
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prostatic growth and development. Franks et al. (1970) separated the epithelial and
stromal components from BPH tissues and found that the growth of the epithelium in
culture was dependent upon the presence of stromal elements. Moreover, Cunha
(1973) demonstrated the interaction between these two cell types using embryonic
mouse tissues, where he demonstrated that the normal development of the urogenital
sinus epithelium was dependent upon the urogenital mesenchyme (stroma). These
studies imply an influence of factors derived from connective tissue. Subsequent
studies showed that the levels of androgen receptor (Lahtonen et al., 1982), oestrogen
receptor (Krieg et al., 1981), steroid metabolizing enzymes (Orlowski et al., 1983) and
steroids (Bartsch et al., 1982) are not the same in the two cell types. Several
investigators have since suggested that the major target for androgen stimulation in the
prostate may be the mesenchyme and not the epithelial cells (Shannon & Cunha, 1984;
Cunha et al., 1987). Furthermore, McKeehan et al. (1984) and Chaproniere &
McKeehan (1986) observed that proliferation of rat and human prostatic epithelial cells
in culture was not androgen dependent. These observations suggest that androgens are
not directly involved in the proliferation and differentiation of prostatic epithelial cells
and that prostatic stroma plays an important role both structurally and biochemically in
maintaining the normal function of the organ. In addition to recognizing the
differences between the stromal and epithelial cells in the prostate, it is important to
recognize that the epithelial cells themselves cannot be treated as a homogeneous group
of cells. Cunha and co-workers (1985) further demonstrated that after adult mice are
castrated the regression of the prostate does not occur uniformally throughout the
gland. The cells in the distal region of the ductal-acinar network are lost well before
those in the more proximal portion of the gland. On injection of testosterone the
number of branch points are restored to normal, demonstrating that the regeneration of




These findings suggest that the mechanism of action of androgens on the prostate
must be expanded to take into account the interactions between the stromal and
epithelial cells which clearly act in concert to ensure the normal development and
function of the prostate. The interaction of certain local tissue 'factors' or growth
factors that are produced in an androgen-dependent manner must also be considered in
the overall regulatory processes involved in prostatic function.
1.3.4. POLYPEPTIDE GROWTH FACTORS
Prostatic epithelial cells have been the focus of attention because not only are they
the target for androgens, oestrogens and progestins, by virtue of their receptors but
they may also be influenced by peptide growth factors and undefined factors secreted
from the surrounding stroma. There is now growing evidence that chemical signalling
in the form of soluble growth factors are involved in maintaining cell to cell
communication and phenotypic expression in the prostate. In support of this
hypothesis are observations of stromal regulation of epithelial differentiation,
demonstrated during the development of the prostate and of other glandular structures
in the foetus (Cunha, 1972; Cunha et al., 1980). Many studies have sought to identify
and characterize these diffusible factors derived from prostatic tissue (Jacobs &
Lawson, 1980; Story et al., 1983; Elson et al., 1984; Jinno et al., 1986).
Mode of action of growth factors
Growth factors may be defined as polypeptides that stimulate cell proliferation
through binding to specific high affinity cell membrane receptors. The receptors are
located on the cell membrane and are usually glycoproteins which communicate with
secondary messenger systems by conformational changes. This often involves the
autophosphorylation of tyrosine residues located on the intracellular domain of the
receptor. The secondary messenger systems utilized are diverse and include changes
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metabolites. For many, but not all growth factors this is followed by DNA synthesis
and cell replication (Hill, 1989 for review).
Those peptide growth factors that have been best characterized are typically
proteins of molecular weight < 30 000. Growth factors do not usually act in an
endocrine manner, the concensus of opinion is that they diffuse over a short distance
through intercellular spaces and act locally, in a paracrine manner (James & Bradshaw,
1984); both endocrine and paracrine mechanisms of action are illustrated in Figure 3.
While classical hormones such as GH and ACTH can influence the overall rate of
growth and maturation, unlike growth factors they do not contribute to the intracellular
signalling within tissues. Although this form of signalling appears to be the primary
role of polypeptide growth factors, growth factors have been identified in plasma and
may act as hormones as well. Those present in serum are presumed to be derived from
platelets and are released during the clotting process (Holley & Kiernan, 1974; Vogel
et al., 1978; Childs et al., 1982; Oka & Orth, 1983). Unlike classical endocrine
hormones each growth factor may be synthesized by a variety of tissues (both adult
and embryonic), and are thought to be released by many, if not all cells in culture
(Shields, 1978). Growth factors are not stored intracellularly in granules unlike
classical hormones such as insulin, and release is largely dependent on de-novo
synthesis.
Growth factors and the prostate
The first investigations with regard to the role of growth factors in the growth and
regulation of the prostate gland was centred on the detection of EGF and its' receptor.
Hirata & Orth (1979) were the first to demonstrate the presence of EGF in the human
prostate using a radioimmunoassay, subsequently Elson et al. (1984) described an
endogenous EGF-like activity in human prostate and seminal plasma, and high




concentrations of EGF have been reported in human prostatic fluid (Gregory et al.,
1986). Subsequent studies also suggest that EGF is associated with human BPH
(Maddy et al., 1987,1989) and prostatic cancer (Eaton et al., 1988; Schuurmans et al.,
1988; Connelly & Rose, 1989; Maddy et al., 1989; Wilding et al., 1989).
In view of the involvement of growth factors in maintaining the functional integrity
of the prostate gland, attempts have been made to identify the mechanisms by which
these growth factors, in particular EGF, act on the prostate. Like other cell types
(Carpenter & Cohen, 1979) the activities of EGF in the human prostate is mediated
through receptors located on the cell surface membrane (Maddy et al., 1987; Eaton et
al., 1988). The receptors are confined to the basal layers of epithelial cells with no
apparent binding in the stromal component. Furthermore, Maddy et al. (1989) found
that prostate cancer tissue had a reduced capacity to bind EGF when compared to
benign tissue, with the depletion in the number of binding sites correlating with the
loss of differentiation of the tumour. The depletion of EGF receptor binding sites may
reflect a down regulation of receptors by the production of endogenous growth factor,
although this remains to be ascertained.
Growth factors other than EGF are also associated with the prostate. Maehama et
al. (1986) characterized a growth factor derived from rat ventral prostate. This rat
prostate-derived growth factor (PrDGF) was distinct biologically from other known
growth factors such as EGF, fibroblast growth factor (FGF), transforming growth
factor a (TGFa) and transforming growth factor [3 (TGF(3) however, PrDGF has
some biochemical similarities to TGF(3. Jacobs et al. (1979) and Jacobs & Lawson,
1980) reported on the presence of a fibroblast growth-promoting factor in crude
extracts of human BPH, well differentiated carcinoma, and postpubertal normal
prostate. This growth factor was distinct from EGF and TGFa in that it did not
compete for the EGF receptor (Story et al., 1983) and it was also distinct from FGF in
that the components were acidic and not basic (Jinno et al., 1986). Additionally, Nishi
and co-workers (1985) purified a growth factor from cytosol preparations of human
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benign adenoma which was capable of stimulating DNA synthesis of BALB/3T3 cells.
This growth factor differed from bovine FGF and EGF.
Growth factors derived from the prostate might be associated with metastatic
disease. A large percentage of patients with prostatic cancer develop bone metastasis
and these osteoblastic lesions may be the result of growth factors produced by the
tumour cells. Indeed several investigators have isolated factors from prostatic
adenocarcinoma (Jacobs et al., 1980) and from carcinoma cell lines (Simpson et al.,
1985) which stimulate osteoblast proliferation. Simpson et al., (1985) identified a
mRNA fraction from PC3 cells which encoded an osteoblast-stimulating activity.
The control of prostatic growth is not just determined by androgens alone but by a
multiplicity of different factors. It is clear that not one, but several, growth factors
may be involved in the development of BPH and prostatic cancer. This supports the
k
hypothesis, forwarded by Sporn & Roberts (1988), that combinations of growth
factors increases the amount of information that can be transmitted.
Growth factors and androgens
The relationship between steroids and growth factors in the prostate is intriguing
and has prompted a number of investigations to elucidate the mechanisms by which
growth factors and androgens might modulate growth of the normal and malignant
prostate (Traish & Wotiz, 1987; St-Arnaud et al., 1988; Schuurmans et al., 1988a;
Wilding et al., 1989). In other model systems there is evidence for steroid-hormone
regulation of growth factor content and activity (Byyny et al., 1974; Hosoi et al.,
1981; Mukku & Stancel, 1985; Dickson etal., 1986; Murphy et al., 1986). In breast
cancer Lippman etal. (1986; 1987) have studied in detail the actions of oestrogens and
growth factors, and how they might act together to regulate cell proliferation. There
are several ways in which androgens co-operating with growth factors could regulate




(i) androgens may affect the production of growth factors; this mechanism has
been well documented for oestrogen action in breast cancer, where oestrogens regulate
the production of growth factors in hormone-responsive breast cancer cells (Dickson et
al., 1986).
(ii) Steroid hormones might also suppress the secretion of inhibitory growth
factors; oestrogens have been shown to suppress the secretion of TGF(5 in MCF 7
breast cells thereby increasing the growth of these cells by oestrogen stimulation
(Knabbe et al., 1987).
(iii) Androgens might also modulate growth factor receptor expression, which in
turn may increase the sensitivity to secretory growth factors; progestins have been
shown to modulate EGF receptor levels in breast cancer cell lines (Murphy et al.,
1986).
Of the three mechanisms (for oestrogen modulation of growth factor action in
breast cancer), recent evidence suggests that androgens regulate the production of the
growth factor TGFa (Wilding et al., 1989) and modulate the concentration of EGF
receptors in the androgen-responsive prostate LNCaP cell line (Schuurmans et al.,
1988a; Wilding et al., 1989).
These examples indicate the complex nature and the multiple pathways by which
androgen -sensitive cells might be regulated by steroids. Equally complex is the
progression from endocrine-responsive to -unresponsive prostate cancer. King (1990)
suggested that altered growth factor activity might account for this transition in breast
cancer. Evidence for this, is the clinical observation that steroid hormone-insensitive
breast tumours grow faster and recur earlier than their endocrine- sensitive counterparts
(Clark & McGuire, 1989), and that the EGF receptor is overexpressed in unresponsive
relative to responsive tumours. Moreover, over-expression of the EGF receptor
correlates with an increased rate of recurrence of breast tumours (Harris & Nicholson,
1988). Transition to the unresponsive state was visualised as, in part involving altered




that ras oncogene transfection into MCF-7 oestrogen-responsive breast cancer cells
rendering them oestradioHnsensitive and that TGFa was overproduced (King, 1990)
which confirmed this link. However, paradoxes exist (Liu et al., 1987) and more than
one pathway to insensitivity is not inconceivable. Moreover, the transition to the
oestrogen-unresponsive state in breast cancer might not compare with the situation in
prostate cancer. Nevertheless, there is little doubt that growth factors and their
receptors are important in the progression of cancer, but how is unclear.
1.4 GROWTH FACTORS AND CANCER
Much of the impetus for study of growth factors has come through their probable
role in cancer. Evidence for this role dates from early work showing a decreased
serum requirement for growth of neoplastically transformed cells (Temin, 1966;
Dulbecco, 1970; Paul et al., 1971). Loss of requirement for specific growth factors is
a common finding in many types of cancer cells (Moses et al., 1978; Kaplan et al.,
1982) and could be mediated by (a) the activation of autologous growth factor
synthesis ("autocrine" activation), (b) synthesis of an altered growth factor receptor, or
(c) activation of a post-receptor pathway that bypasses the growth factor requirement.
1.4.1 EVIDENCE FOR THE AUTOCRINE HYPOTHESIS
The concept of autocrine secretion of growth factors was first conceived by Sporn
& Roberts (1985) in the search for the molecular and cellular basis of malignant
transformation. There is now much circumstantial and direct evidence to support the
original hypothesis of autocrine secretion. Many types of tumour cells release
polypeptide growth factors into their conditioned medium (CM) when grown in cell
culture and these same tumour cells often possess functional receptors for the secreted
peptide (Figure 4).
FIGURE 4 : Schematic illustration of the autocrine mechanism of action of growth factors proposed
by Spom & Roberts (1985).
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The peptide growth factors that function via an autocrine mechanism in cancer
cells include TGFa, peptides related to platelet-derived growth factor (PDGF),
bombesin and TGF(3. The action of each of these four peptides is mediated by a
distinct membrane receptor, which in turn activates a post-receptor signalling
mechanism and leads eventually to a primary alteration in the synthesis and release of a
specific growth factor.
The autocrine action of a growth factor in a cancer cell was first described in rodent
cells transformed by a Moloney murine sarcoma virus (De Larco & Todaro, 1978).
The first peptides identified as participating in this transformation were structurally
related to (but distinct from) EGF, and are now universally known as type a TGFs
(Roberts et al., 1983). The only known receptor for these peptides is the EGF
receptor and all of their effects (such as growth stimulation) are thought to be mediated
through this locus. Many data indicate that human cancer cells produce and release
TGFa and have functional receptors for this peptide (De Larco & Todaro, 1978;
Ozanne et al., 1980; Todaro et al., 1980; Kaplan et al., 1982; Marquardt & Todaro,
1982; Halper & Moses, 1983; Roberts et al., 1983; Moses, 1984; Salomon et al.,
1984a, 1986; Dickson et al., 1986), which suggests that these cells will be
continuously activated to grow. Other growth factors produced by transformed cells
such as insulin-like growth factor (IGF) (Dulak & Temin, 1973; De Larco & Todaro,
1978) and fibroblast-derived growth factor (Burk, 1976) may also act as autocrine
regulators of proliferation.
The experimental data providing the most evidence for the autocrine hypothesis
comes from the relationship of the oncogene product of the simian sarcoma virus
(SSV) and PDGF; homologies exist between the c-sis product and the B-chain of
PDGF (Doolittle et al., 1983; Waterfield et al., 1983). SSV product can also function
like PDGF as a growth factor for cells in culture (Deuel & Huang, 1983). The PDGF-
like molecules produced by tumour cells seem to be encoded by cellular genes.
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The signalling pathways activated by an autocrine peptide need not evoke a positive
growth response, as seen most strikingly in the response of cells to TGF(3. Although
this peptide was initially characterized by its ability to stimulate the growth of non¬
neoplastic fibroblasts as colonies in soft agar (Roberts et al., 1983), it has been shown
to be a potent inhibitor of the growth of many other types of cells (Holley et al., 1980;
Tucker et al., 1984). These cells have receptors for TGF(3 and respond with an
inhibition of growth suggesting that in certain cells endogenous TGFfi plays a role in
cell-cycle regulation, specifically in the maintenance of a resting state.
The autocrine hypothesis may be expanded to include the concept that malignant
transformation may be the result not only of excessive production, expression and
action of positive autocrine growth factors, but also of the inability of cells to
synthesize, express or respond to specific negative growth factors they normally
release to control their growth. This loss of negative growth control may result in a
biochemical lesion in either the growth inhibitor, its receptor, or the post-receptor
signalling pathway (Sporn & Roberts, 1985).
1.4.2 ONCOGENE PRODUCTS AS RECEPTORS
Some of the more convincing evidence linking growth factors and cancer has come
from recent work linking oncogenes and growth factor receptors. The oncogenes erb
B,fms and neu are known to encode cell-surface proteins. Cells transformed by these
oncogenes seem to have obtained a growth advantage by mimicking mechanisms of
normal cellular growth. However, in these transformed cells the normal system of
regulation is evaded and the growth advantage is achieved by the cells' growth
autonomy.
The erb B oncogene product bears close similarity to the EGF receptor (EGFR)
(Downward et al., 1984), (see also section 1.5.3). The erb B gene encodes the
transforming protein of avian erythroblastosis virus (AEV) (Yamamoto et al., 1983).
Comparison of the \-erb B protein with the human EGFR shows a large degree of
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homology, the \-erb B product representing a truncated form of the EGFR. \-erb B
encodes the cytoplasmic and transmembrane domains of the EGFR, but lacks the
greater part of the EGF-binding region by which normal growth is regulated
(Downward et al., 1984). The v-erb B protein has been found to induce tyrosine (Tyr)
phosphorylation (the cytoplasmic region of EGFR contains a Tyr kinase domain; see
section 1.5.2) in vivo and in vitro. In addition it contains sequences homologous to
the kinase domain of the EGFR and corresponding regions of retroviral kinases
(Gilmore et al., 1985), suggesting that the unregulated kinase activity may be
responsible for transformation. Thus, the structure of the v-erb B product, consisting
of transmembrane and cytoplasmic, but not ligand binding domains, allows for an
unregulated mitogenic signal.
Similarly, the product of the v-fms oncogene encodes a protein exhibiting
receptor characteristics (Sherr et al., 1985). The v-fms protein product is a
transmembrane glycoprotein with the amino-terminal domain oriented outside the cells
and the carboxy-terminal region in the cytoplasm (Rettenmier et al., 1985). It has been
shown that the v-fms products are expressed on the cell surface and are associated with
clathrin, clathrin-coated pits, and endocytotic vesicles (Marger et al., 1984);
characteristics typical of receptor molecules. Common to growth-related receptors, v-
fms displays in vitro phosphorylation of the glycoprotein at Tyr (Roussel et al., 1984;
Barbacid & Lauver, 1981). It was shown by Roussel and co-workers (1984) that cell
surface expression of the Tyr kinase activity was necessary for v-fms transformation.
The cellular counterpart of the transforming/m5 gene seems to be the receptor for the
murine colony-stimulating factor, CSF-1 (Sherr et al., 1985). The v-fms gene
encodes an altered CSF-1 R, however the mechanism of the subsequent transformation
remains unclear.
In contrast to the two previously mentioned virus-induced oncogenes, v-fms and
v-erb B, the neu oncogene results from a chemically induced mutagenesis. A
phosphoprotein was found to be specifically associated with the neu transforming
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sequence (Padhy et al., 1982), which is required to maintain the neu -induced
transformation (Drebin et al., 1984). Homology between erb B and neu was found
using Southern blot hybridization (Drebin et al., 1985), although related, erb B and
neu are distinct genes, mapping to different human chromosomes (Schechter et al.,
1985). Nucleotide sequence analysis strongly supports the possibility that neu
encodes a receptor like molecule, the predicted product is a transmembrane protein
with a structure similar to EGFR (Bargmann et al., 1986). There is 50% overall
homology between EGFR and neu products with greater than 80% amino acid identity
in the Tyr kinase domain. The sequence shows a hydrophobic signal sequence at the
amino terminus (which is associated with membrane bound molecules) followed by an
extracellular domain. The extracellular domain has two cysteine-rich areas, which are
highly conserved in relation to both the insulin receptor and EGFR. The cytoplasmic
region shows a high degree of homology with EGFR (82%), with neu Tyr residues in
the same positions as EGFR phosphotyrosine sites. Additionally, there is a threonine
(Thr) residue that may serve as a site for negative regulation of receptor expression
(Bargmann et al., 1986).
The nontransforming neu gene (the protooncogene) encodes a receptor for a factor
involved in growth regulation, however the ligand for the cell-surface protein is as yet
unidentified.
The isolation and subsequent characterization of oncogenes have linked their
mechanisms of transformation with various aspects of growth factor activation. It
seems that some oncogenes obtain their growth advantage by conferring growth factor
independence on the transformed cells. This is possible at a number of points in the
normal mitogenic pathway; the growth factor, its transmembrane receptor and
intracellular signalling mechanisms. Oncogenes affecting each level are known
(Heldin & Westermark, 1984; Sporn & Roberts 1985). Activation (that is the
alteration of DNA sequence resulting in RNA expression of proto-oncogenes to
"cancer genes") can occur via point mutations, amplification at the gene level, over-
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expression at the RNA or protein level or chromosomal translocations or
rearrangements (Cooper, 1982; Bishop, 1983; Duesberg, 1985; Klein & Klein, 1985).
Examples of each type have been found in diverse systems, for example the
epidermoid carcinoma cell line A-431 cells possess an amplified EGF receptor DNA
sequence whose transcription produces an abundant and aberrant message which codes
for the external portion of the receptor but lacks the transmembrane and cytoplasmic
portions (Ullrich et ai, 1984). A suggested mechanism of transformation is that the
continual binding of EGF to the aberrant receptor, without the regulatory processes
imposed by the transmembrane and cytoplasmic domains, would result in unregulated
growth (Sporn & Roberts 1985). Characterization of oncogenic evasion of growth
regulation and an understanding of the developmental conditions under which these
ligands function may help in the clarification of both carcinogenic and normal receptor-
mediated mitogenesis.
1.5. EPIDERMAL GROWTH FACTOR
Since it became clear that the proliferation of cells in vivo and in vitro is controlled
by hormones and growth factors, several growth factors have since been isolated and
purified. One of the most characterized, EGF was first described by Cohen in 1962 as
a peptide which would stimulate precocious eyelid opening and tooth eruption in
newborn mice. Since then it has been realized that EGF may have a potential role in
human disease (Carpenter et ai, 1978).
1.5.1 CHARACTERISTICS OF EGF
EGF was isolated and its amino acid sequence determined (Savage et ai, 1972) a
decade after Cohen (1962) first described the extract from mouse submaxillary gland.
Urogastrone (an inhibitor of gastric acid secretion) which was purified from human
urine, was found to be almost identical to EGF in amino acid sequence and action
(Cohen & Carpenter, 1975; Gregory, 1975). EGFs' ability to stimulate the growth of
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cultured cells was soon recognised (Carpenter & Cohen, 1975; Hollenberg &
Cuatfecasas, 1973). EGF is a single 6 kDa polypeptide chain of 53 amino acids, with
3 internal disulphide bonds (Taylor et al., 1972). EGF is synthesized from a precursor
(prepro EGF) which may be as large as 128 kDa (Gray et al., 1983), and is composed
of 7 EGF-like peptides (Scott et al., 1983). Our understanding of the processing of
the prepro EGF molecule is still very limited. In the mouse salivary gland the
precursor molecule is broken down to the 53 amino acid mitogen, which is associated
in the cell with several binding proteins in cytoplasmic granules (Kasselberg et al.,
1985). It is proposed that in other tissues (e.g. kidney) the EGF precursor is
expressed as a transmembrane protein, but there is no indication of biological activity
for the EGF precursor. EGF was originally thought to have a restricted range of tissue
expression, but has now been described from a large variety of tissues (Waterfield,
1989).
EGF is mitogenic for a variety of cultured mesenchymal and epithelial cells. The
mitogenic activity of EGF is strongly potentiated by other hormones such as insulin
and IGF-1 (Rose et al., 1975; Shipley et al., 1984; Hiraki et al., 1987), and it also acts
in synergism with PDGF (Leof et al., 1983). Aspects of differentiation are also
induced following EGF treatment in certain in vitro cell lines and in vivo models (Oka
et al., 1983; Weissman & Aaronson, 1983). In addition to its mitogenic effect, EGF
also induces various early and delayed responses in the cell. Early responses include
stimulation of ion and nutrient transport (Hollenberg & Cuatrecasas, 1973),
enhancement of the phosphorylation of endogenous membrane proteins (Carpenter et
al., 1979), induction of specific changes in the organization of the cytoskeleton
(Schlessinger & Geiger, 1981) and changes in cell morphology (Chinkers et al.,
1979). Delayed responses include the activation of the enzyme ornithine
decarboxylase (Stastny & Cohen, 1972) and enhancement of the biosynthesis of






growth factors, EGF induces a variety of cellular responses, the so called "pleiotropic
response".
1.5.2 EGF RECEPTOR
Specific receptors in the cell membrane of target cells interact with EGF to initiate
and maintain a complex series of biochemical and morphological events leading to cell
growth (Carpenter et al., 1975; Das etal., 1977; Carpenter & Cohen, 1978). The
EGF receptor was first purified from A-431 cells, a cell line which has an unusually
high number of receptors for EGF (Fabricant et al., 1977; Cohen et al., 1982.,
Kawamoto et al., 1983). In the initial studies, the purified receptor had an apparent
molecular weight of 150 kDa; but subsequent purification methods that eliminated
calcium from the assay buffers indicated that the actual size of the receptor was 175
kDa (Cohen et al., 1982). Further characterization demonstrated that the receptor is an
integral membrane protein exhibiting an extracellular binding domain that serves to
bind the ligand EGF, and other EGF-like molecules, a transmembrane region and
intracellular domain. A schematic diagram of the EGF receptor is shown in Figure 5.
The extracellular domain of the EGF receptor which accommodates high affinity
binding is characterized by two structural features: a high cysteine content
(approximately 10%) dispersed in two clusters and a relatively large number of
canonical sequences for A -linked glycosylation. The extracellular cysteine residues
are more likely to occur in the form of disulphide bonds. The ligand binding domain
of the EGF receptor is also characterized by a relatively high level of A-linked
carbohydrate (Soderquist & Carpenter, 1984).
FIGURE 5: A schematic illustration of the EGF receptor showing the extracellular,
transmembrane and cytoplasmic domains. Indicated are amino (N) and carboxy (C) terminal ends of
the receptor polypeptide chain, potential binding sites for the ligand ATP and endogenous substrates.
Cysteine residues (open circles) that may play a role in forming the ligand binding pocket and tyrosine
residues (filled circles) involved in receptor function are emphasized (after Yarden & Ullrich, 1988).
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The cytoplasmic portion of the EGF receptor has been intensively studied since the
Tyr kinase activity (that is encoded in this region of the molecule) was considered to be
the primary effector system in the transmembrane signalling process. Tyr kinase
activity is present in several other growth factor receptors and in several oncogene
products (Anzano et al., 1982). There is a large region in the cytoplasmic domain that
shares sequence homology with other members of the Tyr kinase family (the src kinase
of the Rous sarcoma virus). This region, considered to constitute the catalytic domain
(Tyr kinases) of the receptor, contains the binding site for ATP.
Immediately after the membrane-spanning domain of the EGF receptor, at the
cytoplasmic interface, is a 13-residue sequence which is highly enriched in basic amino
acids. This sequence probably functions as a "stop transfer" sequence following the
insertion of the amino-terminal portion of the EGF receptor polypeptide chain into the
lumen of the endoplasmic reticulum. It is a common feature of other growth factor
receptors and is probably important for the correct translation and membrane insertion
of the receptor. This region of the EGF receptor also contains a Thr residue, which
has been shown to be a target for protein kinase C phosphorylation (Hunter et al.,
1984; Davis & Czech, 1985) and may therefore play a role in signal modulation.
The catalytic portions of the EGF receptor contains an ATP binding site and a
carboxy-terminal region that includes the Tyr kinase domain. Proteolysis experiments
suggest that a hinge region separates the hydrophilic tail from the adjacent Tyr kinase
domain (Gullick et al., 1985; Ek & Heldin, 1986). In response to EGF the receptor is
capable of autophosphorylation on Tyr residues (Dailey etal., 1978; Gill & Lazar,
1981).
EGF receptor function and regulation
The EGF receptor can be viewed as a transmembrane allosteric enzyme, whose
activity is regulated by noncatalytic domains. With the exception of haemopoietic
cells, nearly all cell types have been reported to display some level of EGF binding
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capacity (Carpenter & Cohen, 1979). Human fibroblasts have between 40 000 and
100 000 specific EGF receptors per cell, while the human epidermoid carcinoma cell
line A-431 has over 3 million receptor sites per cell. It is not clear what role the
expression of such a large number of EGF receptors plays, however over expression
of the EGF receptor has been reported for a substantial number of carcinoma cell lines
and tissues (Inman & Carpenter, 1986).
The initiation of cellular responses by EGF is a direct result of the growth factor
binding to specific membrane receptors. Cells which are exposed to increasing
concentrations of EGF gradually lose a substantial fraction of their receptors for the
respective hormones. This down regulation depends upon ligand concentration, time
and temperature. When the cells are returned to medium free of ligand, the number of
receptors returns to normal within 8-16 hours (Carpenter & Cohen, 1976).
Quantitative binding experiments with radiolabeled EGF indicate that the
stoichiometry of ligand binding to the EGF receptor is 1:1 (Weber et al., 1984). EGF
binding sites appear to be functionally heterogeneous with different receptor classes,
that have distinct affinities toward EGF. High affinity EGF receptors with an apparent
IQ of 1-3 x 10"10M comprise 5-10% of the total receptors, whilst the remaining low
affinity receptors have an apparent IQ of 2-15 x 1(V9M (King & Cuatrecasas, 1982;
Kawamoto et al., 1983; Schlessinger, 1988). However, the occurrence of two classes
of EGF binding site is not a uniform finding, and the interpretation of more than one
binding site may well be due to difficulties in analysing binding data. Scatchard
analysis, which is usually employed for the analysis of binding data is not ideal as it
unevenly "weights" the lowest ligand concentrations. This makes interpretation of
binding data difficult, and is prone to error when more than one binding site is
predicted (Bennett & Yamamura, 1985).
After the growth factor binds to the receptor, the receptors aggregate and become
localized into coated pit regions on the cell surface (Gorden et al., 1978). It is not
known whether the process of microaggregation may be a relevant mechanism for the
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induction of the mitogenic activity of EGF (Schlessinger, 1980; Shechter et al., 1978;
Schlessinger, 1979), nor is it clear whether internalization of aggregated EGF-receptor
complexes is required for the biological activities of the growth factor. Following
internalization, the clustered EGF-receptor complexes pinch off by an energy-
dependent process and form coated (and non-coated) vesicles. The endocytic vesicles
are processed inside the cells and EGF is degraded by lysosomal enzymes, although in
some cases the internalized receptors appear to be recycled to the cell surface with the
gradual release of recycled ligand into the medium (Teslenko et al., 1987).
The binding of the growth factor to its receptor induces a conformational change in
the receptor molecule. This conformational change enhances the activity of the protein
kinase, causing a rapid phosphorylation of several cellular proteins, including the
receptor itself (Carpenter et al., 1978; King et al., 1980; Cooper et al., 1982; Gates &
King, 1982; Sawyer & Cohen, 1985). Both ATP and GTP can act as the phosphate
donor of the phosphorylation reaction and either Mn2+ or Mg2+ is required for optimal
activity of the protein kinase (King et al., 1980). The majority of EGF receptor
autophosphorylation sites are located at the carboxy-terminus, with the major site being
just 13 residues from the end of the molecule (Downward et al., 1984). It is generally
believed that Tyr phosphorylation is the major signalling event directed by the EGF
receptor. The fact that other growth factor receptors and a large number of oncogene
products demonstrate Tyr kinase activity strengthens the argument that Tyr kinases
have a principal role in growth factor regulated activities. Activation of Tyr kinase
activity and autophosphorylation are believed to represent the primary molecular events
initiating the transmission of the mitogenic signal inside the cell, because receptor
mutants devoid of kinase activity are defective in the transduction of the mitogenic
effect of EGF (Livneh et al., 1986). Phosphorylation of the EGF receptor by protein
kinase C, specifically on Thr-654, results in a direct reduction of the EGF receptors'
affinity for its' ligand and diminishes the autophosphorylation activity of the receptor
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(Hunter & Cooper, 1985). The mechanism(s) by which these modulations occur is
not clear.
EGF receptor transmodulation by heterologous ligands
The EGF receptor is envisaged as an "allosteric" protein where various ligands
(allosteric regulators) can bind at various functional sites on the molecule and modulate
the binding and response to EGF. The ligand binding affinity and the protein Tyr
kinase activity of the EGF receptor can be regulated by the phorbol ester myristate
acetate (PMA) or by growth factors such as bombesin or PDGF, which bind to
specific receptors (Schlessinger, 1986). Both PMA and PDGF induce
phosphorylation of Thr-654 of the EGF receptor by activating the Ca2+-dependent
protein kinase C. It was suggested that the phosphorylation state of this residue may
play a role in receptor transmodulation (Hunter & Cooper, 1985; Schlessinger, 1986).
Indeed, by the use of receptor mutants it was established that phosphorylation of Thr-
654 by protein kinase C and protein kinase C-independent mechanisms (Friedman &
Rosner, 1987) operates as a negative control mechanism for EGF induced
mitogenesis, by reducing the affinity of the receptor for its ligand and diminishing the
autophosphorylation activity of the receptor (Hunter & Cooper, 1985).
1.5.3 THE TRUNCATED EGF RECEPTOR
The \-erb B oncogene of AEV which encodes for the truncated EGF receptor is
described in section 1.4.2. This truncated receptor, which is devoid of most of the
extracellular ligand binding region and 13 amino acids from the C-terminus may act as
a constitutively active EGF receptor (Downward et al., 1984a; Ullrich et al., 1984;
Kris et al., 1985). However, Riedel et al. (1987) have shown that a chimeric receptor
composed of the extracellular and transmembrane regions of the human EGF receptor
attached to the cytoplasmic region of avian \-erb B was still able to transform cultured
rat-1 cells. Moreover, the binding of EGF to the chimeric receptor augmented its'
transforming activity. This suggests that, in addition to the extracellular and C-
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terminal deletions in v-erb B, structural differences between \-erb B and the
cytoplasmic region of the EGF receptor may be major factors influencing the
transforming potential of v-erb B (Riedel et al., 1987).
1.5.4 TRANSFORMING GROWTH FACTOR a
The EGF receptor serves as the binding site not only for EGF but also for other
polypeptide growth factors. The most interesting in terms of their association with the
transformed state are the transforming growth factors, alpha and beta (TGFa &
TGFp). TGFs were first identified by Todaro and co workers in 1976 when they
observed that cells transformed by murine sarcoma viruses had reduced or absent cell
surface receptors, when compared to the untransformed counterparts or with cells
transformed by other viruses. It was subsequently shown that sarcoma virus
transformed cells produced a family of polypeptide growth factors which bound to the
EGF receptor and induced cell proliferation. In addition to the mitogenic properties,
the sarcoma growth factor (SGF) as it was then called, induced normal fibroblasts to
grow in soft agar and to express phenotypic properties of transformed cells. SGF was
subsequently found to consist of both TGFa and TGFp, with the binding of the EGF
receptor solely due to TGFa, and morphological changes of the fibroblasts being due
to the co-operative effect of TGFa and (3. As outlined in section 1.4.1, TGFs have
been implicated in the autocrine growth of tumour cells (Sporn & Roberts, 1985) and
were shown to be produced by different human tumour lines (DeLarco & Todaro,
1978; Ozanne et al., 1980; Roberts et al., 1980; Sporn & Todaro, 1980; Todaro et al.,
1980; Kaplan et al., 1982; Marquardt & Todaro, 1982; Halper & Moses, 1983;
Roberts et al., 1983; Moses, 1984; Salomon et al., 1984a, 1986; Dickson et al.,
1986). Moreover, similar TGFs were detected in mouse embryos (Proper & Moses,
1981) and foetal calf serum (Bjoroson & Moses, 1980). The TGFas from these
sources were isolated and were found to have the following properties; (i) their
molecular weights range from 5 kDa to 24 kDa, (ii) they are heat stable polypeptides
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containing disulphide bonds, (iii) they compete for binding with [125I]-EGF for the
EGF receptor, and (iv) they induce DNA synthesis and colony formation in soft agar.
TGFa is a Mr 5600 single chain polypeptide with 3 intrachain disulphide bonds.
It shares 30-35% sequence homology with human and mouse EGF (Marquardt et al.,
1984) and competes with [125I]-EGF for binding to the EGF receptor (Pike et al.,
1982; Massague, 1983). TGFas and EGF show a variety of biological actions similar
to EGF, indeed their biological activities when assayed in cell culture systems are
almost identical (Bascom et al., 1989), although in some cases TGFas are more potent
than EGF (Stern et al., 1985; Ibbotson et al., 1986).
The secretion of biologically active TGFa occurs via a membrane-associated
intermediate (Bringman et al., 1987; Teixido et al., 1987). The 50 amino acid form of
TGFa is derived from a 160 amino acid precursor which is anchored to the cell surface
via its C-terminus. As well as the 50 amino acid TGFa mitogen, higher molecular
weight forms are released from the N-glycosylated 160 amino acid precursor. No
biological activity has been attributed to the surface associated TGFa precursor, but
unprocessed membrane bound TGFa could still be available for interaction with the
EGF receptor, thus permitting a role for TGFa in direct cell-to-cell signalling
processes.
The presence of transforming growth factors in mouse embryos and in foetal calf
serum suggest that both foetal development and neoplastic transformation may be
affected by similar growth factors (Sporn & Todaro, 1980). Sporn & Todaro (1980)
suggested that malignant transformation may result from the inappropriate expression
of growth factors which are required in normal early embryogenesis. Nevertheless,
the precise role of TGFa in neoplasia remains uncertain as recent evidence suggests
that TGFa production occurs in normal adult epithelial cells that are responsive to the
growth factor, suggesting the possibility of normal autocrine regulation of cell
proliferation (Bascom et al., 1989).
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EGF itself is capable of inducing certain aspects of the transformed phenotype
(Carpenter et al., 1979). It has been shown to enhance both the incidence of
transformation of granulosa cells by Kirsten sarcoma virus (Harrison & Auersperg,
1981) and the carcinogenic effect of skin tumours in mice, the latter by chemical
induction (Rose et al., 1976).
1.5.5 EGF RECEPTOR LEVELS IN CANCER CELLS
Many workers have sought to correlate the level of EGF receptors to cancer,
although the results of such studies have failed to reveal a simple correlation between
the two. In some cases EGF receptor levels are higher in malignant as compared to
normal tissues; e.g. several different squamous cell lung carcinomas express high
concentrations of EGF receptor levels compared to the normal lung. In contrast, other
lung carcinomas have undetectable EGF receptor levels (Todaro et al., 1976; Hirata et
al., 1983; Hendler & Ozanne, 1984). Similarly, increased levels of EGF receptors are
found in some breast cancer cells as compared to normal cells, whilst in others the
levels of EGF receptors are reduced (Fitzpatrick et al., 1984).
EGF receptor concentration appears to vary according to the cell type and the stage
of differentiation of the tumour. Poorly differentiated bladder and breast tumours
express higher levels of EGF receptors (Neal etal., 1985; Sainsbury et al., 1985) than
other histological grades of the cancer. In the case of prostatic tumours, EGF receptor
levels are highest in well differentiated tumours and undetectable in those which are
poorly differentiated (Maddy et al., 1989).
It is clear from the above studies that EGF receptor levels may be decreased,
increased, or not changed in cancer cells as compared to their normal counterparts.




1.6 MODEL SYSTEMS FOR THE STUDY OF PROSTATE
CANCER
Our understanding of cancer has been enhanced by the use of both in vivo and in
vitro model systems. The ideal model would reproduce the pathology seen in the
human disease, demonstrate metastasis, be capable of reproducible replication, be
sensitive to hormonal manipulation and be amenable to quantitative analysis. With the
multiplicity of conditions to be met and the complexity of the natural disease it is easy
to draw erroneous conclusions from an oversimplified model system. It is evident that
some of the above parameters cannot be readily met with one model alone, and
therefore a combined approach, using several model systems is more appropriate.
In several instances normally occurring disease in lower animals have provided
model systems with which significant progress has been made in our understanding of
cancer. However, no animal model system is presently available for the study of
human prostatic neoplasia which satisfies the broad range of requirements listed above.
Spontaneous adenocarcinoma of the prostate has rarely been reported amongst
nonhuman mammals. Of the common laboratory animals, certain strains of aged rats
appear to have the highest instance of spontaneous prostatic tumours, and the
establishment of transplantable tumours offers a useful model system.
The Copenhagen rat Dunning tumour model, a spontaneous tumour found in a
Copenhagen breeder rat (Dunning, 1963), is perhaps the most useful of such animal
models. The tumour has been found to resemble human prostatic cancer in its
histologic appearance, ultrastructure, and most significantly in its' metastatic
capabilities (except that it does not metastasize to the bone). Although there are
difficulties with this model due to variations in the embryology, histology and
biochemistry of the animal prostate, it remains an unquestionably useful model and
provides valuable information on prostatic tumour progression from the initiated cell(s)
to the metastatic progeny. With the exception of the aged rat, spontaneously occurring
30
INTRODUCTION
neoplasms occur with frequency only in man and the dog. Metastases occur amongst
dogs with prostatic carcinoma, while bone metastases are not unusual.
1.6.1 HUMAN PROSTATE TUMOURS IN VITRO AND IN VIVO MODELS
There are several approaches taken for performing in vitro and in vivo studies on
human prostatic carcinomas; namely organ explant cultures, short term primary
cultures and cultures of established cell lines.
Organ culture of the prostate
Organ culture originated as a means for studying the interrelationships between
different types of tissue in the same organ during growth and differentiation with the
maintenance of normal cell interrelationships, but free of the more complex organ
interactions or even tissue interactions common in vivo. There are many advantages to
this model namely: (i) the maintenance of organ architecture plus tissue and cell
relationships; (ii) long term maintenance of epithelial cells; (iii) the possibility to study
mechanisms of growth control and phenotypic expression; (iv) the possibility to study
the direct effects of exposure to hormones and other agents singly and in combination,
in the absence of host homeostatic mechanisms and (v) interactions between epithelial
and fibroblast cells from human prostatic tissues can be studied. However, there are
also limitations to this procedure: (i) heterogeneity of tissue samples; (ii) alteration in
phenotypic expression in one or more cell types; (iii) complications resulting from
infected tissues; (iv) absence of systemic effects; (v) lack of systemic metabolism of a
drug to its active form, and (vi) the tendency toward homogeniety of cell populations
due to degeneration, necrosis or overgrowth (Merchant, 1976; Sandberg &
Kadohama, 1980; Heatfield, 1987).
Primary cultures of the prostate
Short term primary culture comes some way between explant cultures and
established cell lines. Primary culture is a culture started from cells, tissues or organs
taken directly from organisms. The many advantages to this model include: (i) an
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opportunity for studying prostatic cells in a state in which the cell populations are
representative of the tissue of origin; (ii) the investigation of changes in nutritional,
environmental or other factors (Merchant, 1987); (iii) the possibility to study stromal
epithelial interactions and the signalling mechanisms involved between these two cell
types, and (iv) the opportunity to study the direct effects of exposure to hormones and
other agents singly and in combination. However, there are limitations to this
procedure which are similar to those listed for organ culture, namely: (i) alteration in
phenotypic expression in one or more cell types; (ii) complications resulting from
infected tissues; (iii) absence of systemic effects, and (iv) lack of systemic metabolism
of a drug to its active form. Other disadvantages exclusive to this model include: (i)
the difficulty in separating and culturing homogeneous cell populations; (ii) lose of
androgen sensitivity, and (iii) maintenance of viable cultures after sub-culturing (Peehl
et al., 1986).
Prostatic carcinoma cell lines
Human prostatic adenocarcinomas are notoriously difficult to culture in vitro or in
vivo in immunodeficient animals (Lechner et al., 1980; Reid et al., 1981), which may
be due to complex hormonal and nutritional requirements of prostatic cells. As a result
few human prostatic tumour cell lines exist. Table 1 lists the characteristics of five
established human prostatic cell lines reported in the literature (Kaighn et al., 1979;
Stone et al., 1978; Horoszewicz et al., 1983; Ito et al., 1985). Out of the five lines,
four originated from tumours recovered from metastatic sites rather than the primary
prostatic tumour. Furthermore, only two out of five remain androgen-dependent,
although the LNCaP line is androgen sensitive in culture.
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TABLE 1: HUMAN PROSTATIC CARCINOMA CELL LINES
Cell line Origin Hormone- Growth capacity Metastatic
dependent8 in vitro in vivo b capacity c
PC-3 metastasis to bone no yes yes poorly
metastatic
DU 145 metastasis to brain no yes yes not metastatic
LNCaP metastasis to lymph no yes yes not metastatic
node
PC 82 primary yes no yes not metastatic
HONDA metastasis to testicle yes no yes not metastatic
a Hormone-dependence indicates preferential growth in intact male nude mice, as compared with female
or castrated nude mice. Preferential growth may be absolute or represent differences in growth rate.
b In vivo refers to growth in athymic nude mice.
c Metastatic capacity in athymic nude mice.
The apparent inability of these lines to metastasize in athymic mice eliminates the
opportunity to study metastatic capacity. However, sublines of the PC-3 line which
metastasize in nude mice are now available (Kozlowski et al., 1984; Ware et al., 1986;
Ware, 1987). The DU 145 line has remained intractable to most manipulations of the
host, although Kozlowski and co-workers (Kozlowski et al., 1984) reported that
implantation of Silastic tubes of ^-estradiol into nude mice prior to DU 145-injection
increased the incidence of spontaneous or experimental metastasis. Thus far no
consistent metastasis in nude mice has been reported for the other human prostate
tumour cell lines.
The PC-82 in vivo tumour model was the first transplantable human prostatic
cancer in nude mice. It originated from a prostatectomy specimen, which was
histologically classified as a moderately differentiated prostatic adenocarcinoma
(Hoehn et al., 1980). The tumour is androgen-dependent, secretes prostate acid
phosphatase (PAP) and prostate-specific antigen (PSA) and has androgen receptors
(Brinkmann et al., 1987; van Steenbrugge et al., 1988). However, attempts at
establishing PC-82 in vitro have not been successful.
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The PC-3 cell line was isolated from a bone metastasis of an adenocarcinoma of
the prostate (Kaighn et al., 1979). The characteristics such as growth rate,
morphology, karyotype and ultrastructure are consistent with a poorly differentiated
adenocarcinoma. It grows on soft agar and in suspension culture, it does not have any
acid phosphatase activity, nor does it show 5a-reductase activity (Kaighn et al.,
1980). At the same time as the PC-3 was established, the inception of the DU 145 cell
line was reported. This cell line, like PC-3, is also aneuploid and tumorigenic in nude
mice and is similar to PC-3 ultrastructurally.
The DU 145 cell line
This thesis deals with the DU 145 cell line which was derived from a brain
metastasis and was first described by Mickey et al. (1980). The metastasis was
identified as a moderately differentiated adenocarcinoma, with foci of poorly
differentiated cells. The cells are epithelial in appearance and form colonies in soft agar
suspension culture. The cell line DU 145 also forms solid tumours in athymic nude
mice which reveal a strong similarity to the original patient tumour, although in mice
they do not metastasize. Cell line DU 145 is neither hormone-dependent nor hormone-
sensitive as the cells grow equally well in media containing either foetal bovine serum
or bull serum, which differ widely in their basic hormonal constitution. DU 145
reflects a weakly positive staining reaction for PAP by the method of Stonington et al.
(1975) and had a modal chromosome number of 64 at passage 57. It also showed
several marker chromosomes and a Y chromosome.
The cell lines DU 145 and PC-3 allowed for the first time studies on prostatic
adenocarcinoma cell lines of proven prostatic origin that could be cultured indefinitely




The LNCaP cell line
As a comparison with the DU 145 cell line this thesis also deals with the androgen
sensitive LNCaP cell line whose properties are outlined below.
The LNCaP (Lymph Node Carcinoma of the Prostate) cell line was established
from a metastatic supraclavicular lymph node of human prostatic adenocarcinoma
(Horoszewicz et al., 1983). LNCaP cells contain high affinity androgen receptors
which are present in the cytosol and nuclear fractions of cells in culture and tumours.
It is also the only prostatic cell line that shows androgen-responsive, but not dependent
growth in vitro. Furthermore, in vitro, 5a-dihydrotestosterone and androgens
modulate cell growth and stimulate PAP production (Horoszewicz et al., 1983) and the
cells express PSA. The malignant properties of LNCaP cells are maintained since
athymic nude mice develop tumours at the injection site.
From the parental LNCaP line several sublines have developed either
spontaneously or through clonal selection. Among these are the LNCaP-FGC (fast
growing colony) which is similar to its parent line and differs only in growth rate.
Lately from this subline at least two new lines have been developed, the FGC-GJ and
FGC-JB lines, which show androgen responsiveness. The LNO subline which also
originated from the parent cell line, contains high amounts of androgen receptors, but
is nevertheless androgen-independent (van Steenbrugge et al., 1988).
1.7 SERUM-FREE CELL CULTURE
Tumour cells generally have an altered response to growth factors that regulate the
growth of normal cells. In cell culture, this change is reflected by a shaip decrease in
the requirement for serum proteins (Holley & Kiernan, 1971). It is generally accepted
that the growth of virtually all types of cells requires the presence of serum in the
medium. However, as serum is a complex mixture of poorly characterized
components the use of defined medium for cultured cells is advantageous. Several
laboratories have now perfected the use of defined medium using either a stepwise
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reduction of serum, by adjustment of low molecular weight constituents (Ham, 1981)
or by replacement of serum by hormones and growth factors (Barnes & Sato, 1980).
The observation that cell lines (which were clearly hormone-dependent in vivo ) did not
show hormone-dependent growth in vitro unless the serum added to the culture
medium was first depleted of certain hormones, gave rise to the concept of serum
providing a mixture of hormones which were stimulatory for cell growth (Sato et al.,
1975). In other words, hormones present in the untreated serum were stimulatory for
cell growth and were masking the effects of any additional hormones which might be
added. One of the main concerns in replacing serum in cell culture medium has been to
find combinations of supplements which will support growth of the cells at a
reasonable rate, without radically changing the properties of the cell lines. Although
differences in the biochemical properties of some cell lines do exist in the two culture
conditions (serum and serum-free medium), the differentiated functions expressed by
lines in serum-supplemented media are in general also expressed in serum-free,
hormone-supplemented media (Barnes & Sato, 1980).
It would follow by replacing serum in cell culture media by combinations of
hormones, nutrients, binding proteins and attachment factors this would have several
advantages for cell culture methodology. In most cases serum-containing medium is
an unsuitable substitute for the in vivo environment, as it may be deficient
quantitatively in one or more components essential for the survival and proliferation of
some cell types. Serum might also be expected to be toxic at some concentration for
most cell types, and it contains many substances which normally never come into
contact with most cells of the body (Gospodarowicz et al., 1979), since in vivo no cell
types exist for extended periods in the presence of serum. It is however possible to
replace serum in the culture medium for established cell lines (adapted to grow in
serum-containing medium) by adding to the medium combinations of factors which
can carry out the functions of serum. Several established cell lines representing widely
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divergent cell types may be grown in medium supplemented with hormones, binding
proteins and attachment factors (Barnes & Sato, 1980).
Serum-free systems also allow novel approaches to the recognition and treatment
of disorders such as cancer. Defined media have been used to explore the hypothesis
that some of the properties of neoplastic cells are related to a loss of requirements for
stimulation by one or more hormones or growth factors which are necessary in order
to stimulate growth of normal cells (Cherington et al., 1979; Rockwell et al., 1980).
1.8 SUMMARY
Since the realization that androgens probably play a permissive role in the initiation
of prostatic cancer and that other "factors" may be involved, the interest in growth
factors has blossomed. One of the first investigations of the role of growth factors in
the growth and regulation of the prostate gland was centred on the detection of
endogenous EGF (Hirata & Orth, 1979). Since then, EGF receptors have been located
in human prostatic tissue (Maddy et al., 1987, 1989; Eaton et al., 1988). Maddy et al.
(1989) has subsequently shown that prostatic cancer tissue has a reduced capacity to
bind EGF when compared to benign tissue, with a depletion in the number of binding
sites correlating with the loss of differentiation of the tumour.
Although the action of androgens in initiating prostatic cancer may be permissive
rather than direct, androgens may act together with growth factors to regulate growth
in the prostate. In other model systems there is evidence for steroid hormone
regulation of growth factor content and activity and a similar relationship might exist in
the prostate, as recent in vivo (Traish & Wotiz, 1987; St-Arnaud et al., 1988) and in
vitro (Schuurmans et al., 1988; Wilding et al., 1989) studies suggest.
There is little doubt that growth factors and their receptors are associated with
prostatic cancer, but it is probable that not one but several growth factors may be
involved in the development and progression of prostatic cancer and that growth
factors are pluripotent in their response (Spom & Roberts, 1988); how is unclear.
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Several mechanisms have been proposed by which a cell could evade the normal
cellular growth control: (a) the activation of autologous growth factor synthesis
('autocrine' activation); (b) synthesis of an altered growth factor receptor, or (c)
activation of a post-receptor pathway that bypasses the growth factor requirement.
There is now much circumstantial and direct evidence to support the hypothesis of
autocrine secretion originally proposed by Sporn & Roberts (1985). Many types of
tumour cells release polypeptides (such as TGFa) into their conditioned medium, and
these same tumour cells often possess functional receptors for the secreted peptide.
Autocrine secretion would allow tumour cells to evade normal cellular growth control
by producing and responding to the secreted growth factor.
An unregulated mitogenic signal might also be initiated by oncogene products
functioning as growth factor receptors. The expression of the erb B oncogene product
which codes for a truncated version of the EGF receptor (devoid of the ligand binding
domain), is thought to result in an uncontrolled proliferative response. Similarly,
amplification of the EGF receptor DNA sequence, resulting in over-expression of the
EGF receptor product would lead to unregulated growth. It has also been proposed
that activation of a post-receptor pathway that bypasses the growth factor requirement
might result in an unregulated mitogenic effect, leading to transformation. As yet there
is no evidence for such a mechanism.
Clearly, an understanding of the developmental conditions under which the evasion
of normal growth regulation takes place would help clarify carcinogenic receptor-
mediated mitogenesis.
Our understanding of human neoplastic disease has been enhanced by the use of in
vivo and in vitro model systems. In the case of prostatic cancer some valuable
information has been obtained from animal models, but one must be cautious in
extrapolating such results to the human system. Of the human models available, in
vitro prostatic carcinoma cell lines are particularly useful as they permit the possibility
of studying directly the effects of exposure to hormones and other agents, singly or in
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combination. Unfortunately, very few prostatic carcinoma cell lines are available since
they are notoriously difficult to culture. The LNCaP cell line is the only one which is
androgen-responsive in culture, the remainder being insensitive to hormonal
manipulation. Consequently, very little information has been obtained on prostatic
neoplasia, in particular on the factors involved in the transition of prostatic tumours
from a hormone-responsive to an unresponsive state.
Of those prostatic cell lines available, the carcinoma cell lines DU 145 and LNCaP
provide an opportunity to study the growth responses to EGF-like factors and their
receptors in an androgen unresponsive (DU 145) and androgen-responsive (LNCaP)
system. It is particularly useful to carry out such a comparative study since it is not
inconceivable that the progression of tumours to an androgen-insensitive state might be
due to altered regulation of growth factors and/or their receptors.
The use of serum-free cell cultures was an important consideration in this study
since serum is a mixture of poorly characterized components which is normally
stimulatory for cell growth. Thus, the effect of hormones or growth factors added to
cell cultures may be masked by those present in the untreated serum. More
importantly, serum-free medium has provided the opportunity to study the loss of
requirement for a particular growth factor or hormone, thought to be an important
property of neoplastic cells.
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1.9 Objectives of the present investigation
Thus the objectives of this study were:
1. To investigate and compare the growth responses by EGF-like molecules on the
androgen-insensitive DU 145 and androgen-sensitive LNCaP cell line.
2. To characterize the EGF receptor using radio ligand binding and investigate the
expression of the truncated EGF receptor.
3. To investigate the relationship between androgens and EGF in relation to EGF
receptor expression and activity.









The cell line DU 145 was obtained from Dr D. D. Mickey, Department of Urology,
University of North Carolina, Chapel Hill, U.S.A. DU 145 is a long-term culture cell
line derived from a human prostatic adenocarcinoma metastatic to brain (Mickey et al.,
1980). The cells arrived at the 50th passage and were immediately subcultured. Cells
between passage numbers 60-70 were used for all experiments.
LNCaP
The LNCaP cell line (derived from a fast growing colony, FGC) was kindly
donated by Dr C. Eaton, Tenovus Institute, Cardiff, Wales. The LNCaP cell line was
originally derived from a lymph node carcinoma of the prostate. The cells used in this
study were a subline of the original parent LNCaP (Horoszewicz et al., 1983). This
subline is similar to its parent line and differs only in growth rate. Cells from passage
numbers 75-85 were used for all experiments in this investigation.
2.1.2 POLYPEPTIDE GROWTH FACTORS
Epidermal growth factor from mouse submaxillary gland (mEGF; receptor and
tissue culture grade) was purchased from Collaborative Research (c/o Universal
Biologicals Ltd., St. Ann's Rd., London). Rat transforming growth factor alpha
(rTGFa) and human EGF (hEGF) or urogastrone were kindly donated by Dr H.
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Gregory, ICI, Macclesfield, U.K. rat TGF-I (rTGF-I) was purchased from Peninsula
Laboratories Europe Ltd., St. Helens, Merseyside, U.K. as part of a
radioimmunoassay kit (RIA). Venom nerve growth factor (NGF) was purchased from
Sigma as electrophoretically pure.
2.1.3 HORMONES
Human growth hormone (hGH) was obtained from NIADDK, Bethesda, MD,
U.S.A. The synthetic androgens 7a17a-dimethyl-l9-nortestosterone (DMNT;
Mibolerone) and 17a-methyl-17p-hydroxy-estra-4,9,ll-triene-3-one (R1881) were
purchased from Amersham International pic, Berks, U.K and Du Pont, New England
Nuclear, Boston, U.S.A. respectively.
2.1.4 RADIOCHEMICALS
[Methyl-3H] Thymidine; specific activity 74GBq/mmol.
[125I]-mEGF; specific activity 3.7MBq/|ig.
[125I]-hEGF; specific activity 49TBq/mmol.
The above radiochemicals were supplied by Amersham International pic.
[125I]-rTGF-I was obtained from Peninsula Laboratories Europe Ltd. as part of a
RIA kit.
2.1.5 ANTIBODIES
The mouse monoclonal antibody (Mab) EGFR 1 of the IgG class was obtained
from Amersham International pic. This Mab is directed against the native extracellular
domain of the 175 kDa EGF receptor.
The mouse Mab F4 was kindly donated by Dr W. Gullick, Department of
Oncology, Hammersmith Hospital, London, U.K. This Mab was produced to a




Anti rabbit human EGF was used as part of a RIA for detection of hEGF and was
kindly donated by Dr H. Gregory, ICI, Macclesfield, U.K.
Anti rTGF-I, a rabbit anti rat TGF-I antiserum was purchased from Peninsula






Figure 6 gives an overview of the analytical techniques applied to the cell lines DU
145 and LNCaP. The first part of the investigation involved studying the effects of
EGF-like growth factors on cell proliferation and DNA synthesis, using the techniques
of cell enumeration and [3H]-Thymidine incorporation. In the second part of the study
the EGF receptor was characterized using a radio-ligand exchange assay with [125I]-
EGF (RRA) and by Western blotting. Thirdly, EGF-like bioactivity of medium
conditioned by DU 145 cells (conditioned medium; CM) was analysed using an EGF
radio-receptor competition assay (RRA) and [3H]-Thymidine incorporation. EGF and
TGFa immunological activity in the CM was analysed using RLAs for the detection of
hEGF and rTGF-I. EGF-like components in the CM were partially purified using gel
filtration, reverse-phase high pressure liquid chromatography (rHPLC) and sodium
dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE).




2.3.1 CELL CULTURE MEDIA
DU 145 and LNCaP cells were cultured in complete media and serum-free media
(SFM), as described below. RPMI-1640 (Flow Laboratories, Irvine, Scotland),
which is a basic nutrient medium consisting of various amino acids, glucose, vitamins,
inorganic salts, buffering salts and pH indicator, was used for both media.
2.3.1.1 Complete medium
To RPMI-1640 was added sterile 10% foetal calf serum (Gibco, Paisley,
Scotland), 1% of the amino acid L-glutamine (Flow laboratories) and the antibiotics
penicillin (100 units/ml; Gibco) and streptomycin (100 |ig/ml; Gibco). The medium
was aliquoted into volumes of 100 ml and stored at -20°C in sterile glass bottles which
had previously been autoclaved at a pressure of 15 lb/in2 for 20 mins.
2.3.1.2 Serum-free medium
The serum-free supplemented medium used in this study was a modification from
that used by Kaighn et al. (1981) and Barnes & Sato (1980) for the culture of the
prostatic cell line PC-3, as this cell line has similar characteristics to DU 145.
The basic nutrient medium, RPMI-1640 enriched with trace elements was used
instead of PFMR-4 (Kaighn et al., 1981). Stock solutions of the constituents of the
SFM were made up in RPMI-1640 or ethanol and were filter sterilized (0.2 pm;
Gelman Sciences Inc. Ann Arbor, Michigan, U. S. A) before addition to the medium.
Insulin (Sigma Chemicals, Poole, Dorset), transferrin (Sigma) and
phosphoethanolamine (Sigma) were made up in RPMI-1640 and stored in aliquots at
-20°C. Both insulin and transferrin were added to RPMI-1640 at a concentration of 10
mg/1 and phosphoethanolamine at a concentration of 50 pg/1. Hydrocortisone (100 x
stock; Sigma) and 3,3',5-triiodo-thyronine (1000 x stock; Sigma) were dissolved in
100% ethanol and were added to the medium at concentrations of 1 mg/1 and 2 ng/1
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respectively. Trace element mix (Gibco) was reconstituted in 10 ml of sterile water
and 0.1% of this solution added to the medium. RPMI-1640 was also supplemented
with the amino acid L-glutamine (1%) along with the antibiotics penicillin (100
units/ml) and streptomycin (100 (ig/ml). The medium was aliquoted into volumes of
100 ml and stored at -20°C in sterile glass bottles which had previously been
autoclaved at a pressure of 15 lb/in2 for 20 mins.
2.3.2 CULTURE OF CELL LINE DU 145
The cell line DU 145 was routinely maintained in complete medium, but for the
purposes of this study a serum-free line was developed, by repeated subculture at high
density, of DU 145 in RPMI-1640 SFM. The cell line DU 145 was maintained at
37°C in a humidified atmosphere of 95% air and 5% CO2. All tissue culture
preparations were performed under sterile conditions in a sterile air cabinet
(Microbiological Class II; Howarth Air Engineering Ltd.). Cells were grown in
monolayer culture in 75cm2 tissue culture flasks (Coming, Staffordshire, England),
and rapidly growing cultures were routinely harvested by trypsinization and passaged
once per week 1: 3 (1.5 xlO6 cells/75cm2 flask). This procedure was performed by
disrupting the cells, which adhere firmly to the plastic tissue culture flasks by rinsing
in sterile Dulbecco 'A' phosphate-buffered saline (Dulbecco 'A' PBS; Oxoid Ltd.,
England) and once with 0.25% trypsin and 0.02% EDTA (Gibco). The cells were
then incubated for 5 mins at 37°C and subsequently resuspended in 45 ml of SFM
supplemented with 0.5% foetal calf serum (0.5% FCS). FCS was added to the SFM
to facilitate plating. The cells were dispersed by pipetting to obtain a single cell
suspension and were then seeded 1: 3 into 75cm2 flasks. The cells were subsequently
maintained in SFM without FCS (15 ml/flask).
The culture of DU 145 in SFM yielded slow but sustained growth, the population





in SFM reduced the growth rate to approximately 60 hours (Figure 7). Growth of this
cell line in SFM was also population dependent (Kaighn et al., 1981), cell densities
below 1 x 104 cell/cm2 adhered to the culture flask, however the cells would lift off
when SFM without FCS was added. Densities of (2 x 104- 4 x lOVcm2) were chosen
as optimal for growth experiments with EGF.
2.3.3 CULTURE OF CELL LINE LNCAP
The cell line LNCaP was routinely cultured in complete medium. For this study,
attempts were made to culture in SFM by repeated subculture at high density.
However, due primarily to lack of time and problems with culturing LNCaP (these
cells adhere loosely to the culture vessels) this cell line was maintained in complete
medium, but all growth and receptor binding experiments were carried out in SFM
after plating in complete medium. LNCaP cells were maintained at 37°C in a
humidified atmosphere of 95% air and 5% CO2 in 75cm2 plastic flasks (Coming).
This cell line was passaged routinely once per week 1:3 (1.5 xlO6 cells/75cm2 flask
with 15 ml/flask). LNCaP cells were subcultured using a solution of sodium citrate
(0.08M) instead of trypsin which is less harsh, as the cells are easily dislodged and re¬
attachment is slow. The flask of cells was rinsed with Dulbecco 'A' PBS, once with a
0.08M solution of sodium citrate and the cells subsequently resuspended in complete
medium. For growth and receptor studies cells were plated in complete medium and
after 3 days (in which maximum attachment to the plastic culture plates is achieved),
the cells were maintained in SFM. In case of carry over from serum proteins, the
FIGURE 7: Growth curve for the DU 145 cell line in complete medium and SFM. A 6 well plate
(9.6cm2/well) was seeded with 0.5 x 10s cells/well or 2x10s cells/well and grown in complete
medium (□) or SFM (■ ) for a period of 9 days. At 3 day intervals, the cells from triplicate
wells were removed by trypsin-EDTA treatment and counted in a haemocytometer. The curve








monolayers were washed with SFM (once for eight hours and then rinsed in SFM)
before the addition of test solutions (EGF and/or androgens). All growth experiments
were carried out at a cell density of 2 x 104 cells/cm2. The population doubling time
for LNCaP-FGC is approximately 67 hours in the presence of 10% FCS (Figure 8a),
but growth is reduced to 154 hours when cultured in SFM (Figure 8b).
FIGURE 8: (a): Growth curve of the cell line LNCaP. Cells were plated at a density of ZxltiVcm2 in
6 well plates with 10% FCS. At particular time intervals triplicate wells of cells were harvested and
counted. The curve indicates a population doubling time of 67 hours.
FIGURE 8: (b) Effect of 10% FCS and SFM on the proliferation of LNCaP cells in culture. LNCaP
cells were counted following attachment at 3 days (Day 0). Cells were further incubated with 10%
FCS or SFM for 6 days, harvested and counted. The growth rate of cells grown in 10% FCS was
approximately 2.3 times that of cells growth in SFM. The doubling time of cells grown in SFM
was reduced to 154 hours.
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2.4. CELLULAR GROWTH AND MEASUREMENT OF DNA
SYNTHESIS
Cell growth was measured by enumeration, and DNA synthesis by the
incorporation of [3H]-Thymidine. Cell viability was determined by Trypan Blue-
exclusion; the stain is taken up into the membrane of dead cells leaving viable cells
clearly distinguishable. Cells were counted using a Biirket type haemocytometer on an
inverse phase-contrast light microscope.
In this section general methods used for cell enumeration and DNA synthesis are
outlined, followed by sub sections detailing modifications.
2.4.1 CELL ENUMERATION OF DU 145 CELLS: GENERAL METHOD
Subconfluent DU 145 monolayers from 75cm2 culture flasks were washed once
with Dulbecco 'A' PBS and disrupted by trypsinization as described in section 2.3.3.
The cells were resuspended in SFM/0.5% FCS, after pipetting several times to obtain a
single cell suspension. The suspension of cells was subsequently pelleted at 1500 rpm
for 10 mins, resuspended in 15 ml of SFM/0.5% FCS and an aliquot (lOOjil) of the
cells taken and diluted 1:2 with trypan blue dye (0.03% final concentration) and
counted on a haemocytometer with an inverse phase-contrast light microscope. The
cells were then plated in either 6 well plates (9.6cm2), at a density of 2x10s cells/well
in lml of medium/well, or at a density of 50x103 cells/well in 24 well plates (2cm2) in
lml of medium/well. The test growth factor was added 24 hours later in SFM (2
ml/well to 6 well plates or 1 ml/well to 24 well plates) to the plated cells for up to nine
days, with medium changes on alternate days. After this period the cells were
harvested with trypsin and counted.
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Modifications to general method
(a) The effect ofEGF on cellular growth
The effect of mouse EGF (tissue-culture grade*) on the growth rate of DU 145
cells was measured by comparing changes in growth rate in treated cells with the
growth rate in untreated cells.
EGF (which was previously made up in SFM or complete medium at a stock
concentration of 100 nmol/1) was added to monolayer cultures at various
concentrations (0.01-10nmol/l), for up to nine days. After this period the cells were
harvested and counted.
(b) The effect ofplating density on the growth ofEGF treated cells.
The effect ofEGF on the growth rate of the serum-free DU 145 cell line was
investigated at various cell densities.
DU 145 cells were seeded in 9.6cm2 wells in 6 well plates at innocula of lxlO4,
2X104 and 4 xlO4 cells/cm2. EGF (0.3nmol/l) was added in SFM 24 hours later, with
changes of medium on alternate days. After six days the cells were harvested with
trypsin and counted.
2.4.2 CELL ENUMERATION OF LNCAP CELLS: GENERAL METHOD
Subconfluent monolayers from 75cm2 tissue culture flasks were washed once
with Dulbecco 'A' PBS and disrupted using a solution of sodium citrate as described
in section 2.3.4. The cells were subsequently resuspended in complete medium, after
pipetting several times to obtain a single cell suspension. The suspension of cells was
pelleted at 1500 rpm for 10 mins, resuspended in 15 ml of complete medium and an
*The tissue culture grade of EGF used for all the growth experiments had previously been tested by
Collaborative Research Inc. for mitogenic activity. Human foreskin fibroblasts were grown for seven
days in DME plus 10% foetal bovine serum. EGF (4ng/ml) in this culture medium caused a 1.54
fold increase in cell number over control cultures without EGF
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aliquot (100(J-1) counted on a haemocytometer. In all experiments with LNCaP, cells
were seeded in complete medium for 3 days, at a density of 2x104 cells/cm2 in 6 well
culture plates. After three days the cells were washed with Dulbecco 'A' PBS before
the addition of SFM, which was left in contact with the cells for approximately eight
hours. After this time the test growth factor and/or androgen was added in SFM to
each well, in a volume of 2ml/well, with control wells receiving no growth factor. The
medium was changed after 3 days and after 6 days the cells were harvested with
trypsin and counted.
Modifications to general method
(a) The effect ofEGF on cellular growth
The proliferative response to EGF was investigated in the cell line LNCaP. EGF
(diluted in SFM) was added to monolayer cultures of LNCaP cells over the
concentration range 0.01-10nmol/l. After 6 days, the cells were harvested and
counted. Cells without added growth factor were used as controls.
(b) The effect ofEGF and androgens on cellular growth
The proliferative effects of the synthetic androgens Mibolerone and R1881 were
investigated on the androgen-sensitive LNCaP cell line. These synthetic steroidal
androgens have several times higher affinity than 5a-dihydrotestosterone to the
androgen receptor (Liao et al„ 1973). Both ligands are metabolically stable, but as
Mibolerone is more stable chemically, it was generally used in preference to R1881.
Stock solutions of these androgens were made up in 100% ethanol (end concentration;
<0.1% ethanol). The androgens at a concentration of 0.1 nmol/1 were added (singly
or in combination with EGF) to plated LNCaP cells, and after 6 days the cells were
harvested with trypsin and counted.
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2.4.3 [3H]-THYMIDINE INCORPORATION IN DU 145 CELLS: GENERAL
METHOD
Subconfluent cells from 75cm2 tissue culture flasks were rinsed with Dulbecco 'A'
PBS, and trypsinized as previously described in section 2.3.3. The cells were then
incubated at 37°C for 5 mins and subsequently resuspended in SFM. The suspension
of cells was pelleted at 1500 rpm for 10 mins, resuspended in 15 ml of SFM with
0.5% FCS and an aliquot of cells (lOOjil) counted on a haemocytometer.
Subsequently, 1 x 104 cells/well (in a volume of lOOpl of suspended cells/well) were
plated overnight in SFM (supplemented with 0.5% FCS to assist plating), in 96 well
plates (0.32cm2). After aspirating off the plating media, the test growth factor (lOOpl)
was added in SFM for 8, 24,48 and 72 hours. After the incubation period, [Methyl-
3HJ Thymidine (specific activity 74GBq/mmol; 37KBq/well; 50pl/well) was added in
RPMI for at least four hours. Each well was then carefully aspirated, the cells
trypsinized (100|il solution/well) and resuspended by gently tapping the plate. Cellular
material (DNA) was precipitated by the addition of 100pi of ice-cold trichloroacetic
acid (TCA; 10%) for two hours. The precipitable cellular material was harvested
(Skatron Combi Cell Harvester, Skatron, Norway) on to filter mats by washing the
wells three times in water and then drying the filter mats at 60°C for 30 mins. Each
disc of filter paper (containing the dried precipitable cellular material) was dispensed
into plastic minivials (Skatron) with 3 ml of scintillation fluid (a Triton x 100 based
cocktail; Vickers Laboratories, Burley-on-Wharfedale, West Yorks, U.K). The counts
per minute (cpm) of each vial was determined in the tritium channel of a Hewlett
Packard scintillation counter. All determinations were carried out with 6 to 12 samples
per 'test growth factor'.
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Modifications to general method
(a) The effect ofEGF on [3H]-Thymidine incorporation
The effect ofEGF (0.001- 10nmol/l) on DNA synthesis of DU 145 cells was
measured by the incorporation of [3H]-Thymidine as outlined in the general method;
section 2.4.3. Growth factor activity was taken as any increase or decrease in
incorporation of [3H]-Thymidine relative to the untreated SFM control.
EGF was added to serum-free cultures of DU 145 cells for periods of 8, 24, 48
and 72 hours after the cells had plated. DNA synthesis was measured after each
incubation time, by the addition of [3H]-Thymidine as described in section 2.4.3.
(b) The effect ofplating density on DNA synthesis ofEGF treated DU 145 cells.
The effect of cell density on the mitogenic response to EGF was investigated using
[3Hj-Thymidine incorporation.
DU 145 cells were seeded at innocula of lxl04, 3x104 and 6X104 cells/cm2 in 96
well plates (with lOOpl/well of suspended cells). EGF (lnmol/1; lOOfil/well) was
added in SFM for 24 hours, with control wells receiving no growth factor. After 24
hours DNA synthesis was measured by the addition of [3H]-Thymidine as previously
described in section 2.4.3.
(c) The effect ofTGFaon incorporation of [3H]-Thymidine
The growth factor TGFa was tested for mitogenic response on the serum free DU
145 cell line.
TGFa (0.01-10 nmol/1) was added to plated cells (1 x 104 cells/well in 96 well
plates) in SFM for 24 hours, with control wells receiving no growth factor. After 24
hours DNA synthesis was measured by the addition of [3H]-Thymidine as previously
described in section 2.4.3.
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2.4.4 [3H]-THYMIDINE INCORPORATION IN LNCAP CELLS: GENERAL
METHOD
Subconfluent cells from 75cm2 tissue culture flasks were rinsed in Dulbecco 'A'
PBS, and once with 0.08M sodium citrate as previously described in section 2.3.4.
The cells were incubated at 37°C for 5 mins and subsequently resuspended in complete
medium. The suspension of cells was pelleted at 1500 rpm for 10 mins, resuspended
in 15 ml of complete medium and pipetted several times to obtain a single cell
suspension. An aliquot of cells (100|il) was counted on a haemocytometer and 2x10*
cells/cm2 (in a volume of lOOpl/well) were then plated in 96 well plates (0.32cm2) for a
period of three days. After this time the 'test growth factor or androgen' was added in
SFM to the LNCaP monolayers for a period of 24 hours. [3H]-Thymidine
incorporation was measured as previously described for DU 145 cells in section 2.4.3.
Modifications to general method
(a) The effect ofEGF on [3H]-Thymidine incorporation in LNCaP cells.
As a comparison with the growth response to EGF in DU 145 cells, [3H]-
Thymidine incorporation assays were carried out, to investigate the effect of EGF on
DNA synthesis in LNCaP cells.
Increasing concentrations of EGF (0.01-10nmol/l) in SFM were added to LNCaP
monolayers for a period of 24 hours, with control wells receiving no EGF. DNA
synthesis was then measured by the addition of [3H]-Thymidine as described in section
2.4.3.
(b) The effect ofEGF and androgens on [3H] -Thymidine incorporation
In some experiments Mibolerone and R1881 were tested on LNCaP cells either
singly or in combination with EGF, to investigate the relationship between growth
factors and androgens.
The synthetic androgens, at a concentration of (0.1nmol/l) were added to
subconfluent monolayers in the presence or absence of EGF for a period of 24 hours.
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After this time DNA synthesis was measured by the addition of [3H]-Thymidine as
described in section 2.4.3.
55
MATERIALS & METHODS
2.5 EGF RADIO-RECEPTOR BINDING ASSAYS
The characterization of the EGF receptor in LNCaP and DU 145 was investigated
using a radio-ligand exchange assay with [125I]-mouse EGF. The EGF binding assay
used for DU 145 was adapted from Carpenter (1985). The EGF binding assay for
LNCaP cells was performed without modification from that of Schuurmans et al.
(1988a). For both cell lines, binding assays were performed with whole cells and not
membrane preparations.
The general method used to characterize the EGF receptor (the ligand-exchange
radio-receptor assay) is outlined in section (2.5.1) and is followed by sub-sections
detailing modifications to this method.
2.5.1 RADIO-RECEPTOR ASSAY FOR DU145 CELLS: GENERAL METHOD
DU 145 cells were prepared and plated for EGF binding assays as described for
cell proliferation experiments (section 2.4.1). All binding assays were carried out on
confluent monolayers (2 xlO5 cells/well), in 24 well plates (2cm2/well). Before
addition of the binding medium the SFM from each well was aspirated and the cells
and binding media were cooled on ice to inhibit receptor internalization. The cell
monolayers were then gently washed with 0.5 ml of Dulbecco 'A' PBS per well and
binding was initiated upon the addition of the appropriate concentration of [125I]-EGF
(specific activity 4MBq/(ig; 100(ll/well; Amersham International pic). To obtain the
correct concentration of [125i]-EGF, unlabelled EGF was added to the labelled
material, with the highest concentration containing approximately 2 x 105 cpm. For
each concentration of EGF, a measurement was made of the total [125I]-EGF binding
and the non-specific binding of radioactivity (that which is not displaced by an excess
of non-radioactive EGF). Non-specific binding was determined in the presence of 100
fold excess unlabelled EGF (200 (il/well; receptor-grade). Each solution was made up
beforehand in RPMI-1640 to a final volume of 0.5 ml, and then added to the
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appropriate well. Each determination was carried out in triplicate (3 x total binding and
3 x non-specific binding). After incubating, unbound was separated from bound
[125I]-EGF by aspirating the contents of each well and then washing the cells three
times with ice-cold Dulbecco 'A' PBS (0.5ml/well) by gently pipetting the wash
solution against the side of the dish. The cells were subsequently solubilized with 1ml
of 0.5N sodium hydroxide, for 15 minutes at room temperature and the dissolved cells
transferred to plastic tubes for counting in a gamma counter. Specific binding was
calculated as the difference between total binding and non-specific binding. For all
binding experiments cell numbers were determined from control wells (usually in
triplicate) in which only RPMI-1640 was added, without labelled or unlabelled EGF.
2.5.2 RADIO-RECEPTOR ASSAY FOR LNCAP CELLS: GENERAL
METHOD
EGF binding assays were carried out on confluent monolayers (2 x 105 cells/well)
in 24 well plates. The assay was essentially similar to that described for DU 145 cells
in section 2.5.1. However, instead of terminating binding by washing the
monolayers, separation of bound [125I]-EGF from free [125I]-EGF was carried out by
firstly aspirating off the medium containing the radioligand and then adding 1ml of ice-
cold Dulbecco 'A' PBS. The cells were resuspended by pipetting several times,
transferred to disposable plastic centrifuge tubes and subsequently pelleted for 10 min
at 1500 rpm. The supernatant was aspirated, and the radioactivity of the cell pellets
measured in a gamma counter. Specific binding was calculated as the difference
between total binding and non-specific binding and all determinations were carried out
in triplicate. As for DU 145 cells, cells were counted in control wells which were















2.5.3 OPTIMIZATION OF EGF BINDING ASSAY FOR DU 145 CELLS
Before further ligand binding characterization of the EGF receptor was performed,
preliminary experiments were carried out to determine the optimal conditions.
2.5.3.1 Separation of bound [125I]-EGF from free [125I]-EGF
Efficient separation of bound [125I]-EGF from free [125I]-EGF is crucial to the
success of binding assays. The major constraint on separation techniques is the rate of
dissociation of the ligand-receptor complex at the temperature of separation of bound
from free ligand. Consequently, a separation procedure that is rapid must be utilized to
avoid losing bound ligand. Washing of firmly bound cell monolayers offers just such
a rapid and efficient way of separating bound from free [125I]-EGF, and in the
preliminary experiment depicted in Figure 9, the optimal number of washes was
determined. To ensure that washing did not dislodge the cells from the tissue culture
wells, after each wash the number of cells was counted. All other experimental details
including the number of cells plated and the addition of radio-ligand are identical to that
outlined under section 2.5.1 for DU 145 cells.
The results depicted in Figure 9 demonstrate that three washes are optimal for
efficient separation of free from bound [125I]-EGF. Greater than three washes
decreased specific binding, which was probably due to the loss in cell numbers. With
less than three washes, non-specific binding was unacceptably high while specific
binding was low. All subsequent separations of bound [125I]-EGF from free [125I]-
FIGURE 9: Optimization of separation of bound [12^I]-EGF from free [125I]-EGF. DU 145 cells
were seeded at a density of 2 x 105 cells/well in 24 well plates. Binding was initiated upon the
addition of [125I]-EGF (2nmol/l; 2 x 105 cpm) with or without lOOx excess unlabelled EGF. After 4
hours at 4°C, binding was terminated by washing 1 to 4 times in ice-cold Dulbecco's. After each
wash the cells in control wells were counted (o). The monolayers were subsequently solubilized in 0.5
N NaOH and the radioactivity counted. Specific binding (□ ) was determined by subtracting non¬


















EGF in radio-receptor assays for DU 145 cells was carried out by washing the
monolayers a maximum of three times.
2.5.3.2 Correlation between specific binding and ceil number
If optimal conditions have been achieved, then increasing the number of cells
exposed to [125I]-EGF should increase the level of specific binding without notably
increasing non-specific binding.
Increasing numbers of cells (50 x lO^OO xlO3) were incubated in 24 well plates
with a constant amount of [125I]-EGF (2nmol/l; 2 x 105 cpm) and lOOx excess
unlabelled EGF . The binding assay was then carried out as outlined in section 2.5.1
for DU 145 cells.
A positive correlation was found between cell number and specific binding (Figure
10) with no significant increase in non-specific binding as the number of cells
increased. Non-specific binding was less than 10% of the total binding with 200, 000
cells/well.
Non-specific binding to the plastic tissue culture plates was also tested. [125I]-
mEGF was added to wells which had previously been coated with or without SFM; no
significant non-specific binding was detected.
2.5.4 RADIO-RECEPTOR ASSAY CHARACTERIZATION OF THE EGF
RECEPTOR
The EGF receptor for both DU 145 and LNCaP cell lines was characterized by a
series of radio-ligand binding experiments. The number and affinity of receptors as
well as the kinetics of association and dissociation of EGF binding to its receptor were
FIGURE 10: Correlation between specific binding and cell number. DU 145 cells were seeded at the
densities indicated in the figure; in 24 well plates. Binding was initiated upon the addition of [12~*I]-
EGF (2 nmol/1; 2 x 105 cpm) with or without unlabelled EGF. After 4 hours, at 4°C binding was
terminated by washing 3x in Dulbecco A PBS and solubilizing the cells in NaOH. Specific binding
(hatched bars) was determined by subtracting non-specific binding (□) from total binding (♦).
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determined. In addition to down regulation and specificity studies, internalization of
EGF binding sites was investigated.
2.5.4.1 Association & Dissociation Kinetics
Steady state binding of [125I]-EGF to DU 145 and LNCaP cell monolayers was
determined at 4°C and 37°C. Confluent monolayers (2 x 105 cells/well; 24 well plates)
and solutions were either cooled on ice for a period of 15 mins, or incubated at 37°C.
After this time the monolayers were incubated with sub-saturating concentrations of
[1251]-EGF (2nmol/l; 2 x 105 cpm) in the presence and absence of lOOx excess
unlabelled EGF. At regular time intervals, bound [125I]-EGF was separated from
unbound [125I]-EGF in triplicate wells as described in sections 2.5.1 (DU 145) and
2.5.2 (LNCaP), and total and non-specific binding determined.
The time course of dissociation of [125I]-EGF bound to DU 145 and LNCaP EGF
binding sites was determined after a steady state had been achieved (this was
determined by association kinetics; steady state was achieved after 4 hours and 6 hours
with DU 145 and LNCaP cells respectively, at 4°C). Dissociation was then initiated
by aspirating the binding medium in each well and adding 0.5 ml of SFM at 4°C. To
determine monolayer bound [125I]-EGF that had dissociated, bound [125I]-EGF was
separated from free [125I]-EGF at various time intervals, in triplicate wells. This
procedure was carried out as described in sections 2.5.1 (DU 145) and 2.5.2
(LNCaP).
2.5.4.2 Saturation & Competition Analysis
The affinity constant and the number of EGF binding sites present on DU 145 and
LNCaP cells were determined using saturation and competition analysis.
Competition Studies
In competition analysis, the concentration of unlabelled ligand displacing 50% of
specific radioligand binding (IC50) and the number of binding sites is determined by
competing labelled ligand with increasing concentrations of unlabelled ligand.
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Confluent LNCaP and DU 145 monolayers (2 xlO5 cells/well, in 24 well plates)
were incubated with [125I]-EGF (2nmol/l; 2 x 105 cpm), with or without increasing
concentrations of unlabelled EGF (0.01-300 nmol/1) at 4°C. After the incubation
period (4 hours and 6 hours for DU 145 and LNCaP cells respectively) separation of
bound [125I]-EGF from free [125I]-EGF was carried out as described in sections
2.5.1(DU 145) and 2.5.2 (LNCaP). For each concentration of EGF the amount of
specific binding from triplicate determinations was calculated by subtracting total
binding from non- specific binding. The data were subsequently analysed and the
binding parameters evaluated by the computer program LIGAND (see section 2.8).
Saturation Studies
In saturation analysis, the amount of radioactive ligand that produces 50%
occupancy (the dissociation constant; IQ), and the total receptor population (Rx) can be
determined by using a range of radioligand concentrations. The labelled ligand
concentrations should optimally cover a range from 10-20% of the estimated IC50 (as
evaluated by competition analysis) to four to five times this value, with excess
unlabelled ligand remaining constant.
Confluent monolayers (2 xlO5 cells/well) seeded in 24 well plates were incubated
with increasing doses of [125I]-EGF (0.02-10nmol/l) in triplicate wells (with or
without a constant amount of unlabelled EGF; 200nmol/l) at 4°C, for either 4 hours
(DU 145) or 6 hours (LNCaP). Separation of bound from unbound [125I]-EGF was
then carried out as described in sections 2.5.1 (DU 145) and 2.5.2 (LNCaP) and the
amount of specific binding for each concentration of [125I]-EGF determined as the
difference between total binding and non-specific binding. The data were analysed and
the binding parameters evaluated by the computer program LIGAND.
Saturation analysis ofandrogen treated LNCaP cells
Several recent studies have shown that EGF receptor levels are modulated by
androgens (Traish & Wotiz, 1987; St-Arnaud et al., 1988; Schuurmans et al., 1988a).
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This relationship was investigated with the androgen-sensitive LNCaP cell line using
the synthetic androgen Mibolerone.
LNCaP cells were plated at a density of 2X104 cells/cm2 in 24 well culture plates.
After three days the cells were washed in Dulbecco 'A' PBS and SFM as described in
section 2.3.4. Mibolerone (0.1nmol/l) was then added to the monolayers for a period
of 6 days, with two changes of medium during this time. After this period, the culture
medium was aspirated and increasing doses of [125I]-EGF (0.05-10nmol/l) were added
to triplicate wells with or without unlabelled EGF (200nmol/l) for 6 hours, at 4° C.
Separation of bound from unbound [125I]-EGF was carried out as described in section
2.5.2, and specific binding determined as the difference between total binding and non¬
specific binding for each radioligand concentration. The receptor number and receptor
affinity were evaluated for androgen treated and untreated LNCaP cells using the
computer program LIGAND.
2.5.4.3 Specificity Studies
The specificity of EGF binding to receptor sites on the DU 145 and LNCaP cell
lines was determined by competing for EGF binding sites with [125I]-mEGF and
various ligands other than mEGF.
Confluent monolayers (2X105 cells/well in 24 well plates) were incubated with
[125I]-mEGF (2nmol/l; 2 x 105 cpm), with or without lOOx excess unlabelled
competing ligands (mEGF, TGFa, hEGF, NGF, GH, and Insulin) in triplicate wells.
After the incubation period (at 4°C for 4 hours with DU 145 cells or for 6 hours with
LNCaP cells) binding was terminated by washing or pelleting the monolayers as
described in sections 2.5.1(DU 145) and 2.5.2 (LNCaP). Specific binding was
determined by subtracting total binding from non-specific binding for each competitor.
2.5.4.4 Internalization of binding sites for EGF
To determine whether EGF was internalized in a temperature dependent fashion by
human prostate cancer cells, the effect of brief exposure to saline/glycine, pH 3.0 on
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monolayer-bound radioactivity was examined. Brief exposure to glycine at pH 3.0
extracts surface-bound ligand without damaging the cell, thus ensuring that only
internalized material will be counted (Costlow & Hample, 1982).
Confluent cell monolayers (2 xlO5 cells/well) were incubated with [125I]-EGF
(2nmol/l; 2 x 105 cpm) in the presence or absence of unlabelled EGF (200 nmol/1), at
4°C and 37 °C. At various time intervals, triplicate dishes were processed following
washing with three changes of ice-cold Dulbecco 'A' PBS (0.5ml/well). Extraction of
surface-bound EGF was carried out at 4°C with 0.5 ml/well of ice-cold NaCl/glycine,
pH 3.0 (50mM Glycine, 0.15M NaCl; Costlow & Hample, 1982). Total binding,
non-specific binding, and the level of specific [125I]-EGF bound was subsequently
determined as previously described in sections 2.5.1 (DU 145) and 2.5.2 (LNCaP).
2.5.4.5 Down-regulation studies
The ability of EGF to down regulate its receptor was investigated in both DU 145
and LNCaP prostate cell lines.
DU 145 and LNCaP cell monolayers (2 xlO5 cells/well in 24 well plates) were pre-
incubated with increasing concentrations of EGF (0.01-10nmol/l) for 24 hours at 37°C;
the control wells received no EGF. After incubating, the monolayers were washed to
remove surface bound EGF with three changes of ice-cold Dulbecco 'A' PBS
(0.5ml/well). Extraction of surface-bound EGF was carried out at 4°C with 0.5
ml/well of ice-cold NaCl/glycine, pH 3.0. Binding was initiated by the addition of
[125I]-EGF (2nmol/l; 2 x 105 cpm) with or without lOOx excess unlabelled EGF, for 4
(DU 145 cells) or 6 hours (LNCaP) at 4°C and the amount of specific binding
determined as previously described in section 2.5.1. Receptor down-regulation was
seen as any decrease in specific binding relative to the untreated control.
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2.6 DETECTION OF THE EGF RECEPTOR AND THE V-
erb B GENE PRODUCT BY WESTERN BLOTTING
The presence of the EGF receptor in both cell lines was further verified by
Western blotting (Harlow & Lane, 1988). Two Mabs were used in this analysis
(EGFR I and F4) which recognize and bind to specific domains on the EGF receptor.
The EGFR1 Mab binds to the native extracellular domain of the 175 kDa receptor. The
Mab F4 binds to the intracellular domain of the EGF receptor and will thus detect both
the 175kDa receptor and the v-erb B gene product (which has a molecular weight of
Mr 68 000).
2.6.1 PREPARATION OF CELL LYSATES
Cell lysates were prepared from confluent monolayers of LNCaP and DU 145
(5xl07cells). The monolayers were washed with Dulbecco 'A' PBS and pelleted by
gentle centrifugation (5 minutes at 1500 rpm). Lysis buffer (2 ml; 50mM Tris, 1%
Triton X-100, 150mM NaCl, 25mM Benzamidine, 0.1% BSA, 0.3mM
phenylmethylsulphonylfluoride; PMSF, ImM dithiothreitol and 10% glycerol, pH 7.4)
was added on ice to the pellet of cells and the lysate was centrifuged at 3000rpm for
30mins (PMSF was dissolved in 100% ethanol and was freshly prepared each time).
The soluble material from the cell lysates was collected and was subjected to SDS-
PAGE as described in section 2.6.2.
2.6.2 SDS-PAGE
The procedure of SDS-PAGE was based on the discontinuous Tris-Glycine buffer
system described by Laemmli (1970) and was performed in a vertical slab gel
electrophoresis tank (Bio-Rad Laboratories Ltd, Watford, Hertfordshire). Sample
buffer (400pl; 0.063M Tris-HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5%
(v/v) 2(3-mercaptoethanol and 0.0013% (w/v) bromophenol blue) was added to lOOpl
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of the solubilized cell lysates and (without bromophenol blue) to molecular weight
standards ('Rainbow markers'; Amersham pic, which consisted of lysozyme, 14.3
kDa; trypsin inhibitor, 21.5 kDa; carbonic anhydrase, 30 kDa; ovalbumin, 46 kDa;
bovine serum albumin, 69 kDa; phosphorylase b, 92.5 kDa and myosin, 200 kDa).
Samples were boiled for 3 mins and were subsequendy electrophoresed on a 7.5%
separating gel with a 4% stacking gel in Tris/Glycine electrode running buffer (0.025M
Tris, 0.19M Glycine and 0.1% (w/v) SDS, pH 8.3) for 5 hours at 35mA/gel, with
continual cooling.
2.6.3 STAINING AND DESTAINING
After electrophoresis, a track of the gel containing the separated cellular material
was stained for protein with Coomassie Brilliant Blue (0.1% Coomassie Blue R-250,
40% Methanol, 10% glacial acetic acid) for 30 minutes with continual shaking. The
gel was destained overnight with continual shaking in a mixture of 40% methanol and
10% acetic acid.
2.6.4 IMMUNOBLOTTING
The protein bands on the gel were transferred on to a nitrocellulose membrane (30
min at 20V; transfer buffer, 48mM Tris, 39mM glycine, 20% methanol, 0.02% SDS,
pH 9.2) using a Trans Blot SD Semi-dry electrophoresis transfer cell (Bio-Rad Labs).
After blotting, part of the membrane corresponding to a track of cell lysate was stained
with amido black (40% methanol, 10% acetic acid and 0.1% amido black) to confirm
efficient transfer of proteins.
The remaining nitrocellulose strips were blocked with 5% (wAO skimmed milk
solution for 10 mins at room temperature. The strips were rinsed in washing buffer
(50mM Tris, 150mM NaCl, 2mM EDTA at pH 7.5) and incubated with Mabs EGFR1
(5|ig) and F4 (2pg), with 2% BSA in washing buffer, for 2 hours with continual
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shaking at room temperature. A mouse Mab, raised against MHC IgG class 2 was
used as a non specific control. The strips were rinsed in washing buffer and incubated
with alkaline phosphatase antibody conjugate mouse IgG (Sigma) for 2 hours at room
temperature. After this incubation period the strips were rinsed once more in washing
buffer and developed by the addition of Naphthol-phosphate (15 mg Naphthol-AS-
MX- phosphate (free acid) in 1.5ml dimethylformamide, added to 75ml saline/0.05M
Tris, pH 8.8 with 75mg Fast Red TR salt; Sigma). The development of the colour
product was terminated by rinsing in water.
Calculation of molecular weights
A calibration curve was constructed by plotting the relative mobilities (Rf) of the
molecular weight markers (Rf = distance of protein migration/distance of tracking dye
migration), against the logio °f the molecular weights. The molecular weights of
unknowns were determined with reference to the standards.
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2.7 PREPARATION AND ANALYSIS OF MEDIUM
CONDITIONED BY DU 145 CELLS
Conditioned medium (CM) from DU 145 cells was collected from confluent
monolayers over a period of 4 months and analysed for the presence of the growth
factors TGFa and EGF, by RIA and a competitive EGF-radio receptor assay (EGF-
RRA). CM was also assayed for bioactivity by the incorporation of [3H]-Thymidine
into DNA of DU 145 cells. The CM was further characterized by gel filtration, rHPLC
and SDS-PAGE, with the fractions and eluted gel material assayed by RRA and RIA.
2.7.1 CONDITIONED MEDIUM PREPARATION
Cells were grown to confluency in 75cm2 tissue culture flasks in SFM, the medium
was changed once and discarded and the cells were grown for a further 48 hours in 20
ml of SFM. The CM was clarified by centrifugation (3 000 rpm for 15 minutes) and
filtered through a 0.2pm filter (Gelman Sciences Inc.); at this stage medium was stored
at -70°C until further use.
Dialysis & concentration of pooled CM
Pooled CM from 50 flasks (1 litre) was dialyzed against 50mM ammonium acetate
(10 litres) (after the addition of freshly prepared PMSF) in Spectrapor 3 dialysis tubing
at 4°C (molecular weight cut-off point of 3500; Pierce-Warriner, Chester, U.K). The
dialysate was continually stirred over 24 hours, with 4 changes of buffer. The
dialyzed CM was transferred into plastic universals, frozen at -70°C and subsequently
lyophilized to dryness. The lyophilized material was reconstituted in 5 ml of PBS
(0.02M Na2HPO4.2H20, NaH2P04.2H20, 0.9% NaCl, pH 7.4) and clarified by




The protein concentration of the concentrated CM from DU 145 cells was
estimated by the method of Bradford (1976) using bovine serum albumin (BSA) as
standard.
Bradford Reagent
Coomassie Brilliant Blue G (lOOmg) was dissolved in 50 ml of 95% (v/v)
ethanolic solution, to which 100 ml of 85% phosphoric acid was added. The solution
was made up to 1 litre with distilled water and filtered through Whatman paper.
Assay
Varying amounts of the BSA solution (0-80 |ig; the assay is linear over this range
for BSA) were dispensed into standard tubes and their volumes brought up to 80pil
with 0.02 M PBS buffer, pH 7.4. Assay tubes contained the solution of CM in 0.02
M PBS, in a final volume of 80(ll. Bradford reagent (5 ml) was added to each tube
and the contents vortexed for 5 sees. The absorbance of the BSA standards and
unknowns at 595nm were measured with a Pye Unicam spectrophotometer (SP6 550
uv/vis). A calibration curve constructed from the BSA standards was used to
determine the concentration of protein in the unknowns.
2.7.3 EGPRADIO RECEPTOR COMPETITION ASSAY
DU 145 cell monolayers were used as the source of EGF receptors in the EGF-
RRA for analysis of competitive activity in the CM.
Confluent monolayers (2 x 10 5 cells/well) of DU 145 cells were incubated with
[125I]-EGF (2nmol/l; 2 x 105 cpm; 100(ll) in the presence or absence of triplicate
aliquots of CM samples (200|il/sample) for 4 hours at 4 °C. Each sample was made up
in RPMI-1640 to a final volume of 0.5 ml; see section 2.5.1. After the incubation
period bound was separated from unbound [125I]-EGF as previously described in
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section 2.5.1. The amount of specific binding for each sample of CM was determined
by subtracting total binding from non-specific binding.
Usually two control wells were set up to test for components in the CM, such as
proteolytic enzyme activity which might have resulted in a false interpretation of
specific binding. Excess EGF was added to these cells (which had previously been
incubated with CM) and specific binding was determined after a further hours
incubation.
The amount of EGF equivalent units in the CM samples was calculated by
comparison with the competition curves derived from unlabelled mEGF with [125I]-
mEGF competing for EGF binding sites on DU 145 cells; see section 2.5.4.2. In this
assay the sensitivity for unlabelled mEGF, hEGF, or TGFa is approximately 0.12ng
per assay with lng of [125I]-mEGF; with 50% competition occurring at 0.6 ng per
assay.
Experiments using the EGF-RRA for analysis of EGF competitive
activity
(a) Concentrated media conditioned by DU 145 cells
Aliquots of concentrated CM were assayed for EGF-like competitive activity.
[125]-EGF was added to DU 145 cell monolayers with or without increasing
concentrations of CM (0.05 - 2 mg/ml) for 4 hours at 4°C. After this time the cells
were processed as previously described in section 2.5.1. Each concentration was
assayed in duplicate and each experiment was repeated at least three times. The
amount of EGF equivalents was calculated from competition curves of [125I]-niEGF
with unlabelled mEGF competing for EGF binding sites. In this assay hEGF and
TGFa were assumed to be equivalent.
(b) Gelfdtration and rHPLCfractions
CM was fractionated using gel filtration and rHPLC (see sections 2.7.6 and
2.7.7). Aliquots (200 |il) of every third fraction were analysed for competitive activity
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and the amount of EGF equivalents was calculated from competition curves produced
by unlabelled mEGF with [125I]-mEGF as outlined above.
(c) Eluted materialfrom SDS-fractions
Fractions from rHPLC demonstrating competitive activity were subjected to SDS-
PAGE (see section 2.7.8). The supernatant of eluted material from SDS-PAGE gel
slices were analysed for competitive EGF-like activity in radio receptor assays as
outlined in section 2.7.3.
2.7.4 RAT TGF-I AND HUMAN EGF RADIOIMMUNOASSAYS
The levels of immunoreactive rTGF-I and hEGF in samples of CM, fractions
from gel filtration, rHPLC and eluted material from SDS-PAGE were determined
using liquid-phase competitive RIAs.
rTGF-I
A commercial kit (Peninsula Laboratories) with rTGF I as radioiodinated tracer and
reference standard was used to detect levels of TGFa in the CM. Antisera to the
synthetic rat TGFI were raised in rabbits. The rabbit anti-rat TGFI antiserum
recognizes both rat and human TGFa, but the level of cross-reactivity with human
TGFa is only 32% of the homologous antigen (rat TGF-I) (Moore, pers. comm.
1989). This correction was taken into consideration in all calculations. Rabbit anti-rat
TGF I does not cross react with either mouse or human EGF. Half-maximal inhibition
of binding of the [125I]-peptide to the antibody occurred at lOOpg/tube.
Briefly, the RIA was carried out over 3 days, on day 1 rat TGF I standards and
samples were incubated at 4°C overnight with rabbit anti-rat TGF I serum. [125]-
rTGF-1 was added the next day to the RIA assay tubes, followed by a further
overnight incubation (4°C). On day 3 goat anti-rabbit IgG serum and normal rabbit
serum as carrier protein was added to the contents of each tube and incubated at room
temperature for 120 min. RIA buffer was subsequently added to each tube and the
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samples were centrifuged at 3000 rpm for 20 min. The supernatant was aspirated and
the radioactivity in the remaining pellets determined. The levels of human TGFa in
each sample of CM were determined from a standard curve of %B/Bo, where Bo is
equal to the amount of [125]-rTGF I competing with anti-rTGF-I without added
unlabelled TGF-I minus the NSB ([125]-rTGF plus the second Ab).
hEGF
hEGF in the samples was detected by the competition of hEGF for [125I]- hEGF
binding to anti-hEGF serum. All dilutions of antibodies and standards were made in
RIA buffer (0.04M phosphate, 150mM NaCl, 0.01M EDTA, 0.5% BSA). lOOpl of a
1:40 000 dilution of anti-hEGF was incubated at 4°C with 100 |il of [125I]-EGF
(specific activity 49TBq/mmol; with approximately 10,000 cpm added per tube) and
hEGF standards (0-20ng in triplicate) or samples. Each tube was vortexed for 5
seconds before incubating at 4°C. After three days, 500(0.1 of donkey anti-rabbit (at a
1:20 dilution; 5(d/tube plus normal rabbit serum at a dilution of 1:200; 0.5(d/tube;
Scottish Antibody Production Unit, Carluke, Scotland) was added, vortexed and
incubated for a further 24 hours at 4°C. Distilled water (500(d) was then added and the
contents of the tubes vortexed and subsequently centrifuged at 3000 rpm for 30 mins.
The supernatant was aspirated and the radiolabel in the pellets was determined by
counting in a gamma counter. Half-maximal competition was observed with 200-250
pg native hEGF. The anti-hEGF-urogastrone does not significantly cross react with
either TGFa or mEGF (Gregory, per. comm. 1988).
2.7.5 BIOLOGICAL ACTIVITY OF CM: EFFECT ON DNA SYNTHESIS IN DU
145 CELLS
Medium conditioned by DU 145 cells was tested for bio-activity in a [3H]-
Thymidine incorporation assay. In the initial experiment spent medium at
concentrations of 3-1000 (ig/ml was added to DU 145 cell monolayers (1 x
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lO^cells/well) for a period of 8, 24, 48 & 72 hours in 96 well plates; SFM was used as
a control. This experiment was repeated with concentraions of 0.01-1000 pg/ml for
24 hours. After this time [3H]-Thymidine was added to each well and the
incorporation of [3H]-Thymidine measured as previously described in section 2.4.3.
Cell viability was > 90% after 24 hours as assessed by the trypan blue exclusion test.
2.7.6 GEL FILTRATION
The supernate of the concentrated CM (10 mg) was applied to a G-100 Sephadex
(Superfine grade, with a fractionation range of 4 000 -150 000 molecular weight)
column (100 x 2.5 cm; Pharmacia (G.B) Ltd., Hounslow, Middlesex) equilibrated and
eluted with 0.02M PBS, pH 7.4 at 4°C. 3 ml fractions were collected and the
absorbance was monitored at 280 nm. Every third fraction was tested for competitive
activity in EGF-RRA (as described in section 2.7.3.b) and immunological activity in
hEGF and rTGF-I RIAs (as described in section 2.7.4).
Calculation of molecular weights
The molecular weights of the fractions from the separated CM were calculated from
a calibration curve of molecular weight markers (thyroglobulin, 670 kDa; gamma
globulin, 158 kDa; ovalbumin, 44 kDa; myoglobin, 17 kDa and vitamin B12,1.3 kDa;
Bio-Rad Labs.). Thyroglobin is not retained with Sephadex G-100 and was used for
calculating the void volume (Vo). The volume eluted (Ve) of each of the molecular
weight markers and unknowns are related to their molecular weights.
2.7.7 REVERSE-PHASE HIGH PERFORMANCE LIQUID
CHROMATOGRAPHY
Trifluroacetic acid (TFA; 0.1%) was added to the supernate of CM (15 mg),
vortexed and spun at 15 000 rpm for 10 mins. The soluble material was loaded on to a
Bio-Rad RP 304 C4 column (250 mm x 10 mm), with a slurry packed guard column of
72
MATERIALS & METHODS
the same material. Before running the aliquot of CM, a blank run was carried out with
buffer alone. The column was equilibrated with 95% Buffer A (0.2|im filtered double
distilled water (DDW), 0.1% TFA; Rathburn Chemicals, Rathburn, Scotland, U.K)
and 5% Buffer B (20% DDW, 80% acetonitrile (MeCN), 0.085% TFA; Rathburn
Chemicals) and the sample eluted with a linear elution gradient of 5%-80% Buffer B,
at a flow rate of 0.5 ml/min at room temperature. The absorbance of each fraction
eluted was read at 280nm, with 1ml fractions collected. Acetonitrile was blown off
each fraction under a stream of air, over 24 hours, and the remaining sample frozen to
-70°C, lyophilized to dryness and reconstituted in 0.5 ml of 0.02M PBS with lg/1
BSA, pH 7.4. Every third fraction was analysed for competitive activity in an EGF-
RRA (as described in section 2.7.3.b) and hEGF and rTGF immunological activity by
RLA (as described in section 2.7.4).
2.7.8 NON-DENATURING SDS-PAGE.
Immunologically and biologically active fractions from rHPLC were subjected to
SDS-PAGE on 12% polyacrylamide slab gels according to the method of Laemmli
(1970). The method was essentially similar to that described in section 2.6.2, but the
gels were run under non-reducing conditions (without 2(3-mercaptoethanol in the
sample buffer), with molecular weight markers (Sigma) ranging from 6.2kDa-66 kDa
(apronitin, 6.2 kDa; cytochrome C, 12.4 kDa; carbonic anhydrase, 29 kDa and
albumin, 66 kDa).
After electrophoresis a track of the gel was stained for protein with Coomassie
Brilliant Blue (as described in section 2.6.3) while the remaining tracks were sliced
into 5mm sections.
Detection of biological and immunological activity
For assay of biological and immunological activity, the method used to extract
materials in individual SDS-PAGE gel slices was essentially similar to that used by
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Stromberg et al. (1986). The material in the gel slices was extracted by adding 1 ml of
1 M acetic acid containing 100 pg of bovine serum albumin as carrier, crushing the gel
slice in a conical tube with a glass rod, and incubating them for at least 24 hours at 4° C
to permit polypeptides to leach out of the gel matrix. The supernatant was collected
following a 5 minute centrifugation, frozen to -70°C, lyophilized and reconstituted in
0.5ml with 0.02M PBS prior to assay. A 100 pi aliquot of each eluate was assayed






All competition and saturation analyses were performed using the weighted,
nonlinear least-squares curve fitting program LIGAND (DeLean, et al., 1978; Munson
& Rodbard, 1980), run on an IBM-PC. Scatchard plot analysis of saturation curves
was not employed due to the difficulty in estimating the lowest ligand concentrations,
which are unevenly "weighted" in Scatchard analysis (Bennett & Yamamura 1985).
The program makes a few assumptions in its analysis; (i) Multiple ligands can bind to
multiple sites, (ii) the binding reaction being analysed is at equilibrium, (iii) the binding
is bi-molecular and reversible and (iv) there is total and true separation of bound ligand
from free ligand.
Statistical Curve Fitting
Curves can be fitted to a single - or multi-site model using the "extra sum of
squares" F- test criterion. Thus a model for two binding sites is retained only when it
fits the data significantly better (P< 0.05 partial F test) than a model for a single
binding site.
Weighting Parameters
Weighting has also been incorporated to reduce the tendency for unreliable points
to unduly influence the location of the curve. Thus, weights are assigned to each point
as the reciprocal of the variance at that point, therefore points with the smaller variance
(more precise) usually receive more weight (Rodbard et al., 1976).
Correction Factors
Correction factors have also been included with this program. The factor (C) in the
program is a fitted parameter which adjusts or scales the values of apparent receptor
concentration for any particular experiment. Thus when comparing experiments the
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scale factor for that curve is adjusted eliminating the variability in apparent receptor
concentration between experiments.
2.8.2 SATURATION ANALYSES
Saturation curves were analysed using LIGAND. The curves were analysed
according to a model for one or two binding sites. A model for two binding sites was
retained only when it fitted the data significantly better (P<0.05 partial F test) than a
model for a single binding site. This method represents a substantial improvement
over the most common graphical Scatchard plot for estimation of affinity constants in
ligand binding studies. The advantage of this method is that it fits raw experimental
data in an untransformed coordinate system, where errors are more likely to be
normally distributed and uncorrelated with the independent variable. The
approximations used in many analyses of binding data are non-existent in this method.
This method calculates the "free" values from the experimentally measured "total"
radioactivity added minus the "bound" values and solving the equations which
represent the mass-action law. Non-specific binding is also estimated as an
independent parameter from the entire data set, rather than by the investigator. The
parameters for the affinity constants and receptor densities are also provided with their
standard errors permitting an assessment of the confidence limits for each parameter
obtained. Curves from several experiments were analysed both separately and
simultaneously.
2.8.3 COMPETITION ANALYSES
For each competition curve, estimates of the affinity of the radiolabeled ligand for
the binding site was obtained from separate independent saturation curves. Statistical
analysis comparing "goodness of fit" between one and two affinity state models was
provided and used to determine the most appropriate model for the ligand being
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examined. A model for two binding sites was retained only when it fitted the data
significantly better (P<0.05 partial F test) than a model for a single binding site.
Different curves were then analysed simultaneously to find an estimated value common
to both curves, the parameters were constrained to be estimated as a common value.
The effect of this constraint on the goodness of fit was tested and the shared
parameters were considered statistically indistinguishable if the constraining process
did not significantly worsen the simultaneous fit
2.8.4 OTHER STATISTICAL ANALYSIS
In some experiments, statistical significance was determined using a two-tailed




RES U LT S
In this chapter the results are presented as follows:-
1. Comparative study between DU 145 and LNCaP cell lines
(a) Growth responses to EGF, TGFa and androgens
(b) Characterization of the EGF receptor
(c) Analysis of the EGF and truncated receptor expression by Western blotting.
2. Analysis of medium conditioned by the DU 145 cell line for production of EGF-
like molecules.
3.1 A COMPARATIVE STUDY OF THE GROWTH
RESPONSES AND BINDING OF EGF BETWEEN THE
CELL LINES DU 145 AND LNCAP
The relationship between EGF binding and the growth response of a cell line to
EGF was investigated and compared in the androgen-insensitive (DU 145) and
androgen-sensitive (LNCaP) prostatic carcinoma cell lines. Earlier studies have
touched on the possibility of a synergistic relationship between EGF and androgens
(Traish & Wotiz, 1987; St-Arnaud et al. 1988; Schuurmans et al. 1988a) and it was the
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RESULTS
3.1.1 THE EFFECTS OF EGF ON GROWTH AND DNA SYNTHESIS OF DU
145 AND LNCAP CELLS
The effect of growth factors and/or androgens on the growth rate and DNA
synthesis of the cell lines DU 145 and LNCaP are compared in the following section.
The experiments with DU 145 and LNCaP were carried out with the cell lines cultured
in SFM, with the exception of the experiment described in the following section
(3.1.1.1).
3.1.1.1 Growth response of DU 145 to EGF in serum-containing
medium
The results depicted in Figure 11 demonstrate the impact of increasing
concentrations of EGF on the growth of the cell line DU 145 over a period of 9 days.
For the first 24 hours EGF had no discernable effect on cell growth, whereas after 3
days, EGF concentrations greater than 0.1 nmol/1 inhibited growth in a dose-dependent
fashion. This inhibitory effect on the growth of these cells was more pronounced after
nine days, with EGF concentrations less than 0.1 nmol/1 now significantly inhibiting
proliferation (P < 0.001). EGF at a concentration of 10 nmol/1 exerted the maximum
inhibition on the growth of these cells, with this effect seen as early as 3 days after
EGF was added (Figure 12). As the number of days exposure to EGF increased, a
FIGURE 11: Dose-response effect ofEGF on cell proliferation ofDXJ 145 cells in the presence of
foetal calfserum. Cells in the exponential phase of growth were seeded in 9 well plates (5 000
cells/ cm2) with 10% FCS. After plating (24 hours), EGF (0.01-10nmol/l) was added to triplicate
wells for periods of 1 (Fig.lla), 3 (Fig.llb), 6 (Fig.llc) & 9 days (Fig.lld) and the cells counted
after these times. Each data point represents the mean ± SD (n = 9) of three separate experiments
normalized relative to the untreated control in 10% FCS. The control is represented by the dotted
line at 100%.
FIGURE 12: Time course ofEGF inhibition of cell proliferation ofDU 145 cells. Cells were plated
as described above, EGF (10 nmol/1) was added for up to 9 days and the cells subsequently counted.
Each data point represents the mean ± SD (n = 9) of three separate experiments normalized relative




trend towards inhibition was apparent which after nine days was more pronounced,
inhibiting cell proliferation by 40%± 9, relative to the untreated control (P < 0.001).
3.1.1.2 The effects of EGF on growth and DNA synthesis of DU
145 cells
The effects of EGF on the proliferation and DNA synthesis of a serum-free DU
145 line was investigated in a parallel study, the results of which are depicted in
Figures 13, 14, 15 & 16.
No detectable effect in cell numbers was apparent after 24 hours exposure to EGF,
whereas after 4 days EGF concentrations greater than 1 nmol/1 significantly inhibited
growth (P< 0.05). Similarly on day 6, EGF concentrations greater than 1 nmol/1
inhibited growth (P< 0.05), with lower concentrations up to 0.3 nmol/1 now
stimulating proliferation. Eight days after exposure to EGF this biphasic effect on
growth was abolished, with concentrations which had previously stimulated growth
now inhibiting proliferation.
The data summarised in Figure 14 depicts concentrations which maximally
stimulated (0.3 nmol/1; Fig 14a) and inhibited (10 nmol/1; Fig. 14b) proliferation
expressed as a function of time. Only on day 6 did EGF (0.3 nmol/1) stimulate
proliferation, with an increase of 12%± 12 in cell number, but this increase was not
FIGURE 13: Dose-response effect ofEGF on cell proliferation ofDU 145 cells in SFM. Cells in the
exponential phase of growth were seeded in 24 well plates (50 x 103 cells/well) or 9 well plates (2 x
105 cells/well). After 24 hours EGF (0.01-10nmol/l) was added in SFM to serum free cultures for
1 (Fig.13a), 4 (Fig.l3b), 6 (Fig.l3c) and 8 days (Fig.l3d) and the cells counted after these times.
The data are expressed as mean percentages ± SD (n = 12) of the untreated control, where the control
is 100%. Four separate experiments were performed.
FIGURE \4:Time course ofEGF stimulation and inhibition of cell proliferation ofDU 145 cells.
Cells were plated as described above, EGF (0.3 nmol/1, Fig. 14a; 10 nmol/1; Fig.l4b) was added to
SFM cultures for up to 8 days and the cells subsequently counted. Each data point represents the
mean ± SD (n = 12) of four separate experiments and the data are normalized relative to the
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RESULTS
statistically significant (P > 0.05) and by day 8 inhibition rather than stimulation of
growth was apparent. EGF at a concentration of 10 nmol/1 inhibited growth as early as
day 1, and after 8 days this inhibition was more pronounced, with a decrease of
47%±12 (P < 0.001) in cell number relative to the untreated control.
In a parallel study the impact of EGF on [3H]-Thymidine incorporation was
investigated (Figures 15 & 16). No effect was noted after 8 hours treatment with
EGF, but at 24 hours EGF stimulated [3H]-Thymidine incorporation in a dose-
dependent manner. This stimulatory effect was still discemable at 48 hours and 72
hours with EGF concentrations up to 1 nmol/1. At 72 hours an inhibitory trend was
apparent, with EGF concentrations greater than this value now inhibiting [3H]-
Thymidine incorporation. The maximum increase in [3H]-Thymidine incorporation
(26%±13; P < 0.001) was noted after 24 hours exposure to 1 nmol/1 EGF (Figure
16a). Although still apparent after 72 hours, [3H]-Thymidine incorporation decreased
slightly and was not significantly different from the untreated control. Incorporation of
[3H]-Thymidine increased with 10 nmol/1 EGF after 8 hours and reached a plateau at
24 hours. Thereafter, DNA synthesis decreased and was inhibited at 72 hours,
although not significantly (P > 0.05; Figure 16b).
FIGURE 15: Dose-response effect ofEGF on [3H]-Thymidine incorporation ofDU145 cells. Cells
(1 x 104 cells/well) were plated overnight in SFM/0.5% FCS in 96 well plates. EGF (0.001-10
nmol/1) was added in SFM (6 replicates/ EGF concentration) for 8 (Fig. 15a), 24 (Fig. 15b), 48
(Fig. 15c) & 72 hours (Fig.l5d). [3 H]-Thymidine (37Bq/well) was then added for 4 hours, the cells
were trypsinized and 10% ice-cold TCA added for 2 hours. The cells were then harvested on to filter
mats, dried and counted in scintillation fluid. Each data point represents the mean ± SD (n=60) of
10 separate experiments and the data are normalized relative to the untreated SFM control (100%).
FIGURE \6:Time course ofEGF stimulation of [3H]-Thymidine incorporation ofDU 145 cells. The
experiment was performed as described in Figure 15. EGF (1 nmol/1, Fig.l6a; 10 nmol/1, Fig.16b)
was added to serum free cultures for 8,24,48 & 72 hours. [3H]-Thymidine incorporation was
subsequently measured in TCA precipitable material. Each data point represents the mean ± SD (n











































cell density (cm )
RESULTS
3.1.1.3 Cell density dependence of EGF response by DU 145
cells
The proliferation of cell lines in a defined medium free of serum largely depends
upon the interplay between population density, hormones and growth factors. Kaighn
et al., (1981) demonstrated that the growth of the DU 145 cell line in serum-free
medium was population dependent and that these cells only responded to hormones
and growth factors at high cell density. This was further confirmed by the present
study where sustained growth of DU 145 cells in SFM was found to be dependent
upon high plating densities (> 104 cells/cm2). Cells would detach spontaneously if
seeded at densities less than 104 cells/cm2 and this effect was not overcome by the
addition of growth factors. However, the weak stimulatory response to EGF observed
in section 3.1.1.2 may have been due primarily to the population density. To test this
hypothesis the growth response to EGF was studied at different cell densities.
DU 145 cells were seeded at innocula of lxlO4, 2X104 and 4X104 cells/cm2 and the
growth response to 0.3 nmol/1 EGF was measured after 6 days. The results in Figure
17a indicate that EGF did not stimulate or inhibit cell growth significantly as the
seeding density was increased from lxlO4 to 4 xlO4 cells/cm2. Cell numbers were
only enhanced by 12±18% at a seeding density of 2 x 104 cells/cm2, although this
effect was not significantly different from control values (P > 0.05).
In a parallel study DU 145 cells were seeded at innocula of 1 xlO4- 6X104 cells/cm2
and DNA synthesis was measured by [3H]-Thymidine incorporation after treating the
cells for 24 hours with 1 nmol/1 EGF (Figure 17b). Overall, varying the cell density
did not greatly enhance the mitogenic effect of EGF. The maximal stimulatory effect
FIGURE 17: The effect of cell density on the response to EGF. Cells were seeded at innocula of 1 x
104 - 6 xlO4 cells/cm2 in 24 or 96 well plates. After plating (24 hours later) EGF (0.3 nmol/1 or
1 nmol/1) was added for 6 days and the cells subsequently counted or for 24 hours and [3H]-
Thymidine incorporation measured. The results are expressed as means ± SD relative to untreated















with EGF was noted at a seeding innoculum of 3 x 104 cells/cm2, where DNA
synthesis was stimulated by 26%±20 (P< 0.001) relative to control values. Densities
greater than 3 x 104 cells/cm2 did not enhance this effect on [3H]-Thymidine
incorporation. However this stimulatory response by EGF was abolished when the
density was reduced to 1 x 104 cells/cm2.
3.1.1.4 Dose-response effect of TGFa on DNA synthesis of DU
145 cells
One class of growth factors which shares sequence and structural homology with
EGF and shows a variety of biological actions similar to EGF are the alpha TGFs.
TGFas are potent mitogens for a number of cell types and bind to and interact with the
EGF receptor (Massague, 1983). Consequently TGFa was assayed for its effect on
the incorporation of pH]-Thymidine in DU 145 cells, as a comparison to EGF (Figure
18). TGFa had very little effect on DNA synthesis after 24 hours as measured by
[3H]-Thymidine incorporation. A weak, but significant stimulatory response was
noted at a concentration of 0.03 nmol/1, with an increase in incorporation of 17%±10;P
< 0.05 relative to control values. TGFa concentrations greater than 0.03 nmol/1
showed a slight tendency towards inhibition, with 10 nmol/1 inhibiting [3H]-Thymidine
incorporation by 17%±11 (P < 0.05).
FIGURE 18: Dose-response effect ofTGFa on DNA synthesis ofDU 145 cells. Cells were seeded in
96 well plates (1 xlO4 cells/well), and after plating TGFa (0.01-10 nmol/1) was added (8 replicates/
TGFa concentration) for 24 hours. [3 H]-Thymidine (37Bq/well) was then added for 4 hours, the
cells were trypsinized and 10% ice-cold TCA added for 2 hours. The cells were subsequently
harvested on to Filter mats, dried and counted in scintillation fluid. Each data point represents the




Summary of effects of growth factors on proliferation and DNA
synthesis of DU 145 cells
The growth of the DU 145 cell line was not stimulated by EGF when these cells
were grown in the presence of foetal calf serum. However, growth was significantly
inhibited with higher concentrations of EGF and this effect was dose-dependent
Prolonged treatment with EGF enhanced this inhibitory effect on these cells, with EGF
concentrations that had previously shown no effect, inhibiting proliferation. Similarly,
EGF inhibited the growth of DU 145 cells grown in SFM, but in SFM a slight
stimulatory effect was noted with concentrations up to 0.3 nmol/1. Although this effect
on growth was not significant, EGF (at a similar concentration) significantly enhanced
DNA synthesis.
TABLE 2: DOSE-RESPONSE EFFECTS OF DU 145 CELLS TO
EGF AND TGFa IN SFM
Addition Cell count pH]-Thymidine incorporation
to culture (% of control) (% of control)
EGF
0.03nM 107± 13 a (4)fc 112 ±14 (10)
0.3nM 112± 12 (P >0.05) (4) 124±13 (P < 0.001) (10)
lOnM 83 ±20 (4) 122 ±12 (io)
TGFa
0.03 nM ND 117±10 (P <0.05) (3)
0.3 nM ND 104±10 (3)
10 nM ND 83±11 (3)
DU 145 cells were seeded at a density of 2 x 105 cells/well in 6 well plates or 1 x 104 cells/well in a
96 well plate. The indicated additions were made 24 hours after seeding. Cell counts were carried out 6
days after the initial addition of growth factors and DNA synthesis was measured by the incorporation
of [3H]-Thymidine after 24 hours. The results are expressed as a percentage of the untreated control
(100%). ND = not determined.
a Mean ± SD.
b Numbers in parenthesis, number of experiments.
The results summarised in Table 2 also depict the response of TGFa on DNA
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were significantly but only minimally affected by TGFa. The concentration of TGFa
which maximally stimulated DNA synthesis was 10 fold lower than that observed for
EGF.
The mitogenic response of DU 145 cells to EGF was not enhanced significantly
by varying the seeding densities of these cells, although the growth of these cells was
density dependent.
3.1.1.5 The effects of EGF on cell proliferation and DNA
synthesis of LNCaP cells
After the initiation of this investigation a report was published by Schuurmans et
al. (1988a), describing preliminary experiments on the growth response to EGF in
LNCaP cells. Therefore, rather than determining the times at which the cells exhibited
maximal stimulation to EGF, as carried out for DU 145 cells (section 3.1.1.2) the
conditions determined by Schuurmans and co-workers were used.
Increasing concentrations of EGF were added to LNCaP monolayers for 6 days to
determine the proliferative effects of EGF (Figure 19a) or alternatively for a period of
24 hours and the incorporation of [3H]-Thymidine measured (Figure 19b). EGF
exerted a biphasic effect on proliferation over the concentrations tested.
FIGURE 19: a) Dose-response effect ofEGF on cell proliferation ofLNCaP cells. Cells were seeded
in 24 well plates (2 x 104 cells/cm2) in complete medium. After 3 days the cells were washed once
with Dulbecco 'A' PBS, SFM was added for several hours and was then replaced by fresh medium
with EGF (0.01-10 nmol/1) and after 6 days the cells were counted. The results are expressed as cell
number relative to the untreated control (100%; dotted line). Each data point is the mean of nine
observations ± SD of three separate experiments,
b) Dose-response effect of EGF on DNA synthesis ofLNCaP cells. Cells were seeded at innocula of
2 x 104 cells/cm2 in 96 well plates in complete medium (as above). After three days EGF (0.01-10
nmol/1) was added in SFM for a period of 24 hours, p H]-Thymidine (37Bq/well) was then added for
4 hours, the cells were trypsinized and 10% ice-cold TCA was added for 2 hours. The cells were
then harvested on to filter mats, dried and counted in scintillation fluid. Each data point represents
the mean ± SD (n=24) of three separate experiments and the data are normalized relative to the
untreated SFM control (100%).
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Concentrations up to 0.3 nmol/1 EGF enhanced proliferation by 98% ± 6 relative to
control values (P< 0.001), with higher concentrations abolishing this stimulatory
effect.
EGF also stimulated DNA synthesis in a dose-dependent fashion, with the
maximal effect observed with 0.3 nmol/1 EGF, increasing [3H]-Thymidine
incorporation by 78±10% (P < 0.001). A dose-dependent decrease in [3H]-Thymidine
incorporation was noted with concentrations greater than 0.3 nmol/1 (Figure 19b).
3.1.1.6 The effects of EGF and the androgens Mibolerone and
R1881 on cell proliferation and DNA synthesis of LNCaP cells
The androgen sensitive LNCaP cell line was used to investigate the relationship
between growth factors and androgens in prostate cancer.
The synthetic androgens Mibolerone and R1881 were added to SFM cultures of
LNCaP cells with and without EGF, for a period of 6 days and the cells counted after
this time (Figure 20) or for 24 hours and incorporation of [3H]-Thymidine measured
(Figure 21).
EGF and Mibolerone independently increased proliferation by 82%±18 (P <
0.001) and 51%±8.5 (P < 0.02) respectively. The addition of EGF and Mibolerone
together to LNCaP cells did not produce a greater stimulatory effect than EGF alone
(77%±12) (that is the effect on proliferation was not additive). Contrary to the
stimulatory effect on proliferation with 0.1 nmol/1 of Mibolerone, R1881 at the same
concentration did not enhance proliferation. However, when R1881 was added to
cells grown in 10% FCS, cell proliferation was inhibited by 74%±14 relative to the
complete medium control (P < 0.001). Mibolerone, at the same concentration also
FIGURE 20: The effect ofEGF and MiboleronelR1881 on cell proliferation ofLNCaP cells. Cells
were seeded at innoculum of 2 x 104 cells/cm2 in 6 well plates. After three days the factors to be
tested were added in SFM as indicated, for 6 days and the cells subsequently counted. Each data
point represents the mean ± SD (n=9) of three separate experiments and the data are normalized













inhibited proliferation when added with 10% FCS, but not by the same extent (65%±7;
P < 0.05).
EGF and Mibolerone independently stimulated DNA synthesis by 80%± 10 and
70±14% respectively (P < 0.001). However, this response was not additive as EGF
and Mibolerone added together did not increase [3H]-Thymidine incorporation above
79%±8 (Figure 21). Moreover, varying the concentration of EGF with Mibolerone
did not enhance DNA synthesis above that already observed with EGF (0.3 nmol/1).
Contrary to the growth response with Mibolerone, R1881 did not increase [3H]-
Thymidine incorporation when added to cultures grown in SFM, but DNA synthesis
was significantly inhibited by 53%±8 (P <0.001; relative to the complete medium
control) when R1881 was added to cultures grown in 10% FCS.
Summary of effects of EGF on proliferation and DNA synthesis
in LNCaP and DU 145 cells
The data from proliferation and DNA synthesis studies with DU 145 and LNCaP
are summarised in Table 3. The androgen insensitive DU 145 cell line was only
minimally affected by EGF unlike the androgen sensitive LNCaP cell line. LNCaP cell
numbers and [3H]-Thymidine incorporation were increased by EGF; almost 2 fold, but
this response with EGF was not affected by the androgen Mibolerone, although alone
Mibolerone enhanced the growth of LNCaP cells. In contrast to Mibolerone, the
synthetic androgen R1881 did not appear to affect cell proliferation or [3H]-Thymidine
incorporation in SFM. However, when LNCaP cells were cultured in complete
FIGURE 21: The effect ofEGF and MiboleronelR1881 on DNA synthesis ofLNCaP cells. Cells
were seeded at innoculum of 2 x 104 cells/cm2 in % well plates. After three days the factors to be
tested were added in SFM as indicated in the figure, for 24 hours and incorporation of [3H]-
Thymidine measured on TCA precipitable material. Each data point represents the mean ± SD




medium, the addition of R1881 to LNCaP cells inhibited both cell proliferation and
DNA synthesis. A similar, but less dramatic effect was noted with Mibolerone.
TABLE 3: DOSE-RESPONSE EFFECTS OF EGF ON CELL
PROLIFERATION AND [3H]-THYMIDINE INCORPORATION OF
DU 145 AND LNCAP CELLS
EGF Cell count [3H]-Thymidine incorporation
nmol/1 (% of control) (% of control)
DU 145
0.03nM 107113° (4) 112 ±14 (10)
0.3nM 112± 12 (P >0.05)(4) 124113 (P < 0.001) (10)
lOnM 83 ± 20 (4) 122 ±12 (10)
LNCaP
0.03 nM 146+11(3) 12518 (3)
0.3 nM 19816% (P <0.001 )(3) 178110 (P< 0.001) (3)
10 nM 110±19 (3) 127112 (3)
DU 145 cells were seeded in 9 well plates (2 x 105 cells/well) for proliferation experiments and 96
well plates at a density of 1 x 104 cells/well for DNA synthesis experiments. LNCaP cells were
seeded at a density of 2 x 104 cell/cm2 in multiwell plates. The indicated additions were made 24
hours after seeding in SFM cultures. Cell counts were carried out 6 days after the initial addition of
growth factors and DNA synthesis was measured by the incorporation of [3H]-Thymidine after 24
hours. The results are expressed as a percentage of the untreated control (100%).
a Mean ± SD.










3.1.2 EGF RECEPTOR CHARACTERIZATION OF DU 145 & LNCAP CELL
LINES
Since EGF affected the growth of both DU 145 and LNCaP cells the next step in
this study was to characterize the EGF receptor of both cell lines. Using a ligand
binding exchange assay the kinetics of association and dissociation were investigated,
along with saturation, competition, internalization, specificity and down regulation of
the receptor. The expression of the EGF receptor and the \-erb B gene product was
also investigated by Western blotting and the results are presented in the following
section.
3.1.2.1 Association kinetics: effect of temperature on the time
course of [125I]-EGF binding
The time course of [125I]-EGF binding to prostatic carcinoma cells was examined at
37°C and 4°C (Figure 22 a & b). Binding of [125I]-EGF to DU 145 and LNCaP cells
was time and temperature dependent. Specific binding of [125I]-EGF increased rapidly
at 37°C, reaching a plateau after 3 hours with DU 145 cells and 5 hours with LNCaP
cells, thereafter a decrease in specific binding was observed with DU 145 cells. At
4°C, binding of [125I]-EGF to DU 145 monolayers also increased rapidly with time and
a steady state was reached after 3 hours, although the percentage of total specific
binding was substantially lower at 4°C than 37°C. Binding of [125I]-EGF to LNCaP
monolayers at 4°C increased at a much slower rate, a steady state was reached 6 hours
FIGURE 22: Effect of time and temperature on specific binding of [?25I]-EGF in DU 145 & LNCaP
cells. Nearly confluent cultures of DU 145 and LNCaP monolayers (2 xlO5 cells/well) were plated
in 24 well plates. Binding was carried out with sub-saturating levels of [125I]-EGF (2nmol/l; 2 x
105 cpm) at 4°C (□) and 37°C (■ ) in the presence and absence of lOOx excess unlabelled
EGF. At the times indicated the monolayers were washed in Dulbecco'A' PBS (3x), the cells were
dissolved in 0.5N NaOH and the radioactivity measured. Specific binding was measured by
subtracting total binding from non-specific binding. The results are expressed as the percentage of
[125I]-EGF specifically bound. Each data point is the percentage mean ± S.D of three separate































































after the addition of [125I]-EGF and the percentage of specific binding was
substantially lower at 4°C than 37°C. Specific binding of [125I]-EGF to DU 145
monolayers at steady state (after 4 hours) was higher overall when compared with the
percentage bound [125I]-EGF to LNCaP monolayers at steady state (6 hours). Based
on these results, subsequent binding studies for both cell lines were performed at 4°C
for 4-6 hours, since at this temperature internalization of EGF is kept to a minimum.
3.1.2.2 Dissociation kinetics
The rate of [125I]-EGF dissociating from the EGF receptor on DU 145 and LNCaP
cells is shown in Figure 23. Dissociation was initiated after 4 hours (DU 145) and 6
hours (LNCaP) incubation at 4°C with [125I]-EGF, at which time a steady state had
been reached for both cell lines. For DU 145 cells, the rate of dissociation at 4°C was
rapid and linear up to 2 hours after dissociation was initiated. The time taken for half
of the EGF-EGF receptor complex to dissociate (t1/2) at 4°C was 1.5 hours. Similarly,
the rate of EGF-EGF receptor dissociation on LNCaP cells at 4°C was rapid and linear
with a ti/2 of 1.75 hours.
3.1.2.3 Competition & saturation analysis of DU 145 and LNCaP
cell lines
Saturation and competition analysis were used to determine whether EGF binding
on DU 145 and LNCaP cells was of high affinity and limited capacity.
(a) Competition analysis:
Increasing concentrations of unlabelled EGF successfully competed with [125I]-
EGF for binding sites on DU 145 and LNCaP monolayers (Figure 24). The binding
FIGURE 23: Time course ofdissociation of 25I]-EGF bound to the EGF receptor ofDJJ 145 and
LNCaP cells. Nearly confluent cells (2 xlO^ cells/well) were incubated with [125I]-EGF (2nmol/l;
2 x 105 cpm) for 4 - 6 hours at 4°C. The binding medium was aspirated and the incubation was
continued in SFM for the times indicated. At various time points triplicate dishes were processed
to determine [12-h]-EGF bound, which is expressed as a percentage of [1251]-EGF bound at time
zero. Each data point is the percentage mean ± SD of three experiments (n = 9).
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parameters from both cell lines, calculated using the computer program LIGAND,
fitted significantly to a one site receptor model (P < 0.05). The dissociation constants
(K<j) were of high affinity and were of the same order of magnitude (0.6± 0.5 nmol/1;
DU145 and 2.3 ±1.7 nmol/1; LNCaP). However, the number of binding sites (R)
from DU 145 cells (3.0 ± 1.0 x 105 sites/cell) were 10 fold higher than those from
LNCaP cells (3.1±1.5 x 104 sites/cell).
(b) Saturation Analysis:
Increasing concentrations of [125I]-EGF saturated receptor binding sites on DU 145
and LNCaP cell monolayers, indicating specific binding of [125I]-EGF (Figure 25).
The data for DU 145 were analysed using the curve fitting program LIGAND and
fitted significantly to one class of binding site (P< 0.05), with an estimated Kd value
of 1.0 ± 0.5nmol/l. The number of binding sites/cell was calculated as 2.0 xlO5 ± 8
dissociation
xlO4. The /\ constant of the EGF receptor in LNCaP cells was calculated as 2.9
± 2.2 nmol/1 and the number of receptor binding sites/cell as 2.5 ± 1.3 x 104; almost
10 fold lower than DU 145 cells.
The means of the binding parameters from saturation and competition analysis
were compared and are tabulated in Table 4. Overall the binding affinity and capacity
for DU 145 monolayers were 1.0 ± 0.6 nmol/1 and 2.5 ± 1 x 105 sites/cell
respectively. The number of binding sites for LNCaP cells was considerably less (2.0
(li^oc»otion
± 1 x 104 ); a 10 fold difference in receptor number. The a constant of 2.8 ± 2.2
nmol/1 was lower overall, but was not significantly different from DU 145 cells.
FIGURE 24: Competition of [?251]-EGF with unlabelled EGF. Confluent monolayers (2 x 105
cells/well) were incubated with [125I]-EGF (2nmol/l; 2 x 105 cpm) and increasing concentrations of
unlabelled EGF (0.01-300 nmol/1) for 4 hours (DU 145) and 6 hours (LNCaP) at 4°C. The cells
were subsequently washed 3x in Dulbecco 'A' PBS, dissolved in 0.5N NaOH and the radioactivity
measured. The affinity constant and the binding capacity of each cell line was determined using the
binding program LIGAND. Four competition curves were analysed from the cell line DU 145 and
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TABLE 4: THE AFFINITY AND BINDING CAPACITY OF EGF
RECEPTORS OF DU 145 AND LNCAP CELLS
DU 145 LNCaP
Kd mol/1 1 ± 0.6 nMfl 2.8 ± 2.2 nM
R sites/cell 2.5 ± 1.0 x 105 2.0± 1.0 x 104
Saturation and competition analysis was performed on confluent DU 145 and LNCaP monolayers (2 x
105 cells/well) in multiwell plates. The affinity constant Kj and the number of binding sites/cell (R)
were calculated using the binding program LIGAND. The means of the Kj and the binding capacity
for both cell lines are shown.
a Mean ± SD.
(c) Saturation analysis ofMibolerone treated LNCaP cells
Several workers have shown that the EGF receptor concentration is modulated by
androgens in the prostate (Traish & Wotiz, 1987; St-Arnaud et al. 1988 and
Schuurmans et al., 1988a). This transmodulatory effect of androgens on the EGF
receptor was further investigated using the androgen sensitive cell line LNCaP.
Mibolerone was added to LNCaP monolayers for a period of 6 days, after which time
the number and affinity of binding sites was determined by saturation analysis and
analysed using the LIGAND binding program (Table 5).
After exposure to Mibolerone for 6 days neither the affinity constant nor the
number of EGF binding sites were significantly altered (P > 0.05).
FIGURE 25: Saturation Curves ofDU 145 and LNCaP cell lines. Increasing doses of [125I]-EGF
(0.01-10 nmol/1) were incubated in triplicate wells with or without a constant amount of unlabelled
EGF (200 nmol/1) for 4 hours (DU 145) or 6 hours (LNCaP) at 4°C. The monolayers were washed
3x with Dulbecco 'A' PBS to separate bound [1^1]-EGF from free [^^I]-EGF, the cells were
subsequently dissolved in 0.5 N NaOH and the radioactivity remaining was evaluated. The affinity
constant and the number of EGF binding sites were determined by the binding program LIGAND.
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RESULTS
TABLE 5: EFFECT OF MIBOLERONE ON THE AFFINITY AND
BINDING CAPACITY OF LNCAP EGF RECEPTORS
Mibolerone no Mibolerone
Kd mol/1 3.5 ± 2.6 nMfl (3)b 2.8 ± 1.8 nM (3)
R sites/cell 2.0+1.1 x 104 2.5+1.3 x 104
Mibolerone (0.1 nmol/1) was added in SFM to LNCaP cell monolayers (2 x 104 cell/cm2) in
multiwell plates for a period of 6 days. Control wells were grown without Mibolerone. After 6 days,
saturation analysis was performed with increasing concentrations of ['^IJ-EGF (0.01-10nmol/l) and a
constant amount of unlabelled excess ligand (200 nmol/lEGF). The affinity constant Ktf and the
number of binding sites/cell (R) were calculated using the binding program LIGAND.
a Mean ± SD.
^ Numbers in parenthesis, number of experiments.
3.1.2.4 Specificity of [125 l]-EGF binding to DU 145 and LNCaP
EGF binding sites
The specificity of [125I]-EGF binding to specific binding sites on DU 145 and
LNCaP cell monolayers was further established by competition experiments with
various peptide hormones and growth factors (Figure 26). Mouse EGF, human EGF
(urogastrone) and TGFa, which are of similar size and structure were equally effective
in competing with [125I]-mEGF for EGF binding sites on DU 145 and LNCaP cells
(>95% competition). However, peptides unrelated structurally to EGF did not
compete with [125I]-mEGF for binding sites on either DU 145 or LNCaP monolayers.
FIGURE 26: Specificity of [^25I]-EGF binding to its' receptor on DU 145 and LNCaP cells. [125I]-
EGF (2nmol/l; 2 x 105 cpm) was added to confluent monolayers with or without lOOx excess
unlabelled competing ligands (mEGF, hEGF, TGFa, NGF, GH and Insulin which were added to
triplicate wells for 4 hours (DU 145) or 6 hours (LNCaP) at 4°C. The monolayers were
subsequently washed, the cells dissolved with 0.5 N NaOH and the radioactivity remaining,
determined. Specific binding was determined by subtracting non-specific from total binding. Each
data point represents the percentage mean ± SD of three experiments, n = 9. The data is expressed





3.1.2.5 Internalization of EGF binding sites
To determine whether [125I]-EGF is internalized by human prostate cancer cells,
the effect of brief exposure to saline/glycine (pH 3.0) on monolayer-bound
radioactivity was examined. The effect of acid extraction on specific [125I]-EGF bound
to DU 145 and LNCaP cells is shown in Figure 27. At 37°C the proportion of
specifically bound [125I]-EGF that was acid elutable decreased rapidly with time.
When apparent steady state binding was achieved at 37°C, the majority of specifically
bound [125I]-EGF had been internalized. The rate of internalization was slower for
LNCaP than for DU 145; after 2 hours the binding capacity of DU 145 monolayers
was reduced by 80%, whereas for LNCaP cells, the binding capacity was reduced by
55%. At 4°C, almost no internalization of the EGF-receptor complex had occurred,
since the majority of specifically bound [125I]-EGF was acid elutable after 6 hours.
3.1.2.6 Down regulation of [125I]-EGF binding sites
Cells which are exposed to increasing concentrations of EGF gradually lose a
substantial fraction of their receptors for EGF (Carpenter & Cohen, 1979 and
Schlessinger et al. 1986). This phenomenon called "down regulation" depends upon
EGF concentration, time and temperature. Down regulation of EGF receptor sites
from DU 145 and LNCaP cells was demonstrated by pre-incubating cell monolayers
with increasing concentrations of EGF for 24 hours (Figure 28). Preincubation of DU
145 and LNCaP monolayers with EGF effectively reduced specific binding of
radiolabelled growth factor. Half-maximal reduction in specific [125I]-EGF binding
FIGURE 27: Internalization ofDU 145 and LNCaP EGF binding sites: Confluent LNCaP and DU
145 monolayers (2 x 10s cells/well) were incubated with [125I]-EGF (2 nmol/1; 2 x 105 cpm) in the
presence and absence of unlabelled EGF (200 nmol/1) at 4°C (□) and 37°C (■ ). At various
time points (as indicated), triplicate dishes were processed by washing 3x with ice-cold Dulbccco 'A'
PBS and extracting surface bound EGF by washing with ice-cold NaCl/Glycine. Total binding,
non-specific binding and acid elutable [1251]-EGF binding to cell monolayers was then determined.
The data is expressed as the percentage mean ± SD of [125I]-EGF specifically bound which was acid








I I » Mlllj I I II III! | II III II11 I I M1IH|
.001 .01 .1 10
m-nj
100
Concentration of EGF in preincubation
medium (nmol/l)
Concentration of EGF in preincubation
medium (nmoi/l)
RESULTS
required a concentration of 0.2 nmol/1 and 0.8 nmol/1 in the preincubation medium of
DU 145 and LNCaP cells respectively.
3.1.2.7 Expression of the EGF and truncated receptor on DU 145
and LNCaP cells by Western blotting
The expression of the EGF receptor from DU 145 and LNCaP cell lysates was
demonstrated by Western blotting (Plates 1 & 2). DU 145 and LNCaP cell lysates
were blotted onto nitrocellulose and incubated with two Mab against the EGF receptor
and a non-specific MHC IgG class 2 antibody which served as a control.
Incubation of DU 145 cell lysates with the monoclonal F4, revealed a distinct
band corresponding to a molecular weight of 170 000 on SDS-PAGE (Plate 1; track
1), but there was no expression of the truncated receptor; i.e. there was no band at 68
kDa (track 1). EGFR1 (which has a higher affinity for the EGF receptor than F4) did
not bind to the EGF receptor from DU 145 cell lysates as there was no expression of
the native EGF receptor on the blotted gel (track 2). Neither the EGF receptor nor the
truncated receptor were expressed in LNCaP cells using Western blotting (Plate 2).
FIGURE 28: Down regulation ofDU 145 and LNCaP EGF binding sites. DU 145 and LNCaP
monolayers (2 x 10s cells/well) were incubated with increased concentrations of EGF (0.01-10
nmol/1) for 24 hours at 37°C, with control wells receiving no EGF. Subsequently, the monolayers
were washed extensively (by washing 3x in Dulbecco 'A' PBS and once with ice-cold NaCl/Glycine)
to remove surface bound EGF. Binding was then initiated by the addition of [125I]-EGF (2 nmol/1;
2 x 105 cpm) in the presence and absence of unlabelled EGF (200 nmol/1) for 4 hours (DU 145) or
6 hours (LNCaP) at 4°C. After the incubation period the monolayers were washed, the cells
dissolved with 0.5 N NaOH and the radioactivity remaining determined. Receptor down regulation
was seen as any decrease in specific binding relative to the untreated control. Each data point





3.1.3 SUMMARY OF RESULTS FROM THE CHARACTERIZATION OF THE
EGF RECEPTOR OF DU 145 AND LNCAP CELLS
The cell lines DU 145 and LNCaP express high affinity EGF receptors with similar
A. constants (K<j = 1 ± 0.6 nmol/1 and 2.8 ± 2.2 nmol/1 respectively), but with
dissimilar receptor numbers. The DU 145 cell line expresses high levels of EGF
receptors (2.5 ± 1.0 x 105 sites/cell) whereas LNCaP cells have 10 fold lower receptor
numbers (2.0 ± 1.0 x 104 sites/ cell).
Further characterization revealed that prostate cells specifically bound, internalized
and down regulated their receptors. The expression of the EGF receptor (Mr 170 000)
on DU 145 cells was further verified by Western blotting but LNCaP cells did not
express the receptor using this technique. Neither DU 145 nor LNCaP cells expressed
the truncated receptor.
Plate 1: Expression of the EGF receptor and the truncated EGF receptor by Western blotting in DU
145 cells. Cell lysates (5 x 107 cells) from DU 145 cells were electrophoresed, blotted onto





3.2 ANALYSIS OF CONDITIONED MEDIUM FROM DU
145 CELLS
The secretion of growth factors by some transformed cells is thought to enable
these cells to proliferate in low serum concentrations, as well as reducing the
dependency upon exogenous growth factors. One mechanism of transformation is
thought to involve cells being able to produce and respond to growth factors (autocrine
secretion), thus conferring a growth advantage over other cells (Spom & Todaro,
1980). TGFas (which bind to the EGF receptor) and other growth factors have been
implicated in the autocrine and/or paracrine growth of tumour cells (Spom & Roberts,
1985). Medium conditioned by DU 145 cells was therefore analysed for the
production of the growth factors EGF and TGFa. The CM was also partially purified
by chromatography and SDS-PAGE.
3.2.1 ANALYSIS OF CONCENTRATED CM FROM DU 145 CELLS
The production of EGF-like activity from medium conditioned (CM) by DU 145
was analysed for (a) EGF-like competitive activity using an EGF-radio receptor assay
(RRA) (b) EGF and TGFa immunological activity using RIAs for rTGF-I and hEGF
and (c) mitogenic activity by [3H]-Thymidine incorporation into DU 145 cells.
Plate 2 : Expression of the EGF receptor and the truncated receptor by Western blotting inLNCaP
cells: Cell lysates (5 x 107 cells) from the LNCaP cell line were electrophoresed, blotted onto





3.2.1.1 Production of EGF-like competing factors
To examine for the presence of specific EGF-like; molecules in the CM from DU
145 cells, increasing concentrations of CM were tested for the ability to compete with
[125I]-EGF for binding to DU 145 cells (Figure 29). Growth factors present in the CM
inhibited [125I]-EGF binding in a dose-dependent fashion. By comparison to the
competition curves produced by unlabelled mEGF with [125I]-EGF (inset of Figure
29), the amount of EGF equivalent units in the samples of CM was calculated. The
50% effective dose for DU 145 lyophilized CM in the EGF radioreceptor assay was
approximately 6 ng/ml, since in this assay 50% competition was equivalent to lnmol/1
(0.6ng/assay) of EGF. Therefore, approximately 30 ng of EGF-like equivalent
molecules were produced in 1 litre of media conditioned by DU 145 cells.
3.2.1.2 Production of immunoreactive EGF and TGFa
Equivalent amounts of concentrated CM were assessed for immunoreactivity using
rTGF-I and hEGF RIAs. The relative amounts of immunoreactive species produced
by DU 145 cells were compared with the levels of biologically active EGF-like
molecules that competed with [125I]-EGF for binding to DU 145 monolayers (Table 6).
Approximately 20.3 ng/litre of immunoreactive TGFa was produced by DU 145 cells,
compared with 30 ng/litre of EGF equivalent molecules (i.e. those which demonstrated
competitive activity with [125I]-EGF). As no EGF was detected when CM was
assayed for hEGF by RIA, the remaining 32% of bioactive EGF-like molecules
FIGURE 29: Production of competitive EGF-RRA activity from medium conditioned by DU 145
cells. Increasing concentrations of DU 145 conditioned medium (CM) were assayed for EGFRRA
competitive activity. [125I]-EGF (2 nmol/1; 2 x 105 cpm) was incubated with or without increasing
concentrations of CM for 4 hours at 4 °C. The cells were then processed by washing 3 x with
Dulbecco 'A' PBS and the radioactivity remaining measured. The amount of EGF equivalent units
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produced by DU 145 cells (of which 68% were immunologically related to
TGFa) could not be attributed to the production of immunoreactive EGF.
TABLE 6: PRESENCE OF EGF RECEPTOR COMPETING
ACTIVITY AND IMMUNOREACTIVE TGFa S IN THE CM OF DU
145 CELLS.
Assay Amount (ng/ litre CM)
RIA
hEGFa -
rTGF-I*' 20.3 ± 2.4
RRA° 30
CM samples were assayed for hEGF, TGFa immunoreactivity by RIA and EGF-RRArCompetitive
activity. Values are normalized to 1 litre of CM produced by DU 145 cells.
a hEGFRIA in which half maximal inhibition of binding occurred at 200 pg/tube.
rTGF-I. 50% competition occurred with 100 pg/tube. The value obtained is the mean ± SD of
duplicate experiments.
c The level of EGF equivalent units was obtained by comparison to the competition curves produced
by unlabelled mEGF with [125I]-EGF
3.2.1.3 Effect of concentrated CM on DNA synthesis in DU 145
cells.
Increasing concentrations of pooled and concentrated CM from DU 145 cells were
added to DU 145 cell monolayers for up to 72 hours and tested for its' effect on DNA
synthesis (by incorporation of [3H]-Thymidine; Figure 30). Initially concentrations
between 3-1000 (ig/ml of CM were tested over this time period and the maximum
FIGURE 30: Dose-response effect ofDU 145 CM on [3H]-Thymidine incorporation ofDU 145 cells.
DU 145 cells (1 x 104 cells/well) were seeded in 96 well plates and increasing concentrations of
CM (3-1000 pg/ml) added for up to 72 hours and concentrations between 0.01-1000 pg/ml for 24
hours. After each incubation period the amount of [3H]-Thymidine incorporated into DNA was
measured by precipitating the cellular material with 10% ice-cold TCA; which was added for 2
hours. The TCA precipitable material was harvested, dried and the radioactivity measured. The data
are expressed as the percentage of pH]-Thymidine incorporated relative to the untreated control with
filled data points representing the mean ± SD of 6 observations and unfilled points as the mean ±





response was noted after 24 hours. The experiment was repeated for up to 24 hours,
with concentrations between 0.01-1000 |ig/ml.
Factors in the CM exerted a biphasic effect on DNA synthesis as early as 8 hours
after the addition of CM and this effect was still prevalent up to 72 hours. The
maximum stimulatory effect on DNA synthesis (after 24 hours) was observed with 30
pg/ml CM (46% ± 28; P < 0.001). Concentrations less than this value (from 0.01 to
lpg/ml) inhibited incorporation of pH]-Thymidine by approximately 50% (P <
0.001).
The decline in incorporation of pH]-Thymidine observed with concentrations
greater than 100 (ig/ml CM was probably due to dilution of nutrients in the serum free
media.
3.2.2 CHARACTERIZATION OF EGF-LIKE PRODUCTION BY DU 145
CELLS
The concentrated CM was fractionated by size exclusion chromatography and
rHPLC and the fractions assayed for EGF-RRA competitive activity and rTGF-I and
hEGF immunological activity. The results are presented in the following section.
3.2.2.1 Gel filtration profile of DU 145 conditioned medium
Concentrated DU 145 CM was subjected to size-exclusion chromatography on a
Sephadex G-100 column, the profile of which is depicted in Figure 31. Absorbance at
280 nm is restricted mainly to the void volume, resulting from the transferrin (Mr 80
FIGURE 31: Gelfiltration chromatography ofconcentrated DU 145 CM. Concentrated CM (10 mg)
was applied to a Sephadex G-100 column (100 x 2.5 cm), equilibrated and eluted with 0.02M PBS,
pH 7.4 in 3 ml fractions. Protein was determined by absorbance at 280 nm ( -). A 200 pi aliquot
of every third fraction was tested for competitive activity in an EGF RRA (-■-) and a 100pl
aliquot tested for immunological activity in hEGF and rTGF-I RIAs (not detected). Molecular
weight markers were thyroglobulin, 670 K; gamma globulin, 158 K; ovalbumin, 44 K;







000) added to the SFM, and to the low molecular weight region (< 1350), due to
coloured pH indicators in the culture media. Analysis of EGF-competing activity in
the column eluants showed a broad major peak of activity between Mr 30 000 and 50
000 and a sharp minor peak of activity at an apparent size of Mr 5 000. However, the
levels of EGF-like competitive activity detected in the fractions were such that only
23% competition was associated with the major peak and 12% activity with the minor
peak. Moreover, neither hEGF nor TGFa immunological activity was detected in the
fractions eluted from the column.
3.2.2.2 rHPLC profile of DU 145 conditioned medium
Medium conditioned by DU 145 cells was chromatographed using rHPLC, and
the fractions examined for immunological rTGF I, hEGF activity and EGF
radioreceptor competitive activity (Figure 32). Associated with the three major 280 nm
absorbance peaks (> 1 Au) in the middle of the gradient was a minor peak of
competitive activity (20% competition), which was equivalent to approximately 1.4 ng
of EGF/ml. Two other major peaks of competitive activity eluted at the beginning and
end of the run. The peak of competitive activity eluting at the beginning of the run
(fractions 7-12) was equivalent to approximately 2.9 ng EGF/ml (43% competition).
The broad peak of competitive activity (fractions 36-40) inhibited [125I]-EGF binding
by 45%, (3 ng EGF equivalents/ml). Interestingly, the only peak of immunoreactive
rTGF I (fractions 12-19, 1.250 ng/ml), also demonstrated EGF-like competitive
activity (32% competition; 2.1ng EGF equivalents/ml). The fractions were also tested
FIGURE 32: Reverse-phase HPLC of concentrated DU 145 CM. Trifluro acetic acid (0.1%) was
added to concentrated CM (15 mg) and the soluble material was loaded on to a Bio-Rad RP 304 C4
column (250 mm x 10 mm) and subjected to HPLC. Every third fraction (200 pi aliquot) was
assayed for competitive activity in an EGF-RRA (-■-) and 100 pi aliquots were assayed for
immunological hEGF (not detected) and rTGF-I activity by RIA (-O-). Protein was determined by
absorbance at 280 nm (-), and the linear gradient is marked by the solid line.
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for immunoreactive hEGF, however hEGF was not detected in any of the rHPLC
fractions.
3.2.2.3 Analysis of rHPLC fractions by SDS-PAGE
To elucidate the molecular weights of the fractions demonstrating EGF-like
competitive activity and TGFa immunological activity, fractions 7-10 and 15-19 were
pooled and subjected to SDS-PAGE under non-reducing conditions. The eluted
material from 5mm gel slices were assayed for immunological rTGF-I and EGF-RRA
activity. However, neither EGF-like competitive activity nor immunological activity
was detected in any of the gel slices.
3.2.3 SUMMARY
The results from the analysis of CM from DU 145 cells clearly show that these
cells produce EGF-like molecules which demonstrate competitive activity. Most of the
competitive activity was immunologically related to TGFa and not EGF. When the
CM was assayed for mitogenic activity, a biphasic effect on DNA synthesis was
apparent, which was dependent upon the concentration of CM. In an attempt to further
characterize the EGF-like factors produced by this cell line, CM was subjected to size-
exclusion chromatography. Two peaks of EGF RRA activity were detected (Mr 30
000 - 50 000 and Mr 5 000) in the fractions eluted from the column, however neither
hTGFa nor hEGF immunological activity were detected. Several peaks of EGF-like
competitive activity were detected by rHPLC, only one of which was related






In well differentiated prostatic carcinoma androgen ablation therapy is often initially
effective, but eventually the carcinoma progresses to a more aggressive form in which
growth is androgen independent. This transition is a major impedance to successful
treatment not only of carcinoma of the prostate but of other tissues, such as breast,
under hormonal control. Since cell growth is no longer under the control of androgens
some other factor(s) must be responsible for proliferation.
Many workers are coming to recognize growth factors as playing the key role in
the progression of androgen-dependent to androgentindependent growth. This
recognition has prompted more subtle considerations of the interplay between growth
factors and androgens in the regulation of prostatic cell growth. A favoured
mechanism is that the progression to endocrine independence may be due to an altered
activity of the growth factor or its' receptor as suggested by King (1990). This
hypothesis has been tested by comparison of androgen insensitive (DU 145) and
androgen-sensitive (LNCaP) cell tines. The comparison permits for the first time a
study of the role of growth factors, in particular EGF, in the progression from
androgen-dependent to androgen-independent prostate cancer.
To test the hypothesis that alteration in growth factor or receptor activity could be
responsible for the progression to androgen independence, three questions were dsked;
(i) is the expression of the EGF receptor different in the two cell tines; (ii) what are the





If alteration in growth factor or receptor activity is responsible for the progression
to an androgen independent state then this may be reflected as differences in the
expression of the receptor, before and after transition. By identifying differences in
receptor expression of an androgen-insensitive and a sensitive cell line, it should be
possible to gain insight into the changes occurring during the transition.
Characterization studies
The binding of EGF to receptors present on DU 145 and LNCaP cells was both
time and temperature dependent and was in agreement with data on EGF binding to
whole cells (Banks-Schlegel & Quintero, 1986; Hader et al., 1987) including studies
with LNCaP (Schuurmans et al., 1988a) and DU 145 (Connelly & Rose, 1989) cells.
However, the rates of association were dissimilar and a higher percentage of
specifically bound EGF to DU 145 cells was found relative to LNCaP cells. The
higher level of [125I]-EGF association to DU 145 cells, reflecting increased levels of
receptors expressed, contrasted with the rate of dissociation which was almost identical
with that of LNCaP cells.
Competition studies with ligands unrelated structurally to EGF revealed that mEGF
binds specifically to the EGF receptor on both cell lines. Furthermore hEGF and
TGFa competed effectively with [125I]-mEGF for binding to the EGF receptor,
although these ligands are immunologically unrelated to mEGF.
Several studies investigating the fate of EGF after binding to cell surface receptors
have demonstrated that EGF becomes internalized by a process called "receptor
mediated endocytosis" (Hollenberg, 1986; Schlessinger, 1986). In terms of hormone-
triggered transmembrane signalling the concept of receptor mobility has evolved as an
important property of receptor function. Thus, the binding of a ligand dramatically
alters the ability of a receptor to migrate in the plane of the membrane and to interact
104
DISCUSSION
with other membrane components (Hollenberg, 1986; Schlessinger, 1986). Only at
physiological temperatures can the binding of EGF lead to receptor clustering and
internalization. Receptor internalization was demonstrated for both DU 145 and
LNCaP cells; this process was both time and temperature dependent, with a slower rate
of internalization for LNCaP than for DU 145 cells.
Cells are known to regulate their responsiveness to hormones through a variety of
mechanisms. One such mechanism, down-regulation, decreases the number of
receptors on the surface of the cell thereby reducing the capacity of the cell to respond
to that particular hormone. Pre-incubation of DU 145 and LNCaP cells with
increasing concentrations of EGF caused a significant loss of [125I]-EGF-binding
capacity, thereby demonstrating receptor modulation. This result is consistent with
several reports demonstrating that cells exposed to increased concentrations of EGF
gradually lose a substantial fraction of their receptors for their respective hormones by
down-regulation (Bradshaw, 1978; Carpenter & Cohen, 1979; Schlessinger, 1986).
Competition and saturation analysis revealed that both cell lines possess EGF
receptors with one high affinity binding site. The binding affinities were similar and
were within the nanomolar range, comparable with the results of the growth
experiments with EGF, where both cell lines were maximally stimulated with
nanomolar concentrations of EGF. Maximal stimulation of DNA synthesis and cell
proliferation was achieved at partial occupancy of the receptor. This finding is
consistent with the majority of findings for EGF, where only a small percentage of
receptor sites need to be occupied to induce the maximal proliferative response
(Schlessinger, 1988).
One or two binding sites? »
There is a lot of controversy as to whether cells possess one or two classes of EGF
receptor. The results of this study demonstrate only one class of EGF binding site for
DU 145 and LNCaP cells, with K<j values of 1.0 ± 0.6 x 10~9 M and 2.8 ± 2.2 x 10"9
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M respectively. Consistent with these findings were those of Wilding et al. (1989),
who found one high affinity EGF binding site for DU 145 (2.0 x 10~9 M) and LNCaP
cells (0.5 x 10"9M). Schuurmans et al. (1988a) also detected one high affinity binding
site for LNCaP cells with a dissociation constant of 0.45 x 10 _9 M. Contrasting with
these findings Connolly and Rose (1989) observed two high affinity binding sites for
DU 145 cells (1.8 x 10 "10 M and 1.1 x 10 -9 M).
In a recent review Schlessinger (1988) stated that EGF receptors are functionally
heterogeneous with different classes of binding site, but how far was this conclusion
influenced by an inappropriate analysis of the data?
In estimating the affinity of a ligand for its' receptor it is usual to employ a range of
radioligand concentrations, from 10 to 20% of the estimated K<j to four to five times
this value (Bennet & Yamamura, 1985). If radioligand concentrations are used which
are outside this range then the data is difficult to interpret by Scatchard analysis. At the
lowest ligand concentrations the differences observed in specific binding are relatively
small and difficult to measure accurately. This often leads to a scatter of points which
can easily be misinterpreted as conforming to a curvilinear relationship (ie. two binding
sites).
The LIGAND method represents a substantial improvement over the graphical
Scatchard plot for estimation of affinity constants in ligand binding studies. The
advantage of this method is that it fits data in an untransformed coordinate system,
where errors are more likely to be normally distributed. The approximations used in
Scatchard analysis are not necessary in the LIGAND method which calculates the
"free" values from the experimentally measured "total" radioactivity added minus the
"bound" values. Non-specific binding is also estimated as an independent parair^pter,
rather than by the investigator. Moreover, weights are assigned to each point, those
with a smaller variance usually receiving more weight (Rodbard et al., 1976). Curves
are fitted to a single or multi site model and a model for two binding sites is only
retained when it fits the data significantly better than a model for a single binding site.
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The extent to which flaws in the Scatchard analysis have lead to serious errors in
the interpretation of binding site data is currently difficult to judge, because it is rare for
authors to present data in a form which can readily be re-analyzed. Although some cell
types clearly do have more than one receptor (eg Boonstra et al., 1985) it is clear that
Schlessinger (1988) is imprudent in concluding that all EGF binding sites are
functionally heterogeneous. In the present study one high affinity binding site for
EGF was consistently found for DU 145 and LNCaP cells, lending further support to
a number of studies (Banks-Schlegel & Quintero, 1986; Davidson et al., 1987; Hader
et al., 1987; Traish & Wotiz, 1987; Carlin et al., 1988; Schuurmans et a/.1988a;
Wilding et al., 1989) which suggest that some target tissues and cell lines express only
one class of EGF receptor.
EGF receptor levels
Although the binding constants from both cell lines were similar there were
substantial differences in the number of receptors expressed by these cells. The
number of binding sites for the DU 145 cell line was calculated as 2 x 105 sites/cell
whereas the LNCaP cell line expresses only 2 x 104 sites/cell; an order of magnitude
lower. Similar findings were recently reported by Wilding et al. (1989), where they
calculated DU 145 cells as expressing 1 x 105 receptor sites per cell and LNCaP cells
as expressing 4 xlO4 receptor binding sites per cell.
Further characterization of the EGF receptor using the technique of Western
blotting, with Mabs EGFR 1 and F4, further verified the presence of EGF receptors
for DU 145 cells. This result confirmed that the EGF receptor of the DU 145 cell line
was present and was structurally intact, at a molecular weight of approximately 170
kDa. However, the EGF receptor was not observed in LNCaP cell lysates using*this
technique, reflecting the much lower levels of receptors expressed by this cell line.
The affinity of the F4 Mab for the EGF receptor in solution is 5-10 fold lower than
the EGFR1 Mab (Gullick et al., 1986), but EGF receptor expression was only
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observed with the Mab F4. The most likely interpretation is that the EGFR 1 epitope,
which is situated in the extracellular domain of the receptor, must be more vulnerable
to destruction by SDS-PAGE than the intracellular F4 epitope. Gullick et al. (1986),
who produced both Mabs, also failed to detect the EGFR 1 epitope by Western
blotting. The extracellular domain of the receptor has a high cysteine content, which
may occur as cross-linked disulphide bonds, a common feature of many extracellular
proteins, to maintain structural stability in extracellular environments. The reduction of
disulphide bonds by |3-mercaptoethanol will radically alter the tertiary structure of such
a cysteine rich region and could therefore destroy the EGFR1 epitope. This possible
role of |3-mercaptoethanol in destroying antigenicity could readily be tested by non-
denaturing SDS-PAGE.
The EGF receptor and androgens
Since the realisation that androgens are not alone in influencing the growth and
regulation of the prostate, several investigations into the role of growth factors and
their relationship with androgens have been undertaken. Davidson et al. (1987)
reported that oestrogen-responsive breast cell lines express relatively low numbers of
EGF receptors (< 70 000 per cell) whilst oestrogen-unresponsive cells express higher
EGF receptor numbers (> 70 000 per cell). The finding of Davidson et al. (1987), that
EGF receptor expression of breast cancer cell lines correlates inversely with the
response of those cells to oestrogens, is repeated in the present comparative study of
the androgen responsive and unresponsive LNCaP and DU 145 cell lines.
In breast cancer the link between the over-expression of the EGF receptor and
endocrine status was complemented by the observation that oestrogen receptor positive
MCF-7 cells were converted (by drug selection) to an oestrogen receptor negative
population that over-expressed the receptor. Over-expression of the EGF receptor is
also associated with an increased recurrence of breast tumours (Harris & Nicholson,
1988). These findings strongly suggest that an alteration in growth factor expression,
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such as over-expression of the receptor, is associated with the transition from an
endocrine-responsive to an unresponsive state. Perhaps a comparable situation exists
for the prostate since the results of this study suggest many parallels between both
models.
The correlation between EGF receptor expression and endocrine status (from these
two different tissues) implies that steroid hormones might influence the response to
growth factors, by altering growth factor receptor expression. However, the nature of
the interaction between androgens and EGF in prostatic cancer remains unclear since
the results reported here demonstrate that androgens do not modulate EGF receptor
expression. The steroidal androgen Mibolerone did not affect either the level of
receptors expressed or the affinity of the receptor, contradicting the results of
Schuurmans et al. (1988a) and Wilding et al. (1989). Both groups detected a two fold
increase in the number of EGF binding sites upon treatment of LNCaP cells with
androgens. Schuurmans et al. (1988a) reported a linear increase in the number of EGF
receptors, after 6 hours exposure to androgens, until a plateau was reached at three
days. However, the increases observed were relatively small, and there was no
statistical treatment of the data. Similarly Wilding et al. (1989) not only failed to
indicate how many times their experiment was repeated but also failed to report any
statistical treatment of their data.
In the binding data reported here considerable inter-experimental variability of
receptor concentration was noted. Correction factors for the variation have been
included in the LIGAND program which adjusts or scales the values of apparent
receptor concentrations for any particular experiment. There is also considerable
variability in LNCaP receptor levels reported in the literature. Wilding et al. (19§9)
estimated 4 x 104 binding sites/cell for LNCaP cells, almost four times the number
reported by Schuurmans et al. (1988a) and twice that reported here.
Considering that there is a large degree of variability when evaluating receptor
concentration between experiments (Munson & Rodbard, 1980) it is perhaps
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imprudent to claim that androgens up-regulate EGF receptors without showing
evidence of statistical significance. In the study here receptor levels appeared to
decrease when the cells were treated with the androgen Mibolerone, but upon analysis
this decrease was shown to be not statistically significant.
It therefore remains questionable as to whether the EGF receptor is up-regulated by
steroid hormones in LNCaP cells, as reported by Schuurmans et al. (1988a) and
Wilding et al. (1989). Indeed, in the normal prostate both Traish & Wotiz (1987) and
St-Arnaud et al. (1988) found that EGF receptor levels are down regulated by
androgens, since castration of mature rats resulted in a significant increase in prostatic
EGF binding, whilst treatment with DHT decreased the number of EGF binding sites.
Although the findings for breast cell carcinomas may not be relevant to the role of
androgens in the prostate it is worth noting that oestrogens do not appear to regulate
the levels of EGF receptor (Murphy et al., 1985; 1986; Headon & Allan, 1989). It is
therefore not inconceivable that the interaction between androgens and the EGF
receptor in the normal prostate may be lost, resulting in neoplastic growth.
Although there does not appear to be a link between the EGF receptor and steroid
hormones in the androgen sensitive LNCaP cell line, it may be that over-expression of
the EGF receptor (eg DU 145 cells) could have resulted in down regulation of the
androgen receptor rendering these cells insensitive to androgen manipulation.
4.2 CELL GROWTH AND EGF
Since numerous studies with in vitro cell lines have reported EGF as a potent
mitogen (Carpenter & Cohen, 1979 for review), it was surprising to discover that
exogenous EGF only minimally stimulated proliferation of DU 145 cells in SFM*
Cell enumeration experiments with DU 145 cells grown in media containing foetal
calf serum showed that these cells were not stimulated at any of the concentrations of
EGF tested. In fact exposure of the cells for three days to higher concentrations of
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EGF resulted in inhibition rather than stimulation of cell growth. Interestingly, EGF
appeared to have a cumulative effect on these cells, for although the lower
concentrations of EGF had no discernable effect after three days incubation, inhibition
at these lower concentrations was seen after incubation for nine days. This was not a
toxic effect since incubation with EGF never resulted in a net loss of cells. One
possible influence was the presence of foetal calf serum in the cell culture medium.
Consequently, the experiment was repeated with DU 145 cells which had been
cultured in the absence of this supplement, for which it was necessary to develop a
serum free line of these cells; see section 2.3.1.2. Although the growth rate of these
cells was slower in SFM than in complete medium, growth was sustained in the SFM
and cells could be sub-cultured successfully.
Results obtained at the highest concentrations of EGF in SFM were essentially
similar to those observed in the presence of foetal calf serum, but at the lower
concentrations of EGF some differences were observed. EGF, up to a concentration
of 0.3 nmol/1, increased both cell numbers and [3H]-Thymidine incorporation into
DNA, in a dose-dependent manner above which inhibition was observed. Although
both measures of mitogenicity were comparable there were differences in the statistical
significance of the increases observed in cell proliferation and [3H]-Thymidine
incorporation. There was an incremental trend in cell numbers with increasing
concentrations of EGF, but the increases seen at each concentration of EGF were not
significantly different from control values. However, [3H]-Thymidine incorporation
into DNA was increased by a statistically significant amount at similar concentrations
of EGF.
It could be argued that the differences in statistical significance reflect the relative
precisions of the two techniques, as cell numbers determined by haemocytometer are
notoriously imprecise. EGF might also stimulate division of the cell nuclei without
concomitant cell proliferation as has been reported for hepatocytes (Sargent et al.,
1988). Similar inconsistences between cell proliferation and [3H]-Thymidine
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incorporation, with respect to EGF, were reported by Connolly & Rose (1989) with
the DU 145 cell line. They observed a three fold increase in incorporation of [3H]-
Thymidine with EGF when DU 145 cells were plated at low cell density (103
cells/cm2), but cell proliferation was not affected at this density. The differences
observed could be a function of cell plating density, or as Connolly & Rose (1989)
have suggested, a deficiency of one or more nutrients in the SFM, with failure of the
cells to proceed from interphase to the M-phase of the cell cycle.
It seems illogical that while DU 145 cells possess large numbers of receptors they
are only minimally affected by exogenous EGF. However such findings are not
unique, the endometrial carcinoma cell line RL95-2 is only marginally stimulated by
EGF (Korc et al., 1987) as are some human embryonal cell lines (Yerbeek et al.,
1988), and yet all possess EGF receptors. The most complex pattern of proliferative
response is seen with the in vitro epidermoid carcinoma cell line A-431 which is
inhibited by nanomolar concentrations of EGF (Chinkers et al., 1981; Barnes, 1982;
Kawamoto et al., 1983), whereas picomolar concentrations minimally stimulate
proliferation (Kawamoto et al., 1983). The biphasic effect observed with EGF on the
proliferation of DU 145 most closely parallels that observed with A-431 cells, although
the concentrations of EGF which inhibited proliferation of DU 145 cells are somewhat
greater.
Other workers have noted no proliferative effect with EGF (Engstrom, 1986;
Salomon et al., 1987). The embryonal carcinoma cell line Tera-2 has high affinity EGF
receptors, but this cell line does not respond proliferatively to exogenous EGF
(Engstrom, 1986). Similarly, ras-transformed mouse mammary epithelial cells
express high affinity EGF receptors, but neither exogenous EGF nor TGFa have^ an
effect on the anchorage-independent growth of these cells (Salomon et al.,1987).
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It is possible to speculate on a number of possible mechanisms which could
account for the apparent contradiction that DU 145 cells are only minimally stimulated
by exogenous EGF, but possess 105 receptor sites/cell:-
(a) Tyrosine kinase activity
Activation of Tyr kinase activity and phosphorylation by ligand binding are
believed to represent the primary molecular events initiating the transmission of the
mitogenic signal inside the cell. Therefore a reduction in Tyr kinase activity,
irrespective of the number of receptors, would cause a reduced mitogenic response by
exogenous EGF. However, this is unlikely because exogenous EGF (at high
concentrations) significantly inhibited cell proliferation of DU 145 cells.
(b) A non proliferative rolefor EGF
The embryonal carcinoma cell line Tera-2 is reported to have high affinity EGF
receptors yet Engstrom (1986) found no detectable proliferative effect with exogenous
EGF. It was suggested that EGF played an alternative (non proliferative) role in these
cells (eg. cell locomotion). However, as was the case with the previous hypothesis,
this explanation is unlikely because high concentrations of EGF significantly inhibited
cell proliferation of DU 145 cells.
(c) The truncated receptor
Although there is no direct evidence that aberrant expression of the EGF receptor
is involved in the transformation of human cells it has been suggested that the
production of the truncated EGF receptor, which lacks the regulatory action of the
ligand binding domain, may leave the tyrosine kinase of the \-erb B gene product in a
constitutively active form (Gilmore et al., 1985; Kris et al., 1985). It is the activity of
the Tyr kinase domain of the EGF receptor which is important in influencing the '
growth rate of cells, thus an abnormal EGF receptor with an uncontrolled Tyr kinase
activity would cause rapid cell division. Aberrant expression of the EGF receptor of
DU 145 cells would also explain why exogenous EGF appeared to have very little
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effect on the growth rate of these cells. However, this is not true for DU 145 cells
because Western blotting revealed only the 170kDa EGF receptor (and not the 68kDa
truncated receptor).
(d) Plating density
Several workers have shown that the response of a cell line in serum-free defined
medium to a particular hormone or growth factor is dependent to a large extent upon
plating density (Holley et al., 1977; Kaighn et al., 1981; Korc et al., 1987; Rizzino et
al., 1988). The effect of density was explored with the serum-free DU 145 cell line;
densities between 1 x 104 cells/cm2 and 6 x 104 cells/cm2 did not greatly enhance the
weak stimulatory response to EGF. Sustained growth of the serum free DU 145 cell
line was dependent upon high plating densities (> 104 cells/cm2), with densities lower
than this value causing cells to round up and detach, even in the presence of EGF.
In a recent study Connolly and Rose (1989) reported that DU 145 cells responded
to exogenous EGF, contradicting the findings reported here. However, this response
was only noted at low cell density and only DNA synthesis was affected and not cell
numbers. They demonstrated a three fold increase in incorporation of [3H]-Thymidine
with EGF when DU 145 cells were plated at low cell density (103 cells/cm2), but at
high plating density (104 cells/cm2) this stimulatory effect was abolished.
How can we account for these differences between the two studies? As
previously mentioned, the serum-free DU 145 cell line would not proliferate at low
density and all attempts to carry out studies at a low seeding density proved to be a
fruitless exercise. Moreover, the DU 145 cell line used by Connolly and Rose was not
a serum-free line, only the growth experiments were carried out with SFM, which
suggests that the differences observed might be due to culturing conditions or to carry
over from serum proteins. Nonetheless, cell density is obviously an important
criterion to take into account with respect to the response to a particular hormone.
Holley et al. (1977) noted that increasing the density of monkey kidney epithelial BSC-
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1 cells decreased the response to EGF. This down regulatory effect was also observed
by Rizzino et al. (1988) with non-transformed rat kidney fibroblasts (NRK cells), iln
contrast to these reports however, Korc et al. (1987) noted that the proliferative
response to EGF of the RL95-2 human endometrial carcinoma cell line was increased
at high plating densities.
In all of these cases the effect of density with respect to the proliferative response
to EGF was observed in serum-supplemented medium. With regard to the serum-free
DU 145 cell line, it would appear that the serum-free culture of these cells is density-
dependent, but not the response to EGF.
(e) TGFa
The growth factor TGFa was tested for its' effect on DNA synthesis of DU 145
cells because DU 145 cells may respond proliferatively to TGFa in preference to EGF.
TGFa has only 35% sequence homology with EGF (Derynck et al., 1984; Marquardt
et al., 1984) yet it binds to the same receptor and appears to have similar biological
properties (Bascom et al., 1989).
TGFa stimulated [3H]-Thymidine incorporation in DU 145 cells, but although this
effect was minimal it was significantly different from the untreated control. However,
there were differences between TGFa and EGF in the response elicited, as 10 fold
lower concentrations of TGFa were required to maximally stimulate the growth of DU
145 cells relative to EGF. This suggests that TGFa has a higher affinity for the EGF
receptor than EGF itself.
There is also evidence to suggest that EGF and TGFa bind to distinct sites on the
receptor (Winkler, 1989). Winkler and co-workers (1989) described an antibody
which blocked the binding of TGFa to the human EGF receptor, but had no effect on
the affinity of EGF for binding to the EGF receptor. This evidence is consistent with
the fact that TGFa has only 35% sequence homology with EGF and is
immunologically distinct from EGF.
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In a preliminary report, Wilding et al. (1988) noted that TGFa, at similar plating
densities, had little effect on the growth of the DU 145 cell line, indeed the growth rate
of DU 145 cells was not significantly altered by TGFa. In contrast, Fernandez-Pol et
al. (1986) reported that TGFa significantly stimulated anchorage-independent growth
of DU 145 cells.
From these studies it appears that there are inconsistencies with respect to the
growth response to TGFa. What these studies do portray is that DU 145 cells are
only minimally affected by exogenous TGFa. The differences in the response elicited
might reflect assay and culture conditions. For example, Shipley and co-workers
observed that TGFa did not stimulate DNA synthesis in serum free cultures of AKR-
2B mouse cells, but stimulated multiple rounds of DNA synthesis in serum-containing
medium (Shipley et al., 1984). However, unlike the DU 145 cell line, EGF induced a
substantial mitogenic response on AKR-2B mouse cells both in the presence and
absence of serum.
It was concluded from these findings that neither EGF nor TGFa, under serum-
free conditions, are potent mitogens for DU 145 cells and that plating density did not
affect this proliferative effect with EGF. Indeed EGFs' action upon these cells was
found to be more inhibitory than proliferative. This inhibitory effect with high
concentrations of EGF was probably due to down regulation of EGF receptors since
this effect was enhanced with time, or as Barnes (1982) and Chinkers et al. (1981)
suggested, to morphological changes caused by high concentrations of EGF. These
workers observed that when inhibitory concentrations of EGF (in the range of 3 nM)
were added to cultures of A431 cells, the cells rapidly round up, detach and cease to
proliferate. Although inhibitory concentrations of EGF did not cause detachment of
DU 145 cells, morphological changes may have resulted in cessation of proliferation.
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(f) Autostimulation by endogenous growth factors
None of the previous examples could explain why DU 145 cells are only minimally
stimulated by exogenous EGF. An alternative explanation is that DU 145 cells are
auto-stimulated by endogenous EGF-like molecules. This is consistent with the
observation that these cells possess receptors, yet they show a slight proliferative
response to exogenous growth factors.
The loss of requirement for specific growth factors is a common finding in many
types of neoplastic cells (Moses etal., 1978; Kaplan et al., 1982) and is also reflected
in a reduced serum requirement for growth. Indeed DU 145 cells readily adapted to
growth in chemically defined, serum-free medium containing no EGF.
EGF and LNCaP
In contrast to its' effect on the DU 145 cell line, EGF elicited a substantial
mitogenic response on the androgen sensitive cell line LNCaP. EGF, in a dose-
dependent manner, induced a two fold increase in cell numbers and [3H]-Thymidine
incorporation into DNA. A similar mitogenic response by EGF was reported by
Schuurmans et al. (1988a) who found that EGF, at similar concentrations to those
reported here, almost doubled the DNA content of LNCaP cells under serum-free
conditions. In a recent report Wilding et al. (1989) noted that exogenous EGF and
TGFa stimulated LNCaP cell growth and that TGFa increased the uptake of [3H]-
Thymidine. They showed that EGF and TGFa, at a concentration of 5 ng/ml, were
equipotent in stimulating cell proliferation, but the extent of the proliferative response
with both ligands was not as pronounced as in the study reported here. Increased
concentrations of TGFa (up to 20 ng/ml) stimulated proliferation 3 fold whereas in the
study presented here, when EGF was used at similar concentrations, cell proliferation
and DNA synthesis had returned to basal levels.
It is difficult to compare the results of the present study with those of Wilding et al.
(1989) because they examined the proliferative response to TGFa over a range of
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concentrations and the effect of EGF at one concentration. Moreover, the proliferation
studies with exogenous growth factors were conducted with LNCaP cells cultured in
the presence of serum and not SFM (as reported here). Nonetheless, both studies
reveal that the LNCaP cell line is responsive to exogenous EGF and that this effect was
substantial, which is not the case for EGFs' effect on DU 145 cells.
Androgens and EGF
As previously discussed the relationship between growth factors and androgens in
the prostate remains unclear although similarities can be drawn between prostate and
breast cancer cells with respect to the proliferative response to EGF, the expression of
the EGF receptor and the mitogenic response to steroid hormones. In common with
DU 145 and LNCaP prostate cancer cell lines, Davidson et al. (1987) reported that the
presence of relatively low numbers of EGF receptors on breast cancer cell lines was
associated with the ability of the cell to manifest a mitogenic response to EGF, whilst
cells with higher EGF receptor numbers failed to respond. Those cells which were
stimulated to grow with EGF were oestrogen-responsive whilst those which were only
minimally affected by EGF were oestrogen-unresponsive (Davidson etal., 1987).
Could it be that the loss of steroid responsiveness of prostatic tumours may be
linked with a loss of dependence or a reduced sensitivity to growth factors, possibly
by autologous production of growth factors ?
The nature of the relationship between androgens and growth factors in the prostate
has remained unclear despite intensive investigations. One such report demonstrated
that androgens, together with EGF directly affected prostatic cancer cell proliferation
(Schuurmans et al., 1988b). This group observed a synergistic effect between the
androgen R1881 and EGF on the proliferation of LNCaP cells. However, the results
of the present study and of others (Eaton et al., 1989; Somnenschien et al., 1989)
demonstrated no such synergistic effect between EGF and androgens on the
proliferation of these cells. Indeed, the increase in cell numbers and DNA synthesis
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reported here was less when EGF and Mibolerone were added together, than the
combined effect of each of these factors added separately. To add to the confusion the
group of Schuurmans published contradictory accounts of the relationship between
androgens and EGF. In the first of these Schuurmans et al.( 1988a) did not observe
the synergism subsequently reported. In the second publication Schuurmans et al.
(1988b) argued for a rapid metabolism of EGF which disguised the synergistic
relationship with androgens unless EGF was administered daily.
Although a rapid metabolism of EGF is crucial to the argument of Schuurmans et
al. (1988b) no experimental evidence for this rapid metabolism was given.
Furthermore, in this study, when DNA synthesis was monitored 24 hours after the
addition of growth factors and androgens (ie. using the same conditions as
Schuurmans et al., 1988b) no synergism was detected. Since the major difference
between this study and that of Schuurmans et al. (1988b) is the use of serum-free
medium (compared with a medium containing serum, but stripped of androgens) it is
possible to argue that the 'synergistic effect' observed by the Dutch group was due to
other factors in the serum. The difficulties of investigating the effect of a single factor
using a medium containing serum were illustrated by the repetition of an experiment to
monitor the effect of R1881 on the growth of LNCaP cells. Although Schuurmans et
al. (1988) found that growth was stimulated when the cells were cultured in a medium
stripped of androgens, R1881 did not affect the growth of LNCaP cells when cultured
in the presence of SFM.
One other important difference between the two studies was the choice of
androgens to demonstrate the synergistic effect with EGF. The synergistic effect
observed by Schuurmans and co-workers was detected in the presence of the synthetic
androgen R1881 and not Mibolerone (as used in the present study). Somnenschien et
al. (1989) reported that both steroids had identical proliferative potencies for the
LNCaP cell line. However, this does not appear to be the case because Mibolerone
stimulated proliferation and [3H]-Thymidine incorporation while R1881 (at the same
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concentration) did not affect the growth of LNCaP cells. Although it would appear
that Mibolerone is proliferatively more potent than R1881 in SFM, when the
androgens were added to cells cultured in the presence of 10% FCS a greater inhibitory
effect was demonstrated with R1881. Since the effect of androgens on growth is
biphasic (increasing concentrations initially stimulating then inhibiting growth;
Somnenschien et al., 1989), the results imply that the "effective concentration" of
R1881 is greater than for Mibolerone. This finding is consistent with the higher
binding affinity of R1881 for the androgen receptor (Schilling & Liao, 1984). 0.1 nM
Mibolerone significantly stimulated both proliferation and DNA synthesis of LNCaP
cells grown in SFM. Therefore the failure of 0.1 nM R1881 to stimulate growth in
SFM studies presumably reflects its' use at a concentration greater than that which
would affect maximum growth.
Differences in the proliferative potency of the two androgens will affect results if
they are tested at the same concentration. However the failure to observe a synergistic
effect with Mibolerone cannot be accounted for by such differences in proliferative
response since Mibolerone significantly stimulated both proliferation and DNA
synthesis, and there is no reason to believe that a genuine synergistic effect between
Mibolerone and EGF would not be detected.
As the results reported here demonstrate, androgens together with EGF affect cell
proliferation and DNA synthesis of LNCaP cells. However, the nature of this
interaction is unclear since the combined effect of EGF and Mibolerone was not
additive, neither was it synergistic.
4.3 AN AUTOCRINE MECHANISM
Since Sporn & Roberts (1980) first conceived the idea that cells could regulate their
growth by the autologous production of growth factors, and that autocrine regulation
may be an important mechanism involved in transformation, autocrine growth control
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mechanisms have been postulated to be important for a variety of tumour systems.
The existence of a TGFa auto-stimulatory loop for DU 145 cells is proposed based on
findings that the cells produce endogenous EGF-like molecules and express high
concentrations of EGF receptors, although neither EGF nor TGFa are potent
mitogens.
Using a specific RIA for TGFa and an EGERRA competition assay, EGF-like
molecules were detected in the medium conditioned by DU 145 cells. A number of
previous studies have reported the production of EGF-related polypeptides by various
cell lines from the colon (Coffey et al., 1986; 1987; Watkins et al., 1988), breast
(Dickson et al., 1986; Perroteau et al., 1986; Lippman et al., 1987), ovary (Bauknecht
et al., 1986) and prostate (Connolly & Rose, 1989; Wilding et al., 1989). The
detection of endogenous EGF-like molecules in the medium of these cells suggests an
involvement in cell transformation since these cells are auto-regulated by virtue of
possessing receptors for the secreted molecule. However, evidence has accumulated
in recent years that the role of EGF/TGFa and their receptor in carcinogenesis is more
complex than first thought.
Initial studies with cultured human breast cancer cell lines indicated that oestradiol
up-regulated growth stimulators such as TGFa (Dickson et al., 1986), and it was
thought that transition to the unresponsive state involved alteration of this factor and/or
its' receptor (King, 1990). This transition was thought to occur via a mechanism
where an increase in growth factor production might occur irrespective of the presence
of androgens. This link was confirmed by the observation that transfection of MCF-7
cells with the ras oncogene, which rendered the cells oestradiol insensitive, up-
regulated TGFa production (Kasid et al., 1985).
In addition to these finding Di Marco et al. (1989) recently demonstrated that the
gene for TGFa was a potent oncogene for NIH 3T3 cells and those cells producing
TGFa over-expressed the EGF receptor. These findings suggest that both ligand and
receptor might induce the transformed state.
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Could a similar mechanism be involved in prostate cancer? The results presented
here demonstrate that DU 145 cells produce EGF-like molecules which may be
autostimulatory. Furthermore DU 145 cells express increased levels of EGF receptor
compared to the androgen sensitive LNCaP cell line.
LNCaP cells are also thought to produce EGF-like molecules, the production of
this ligand is increased by androgen stimulation (Wilding et al., 1989). If LNCaP cells
produce EGF-like molecules why are they responsive to exogenous growth factors?
One possible explanation is that those cells which are unresponsive to EGF/TGFa may
have an increased capacity to secrete TGFa compared to those which are growth factor
responsive.
Paradoxes do exist, however, as several workers have demonstrated a negative
correlation between EGF receptor number and the production of TGFas (Todaro et
al., 1980; Carpenter et al., 1983; Coffey et al., 1986; Sircar & Weber, 1988), contrary
to the findings with breast and prostate cancer. These workers reported a decreased
expression of the EGF receptor with the production of TGFas, suggesting that the
EGF receptor is down regulated by increased production of TGFa.
Recent findings with the breast carcinoma model also contradict earlier studies as
two rodent models demonstrated a decreased TGFa expression in unresponsive
tumours (Liu et al., 1987), whilst oestradiol-responsive MCF-7 cells transfected with
TGFa cDNA over-express TGFa but retain their sensitivity to steroids (Clarke et al.,
1989).
Whether the situation is as complex in the prostate remains to be determined, but it
appears from the findings of this study that DU 145 cells have an increased expression
of the EGF receptor, yet are in general, unresponsive to the mitogenic effects of EGF
and TGFa because of an increased production of TGFa.
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TGFas- immunological and competitive activity
The bioactive EGF-like molecules produced by these cells (demonstrating EGF
RRA competitive activity) are also immunologically related to TGFa, but not EGF.
However, stoichiometrically the level of immunological TGFa activity detected was
not equivalent to the amount of EGF-like competitive activity. The differences could
be attributed to inaccurate assessments of the levels of EGF-like molecules in the CM,
in particular the levels of TGFa since the rTGF-I antibody does not cross-react with
human TGFa and rat TGF-I to the same extent. The amount of bioactive EGF
equivalents in the CM was calculated by comparing the competitive activity of EGF
binding to the EGF receptor, but the molecules detected in the CM are immunologically
related to TGFa and not EGF. Although TGFa binds to the EGF receptor the affinity
of binding may differ, and consequently the levels detected in the CM may be
inaccurate. A second consideration is that the EGF-like molecules produced by DU
145 cells may be related to, but distinct from, TGFa. The secretion of heterogeneous
EGF-like molecules, some identical with and others related to TGFa, might also
account for this discrepancy. Indeed, DU 145 CM fractionated by rHPLC revealed
several components of EGF-like competitive activity, only one of which proved to be
related immunologically to TGFa.
Further evidence supporting the hypothesis that the prostatic cell line DU 145 is
involved in an autostimulatory loop has come from two recent reports (Connolly &
Rose, 1989; Wilding et al., 1989) describing EGF-like molecules in the CM of these
cells. The molecules showed EGF-like competitive activity and were immunologically
related to TGFa, but Connolly and Rose (1989) also detected immunoreactive hEGF.
This is a surprising result because EGF is not thought to be secreted by transformed
cells. Although both ligands were detected by these workers it may be that the RIAs
used to detect EGF cross reacted with TGFa in the CM, since TGFa has




Mori et al. (1986) also claimed to have detected immunoreactive hEGF from
MCF-7 breast cancer cells, but this finding was not confirmed when specific RIAs'
were used in a follow-up study (Perroteau et al., 1986). Perroteau and co-workers
detected immunoreactive TGFa in the medium conditioned by MCF-7 cells and three
other breast cancer cell lines, but no hEGF was detected (Perroteau et al., 1986).
Stimulatory and inhibitoryfactors ?
Media conditioned by DU 145 cells had a significant stimulatory and inhibitory
effect on DNA synthesis of DU 145 cells, which was dose responsive. The inhibitory
effect on the incorporation of [3H]-Thymidine into DNA was demonstrated at low CM
concentrations, whilst higher concentrations stimulated DNA synthesis. This biphasic
effect on DNA synthesis of DU 145 cells could be due to the existence of at least two
regulatory 'factors', one of which has an inhibitory effect on growth, the other
stimulating proliferation or inhibiting the effect of the inhibitory factor. It would
appear from the biphasic effect that the inhibitory factor(s) is either more abundant or
more potent than those which stimulate DNA synthesis.
It is interesting to note that TGF(i which inhibits the growth of tumour derived
epithelial cells (Tucker et al., 1984; Knabbe et al., 1987) also inhibits the growth of the
prostatic cancer cell line LNCaP (Schuurmans et al., 1988). The stimulatory effects of
EGF on the growth of the LNCaP cell line are also inhibited by TGFf) (Schuurmans et
al., 1988). Perhaps TGF[3 may also play a role in the regulation of growth of DU 145
cells, negating the effects of EGF-like molecules. However, without biochemical
analysis it is imprudent to speculate overmuch about the nature of these 'factors'
produced by DU 145 cells.
TGFas - heterogeneous molecules
Fractionation of CM from DU 145 cells by gel filtration chromatography revealed
two molecular forms of EGF receptor binding polypeptides; a major and a minor peak
of EGF-like competitive activity. The minor peak of EGF-like competitive activity had
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an apparent molecular weight of 5 kDa which corresponds in its elution position to the
low molecular weight form of TGFa. However this peak was not immunoreactive
with either anti-hEGF or anti-rTGF-I antisera. The higher molecular weight
component (apparent molecular weight 30 - 50 kDa) may comprise the precursor form
of hEGF previously described in urine (Hirata & Orth, 1979) or the 160 amino acid
precursor form of TGFa (Bringman et a/.,1987; Waterfield, 1989). Consistent with
this result were the findings of Connolly and Rose (1989) who described the size
heterogeneity of EGF-like components secreted by the DU 145 cell line. They found
several peaks of competitive activity from conditioned DU 145 medium, with apparent
molecular weights of approximately 5-6 kDa, together with four additional peaks of
considerably higher molecular weight.
High molecular weight EGF-like molecules have been described by other workers
(Dickson et al., 1986; Stromberg et al., 1986; Culouscou et al., 1987; Eaton et al.,
1988; Connolly & Rose, 1989). Dickson et al. (1986) described a 30kDa component
secreted by the MCF7 breast cell line. Similarly, 48kDa forms have been observed in
Western immunoblots of extracts of medium conditioned by human
rhabdomyosarcoma A673 cells (Stromberg et al., 1986).
Importantly, both bioactive regions from gel filtration analysis failed to compete in
specific RIAs for hEGF or rTGF-I. This lack of immunoreactivity could mean (i) a
lack of immunological relatedness of both components to either hEGF or rTGF-I or (ii)
a problem of sensitivity, due to the dilution of active components by gel filtration. The
latter is more likely because immunoreactive TGFa activity was demonstrated in the
concentrated CM before it was subjected to gel filtration and immunoreactive TGFa
activity was detected in components separated by rHPLC. The lack of hEGF
immunoreactivity in any fraction is consistent with the result for the pooled CM, where
only immunoreactive TGFa was detected.
It was not possible to subject either peak of EGF-like competitive activity separated
by gel filtration to rHPLC directly, due to the low levels of EGF-like competitive
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activity detected and the lack of TGFa immunological activity. Therefore,
concentrated CM was separated using rHPLC (which fractionates components in
smaller volumes thereby increasing sensitivity) and analysed for EGF-receptor binding
activity as well as immunologic rTGF-I and hEGF activity. The results of the rHPLC
revealed several components of EGF-like competitive activity and contrary to the
results obtained with gel filtration, one of these major peaks demonstrated
immunoreactive rTGF I activity. The other peaks of EGF-like competitive activity
were immunologically distinct from both rTGF-I and hEGF.
The major EGF-like competitive activity which eluted at the end of the run is
unusual in that bio-activity increased steadily with increasing acetonitrile concentration
without any sign of peaking; suggesting that this activity is an artifact. Nonetheless, it
appears that the DU 145 cell line secretes several different molecular species that are
EGF-like biologically, only one of which is related immunologically to TGFa. Since
immunological activity is more specific than competitive activity the inability of antisera
to react with the bio-active EGF-like molecules produced by this cell line may be due to
cryptic epitopes. Therefore a wider range of antibodies than is currently available will
be required to detect all EGF-like growth factors of prostate origin.
The reasons why a cell may secrete several molecular species related biologically to
EGF remains unclear, but it raises the possibility that a cell could make subtle changes
in the response elicited by producing different molecular forms of EGF/TGFa.
The major peaks of EGF-like competitive and immunological activity were further
subjected to non-reducing SDS-PAGE in an attempt to elucidate the molecular weights
of the bio-active and immunologically active EGF-like molecules. However, the eluted
material from the electrophoresed fractions did not demonstrate either EGF-like
competitive activity or rTGF-I, hEGF immunological activity. The lack of biological
and immunological activity from these fractions was probably due to the low
concentration of EGF-like molecules eluted from the gel slices. In retrospect Western
blotting would have probably succeeded in identifying the EGF-like molecules,
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although biological activity could not have be elucidated by this method. Nonetheless,
it is clear that the various different classes of TGFs secreted represent distinct











Using the in vitro epithelial cell lines DU 145 and LNCaP the role of growth
factor involvement in prostate cancer was explored, in particular in the progression
from an androgen dependent to an androgen-independent state. By comparing the
growth responses to exogenous EGF and EGF receptor expression it has been
possible to gain some insight into this transition.
A relationship was demonstrated between the proliferative response to EGF, the
expression of the EGF receptor and steroid responsiveness. The androgen-insensitive
DU 145 cell line expresses high levels of EGF receptors yet growth is only minimally
affected by exogenous EGF and TGFa. The inverse was found with the androgen-
sensitive LNCaP cell line which has retained its' capacity to respond proliferatively to
exogenous EGF. The relationship is similar to that found with breast cancer cell lines,
where the presence of relatively low numbers of receptors is associated with the ability
of the cell to manifest a mitogenic response to exogenous EGF, whilst cells with
higher receptor numbers respond only minimally to exogenous EGF (Davidson et al.
1987). Moreover, those cell lines which failed to respond to exogenous EGF were
endocrine-unresponsive, while those cells that retained their capacity to respond were
endocrine-responsive (Figure 33).
The negative correlation between EGF receptor expression, the response to
exogenous growth factor and endocrine status suggests that DU 145 cells, like
endocrine-unresponsive breast cancer cell lines, are generally unresponsive to
stimulation by exogenous growth factors. The available evidence presented here
FIGURE 33: Schematic diagram of the negative correlation between EGF receptor expression and the
proliferative response to exogenous EGF of the androgen insensitive DU 145 and androgen-sensitive
LNCaP cell lines. The diagram shows androgen and EGF sensitivity of LNCaP cells which express
low levels of EGF receptors compared to DU 145 cells, which express high numbers of receptors, are








supports the view that the minimal response is caused by autologous production of
EGF-like molecules, the levels of which are auto-stimulatory. In contrast to this the
androgen-sensitive cell line LNCaP, like oestrogen-responsive breast cancer cells,
appears to have retained its' capacity to respond to exogenous EGF, possibly because
of lower secretion of bioactive EGF-like peptides. Indeed in a recent study Wilding et
al. (1989) demonstrated an autocrine growth-stimulatory loop for LNCaP cells.
Furthermore, the production of EGF-like molecules by LNCaP cells are thought to be
stimulated by androgens (Wilding et al., 1989).
We might envisage that progression to an androgen-independent status may, in
part, be due to a loss of androgen regulation of growth factor production with cells
producing growth factors irrespective of the presence of androgens. The increase in
growth factor expression may in turn increase the expression of the EGF receptor
resulting in down-regulation of the androgen receptor (Figure 34). Studies on the
androgen responsive (SC3) and androgen-independent (SC4) cell lines which are
derived from a mouse mammary tumour (Nonomura et al., 1988) suggest such
mechanisms occur in the progression from androgen dependent to independent cell
status. Other studies with these cells lines imply that progression to androgen-
independence may occur by a mechanism in which the cells obtain the ability to
respond to growth factors (Nonomura et al., 1988) and autonomously produce growth
factor receptors.
Other authors have suggested that as well as up-regulating the production of
growth factors, androgens might also up-regulate the receptor for EGF (Schuurmans et
al., 1988a; Wilding et al., 1989), but this finding could not be substantiated in the
FIGURE 34 : Schematic diagram demonstrating the progression from an androgen dependent to an
androgen independent state. The androgendependent state, where cells respond to androgens by an
increase in growth factor production progress to a state where cells produce endogenous growth factors
irrespective of the presence of androgens. Increased growth factor production may lead to increased
expression of the EGF receptor which in turn may down regulate the androgen receptor.
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study reported here. In the normal rat prostate the EGF receptor appears to be down
regulated by androgens, and it is not inconceivable that this relationship may be lost,
resulting in neoplastic growth.
The discovery that cancer cell lines secrete TGFa has spawned the idea that a cell
could become independent of external growth control. Interestingly, the majority of
findings with transformed cells and indeed the DU 145 cell line reveal that these cells
secrete heterologous TGFas. The EGF-like molecules are related biologically to EGF
and TGFa by virtue of their competitiveness with EGF for binding to its' receptor.
Immunological assays demonstrate that these molecules have a number of similar
epitopes to TGFa. We might envisage a cell producing different molecular forms of
TGFa (which differ in their biological activity) thereby regulating cellular response.
Whether this is indeed the case remains unclear, but what is evident from this study is
the important role of growth factors in prostate cancer. In recognising this a
therapeutic use for growth factors may be imagined, particularly if growth factors and




There are several aspects of this1 study which merit further investigation
The DU 145 cell line, by autologous production of EGF-like molecules, appears to
have little or no need for exogenous EGF or TGFa. The levels of TGFs produced
may be autostimulatory, but this has not been established. It would be possible to
prove or disprove this hypothesis by the use of antibodies, either against the EGF
receptor or TGFa. Blocking the ligand binding site on the EGF receptor or "mopping-
up" excess EGF-like molecules would result in a reduction of the growth rate if the
levels secreted were indeed autostimulatory.
There are problems with this approach; firstly, antibodies raised against the
receptor might not block the TGFa binding site or may act as an agonist. Secondly,
the TGFas produced by the DU 145 cell line and other cell lines are heterologous in
nature, some appear to be immunologically related to but are not identical to TGFa,
while others are quite distinct. Furthermore, antibodies raised against the EGF
receptor might not necessarily block the binding site for TGFa as this ligand appears
to bind to a site distinct from EGF (Winkler et al., 1989).
The secretory products of DU 145 cells must be characterized further, notably the
factors which stimulate and inhibit DNA synthesis. We know that TGFas are
produced by the DU 145 cell line, but other factors such as those which inhibit growth
must be fully characterized. In a preliminary report by Wilding et al. (1988) DU 145
cells were found to transcribe TGFp mRNA and when TGFP was added to these
cells, growth was inhibited. The presence of this growth factor might explain the
inhibitory effect of the CM on the growth of DU 145 cells.
Although the components in the CM were partially characterized by gel filtration
and rHPLC, further biochemical and biological characterization is needed. The
approach taken here, namely to separate both immunological and biologically active
components using gel filtration according to their molecular weights, is problematic
because the samples are eluted in large volumes. The dilution effect could be limited
131
DISCUSSION
by using size exclusion HPLC. The next step would be to separate these active
components of known molecular weight using either ion-exchange or rHPLC.
Biological activity (such as transforming ability on fibroblasts and mitogenic activity)
as well as biochemical characterization (heat and proteases stability) should then be
ascertained.
The androgen-sensitive cell line LNCaP, like oestrogen-responsive breast cancer
cells, appears to have retained the capacity to respond to exogenous EGF. This might
be due to lower secretion of bioactive EGF-like peptides compared to the androgen-
insensitive DU 145 cell line; a hypothesis which could be tested by a direct comparison
of the levels produced.
The relationship between EGF receptor expression and TGFa production is not as
simple as previously thought. Several studies have demonstrated an inverse
correlation between the levels of EGF receptor expressed and the production of
TGFas. These studies have suggested that increased secretion of TGFs is
accompanied by a down regulation in receptor number. Due to the finding with
prostate cancer cell lines of a positive correlation between EGF receptor expression and
the production of TGFas it is clear that many more cell lines must be investigated
before a clear picture emerges.
One of the disadvantages of in vitro studies is that they can never adequately
simulate the in vivo environment. Therefore studies using in vivo models like PC-82
and the Dunning tumour model are necessary to accompany in vitro studies.
Moreover, the limited number of in vitro prostate cell lines available for studying
prostatic cancer severely limits the amount of information that can be accumulated.
This is reflected in the picture that is evolving for breast cancer which suggests that
there is no simple model for the transition to an endocrine-unresponsive state.
The use of primary culture of prostate cells is also necessary because the phenotype
of in vitro cell lines might have changed over the time these cell lines have been in
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culture. More importantly primary culture enables the study of paracrine interactions
between different cell types.
Finally, the hypothesis that an alteration in the activity of the growth factor or its'
receptor is responsible for progression of androgen-dependent to independent growth
could be directly examined. This may be carried out by the use of a cell line, such as
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